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Summary
Extracellular ATP released into the extracellular environment is thought to act as a danger signal on 
dendritic cells, to induce an immune response. The aim of this thesis was to further investigate the 
effect of extracellular nucleotides on human blood and lung derived dendritic cell subsets.
Dendritic cell subsets were generated from monocytes and isolated from human blood and lung 
parenchyma. The maturation state of blood dendritic cells was measured using flow cytometry to 
study cell surface markers, and cytokine release from dendritic cells and lung parenchyma was 
measured using immunoassay.
In lipopolysaccharide (LPS)-matured monocyte-derived dendritic cells, ATP significantly inhibited the 
maturation state of the cells and significantly inhibited the pro-inflammatory cytokine profile induced 
by LPS. In blood myeloid dendritic cells, ATP alone partially increased the maturation state of cells, 
and significantly inhibited the secretion of Th2 cytokines, but had little effect of LPS-matured dendritic 
cells. In plasmacytoid dendritic cells, ATP alone decreased the maturation state of cells, and had no 
effect on pro-inflammatory cytokine secretion induced by resiquimod. However these dendritic cell 
subsets were contaminated with dead cells, which may have affected the response to nucleotides.
In lung parenchyma, nucleotides induced a dramatic increase in the secretion of LPS-induced pro- 
inflammatory cytokines including IL-1(3 and IL-17, most likely due to activation of the P2Yn receptor. 
This response was enhanced in smokers compared to non-smokers. In myeloid dendritic cells from 
lung, a similar cytokine response was seen, indicating that these cells are a source of cytokines from 
the lung. This was not seen in plasmacytoid dendritic cells from lung stimulated with resiquimod.
These findings suggest that ATP released during inflammation is immuno-modulatory on human 
dendritic cells, altering the immune response to infection and that this response is similar in the blood
and the lungs. The study also highlights the impact of smoking on the response to P2 receptor 
activation in the lungs, which may be key in the generation of smoking related diseases.
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Chapter 1 -  Introduction
Recent progress in our understanding of the immune response has led to the theory that danger 
signals (endogenous molecules that are not normally present in the extracellular space) play an 
essential role in the activation of the immune response. Adenosine 5'triphosphate (ATP), a nucleotide 
found in all cell types may act as a danger signal, activating P2  receptors found on dendritic cells to 
cause their maturation. This initiates an immune response which aims to eliminate the invading 
pathogen. However, our current knowledge of this process is limited.
1.1. Danger signals: activation of immunity
The body is continuously being exposed to organisms through inhalation, ingestion or wounds, as well 
as to organisms that inhabit the skin and mucus membranes. While some of these organisms are 
harmful and require clearance to prevent disease, some are innocuous so do not require an immune 
response, and others are beneficial to the body such as the intestinal flora. Therefore, it is vital that 
the body be able to distinguish harmful antigens from innocuous antigens, and also determine what 
type of immune response is required to eliminate the specific organism encountered (Parkin & Cohen,
2001).
To understand how the immune system recognises harmful antigens, first the immune complex must 
be understood. As shown in figure 1.1, an antigen is taken up by an antigen presenting cell (APC), 
processed and presented on a major histocompatibility complex (MHC) class II molecule. Alongside 
this, activation of the APC leads to its expression of co-stimulatory molecules including CD80 (cluster 
of differentiation), CD8 6 , LFA-1 (lymphocyte function-associated antigen-1) and CD40 which form the 
MHC-complex. A naïve T cell expressing a T cell receptor (TCR) binds to the MHC:antigen complex, 
allowing the TCR to recognise the antigen. The T cell provides CD4 or CD8  which provide stability to
the complex, CD28 which binds to CD80/CD86 providing co-stimulation, CD40L which binds to CD40 
providing co-stimulation, and ICAM (intracellular adhesion molecule) which binds to LFA-1 providing 
adhesion of the two cells together. This leads to the activation of the naïve T cell, and the initiation of 
an immune response. In viral immunity, the MHC class I molecule is involved (Parkin et a!., 2001).
Dendritic
cell
MHC
CD40 CD80
CD86
CD28
CD40L
TCR CD3
CD4
ICAM
Naïve T cell
Figure 1.1 -  A simple diagram of the MHC:TCR interaction between dendritic cells and naïve T cells.
The antigen is presented bound to an MHC II molecule by a dendritic cell and recognised by the TCR 
on the T cell. CD3 and CD4 act to stabilise this complex; CD80 and CD8 6  on the DC bind to CD28 on 
the T cell and provide co-stimulation; CD40L on the T cell binds to CD40 on the DC to provide co­
stimulation; ICAM on the T cell binds to LFA-1 on the dendritic cell to provide adhesion and stability of 
the complex (adapted from Parkin et al., 2001).
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There have been multiple theories attempting to explain the complex immune response. The most 
well known until recently is the self/non-self model, which states that each lymphocyte has one type 
of receptor that recognises a foreign antigen, and co-stimulation is provided by pathogen associated 
molecular patterns (PAMPs) found on bacteria and viruses. This allows for only non-self antigens to be 
responded to, as self-reactive lymphocytes are deleted at birth (Ibrahim et al., 1995). However there 
are multiple problems with this theory, in that many foreign entities do not cause an immune 
response, such as food, silicone and bacteria in the gastrointestinal tract, and that mutated tumours 
carrying new antigens are not rejected (Matzinger, 1994).
A more complete theory of immunity that is widely becoming accepted is Matzinger's 'Danger Model' 
(for review see Matzinger, 2002). This theory states that to become activated, the immune system 
requires two signals. Signal one is the antigen being presented by an APC which can be 'se lf or 'non­
self. Signal two is co-stimulation, which is induced on an APC by a danger signal. This means that the 
body does not distinguish between self and non-self, but instead responds to the presence of danger. 
Therefore, while APCs are continuously taking up antigen from the extracellular environment and 
presenting them to T cells (signal one), only when the APC has been activated by a danger signal 
(signal two) will it up-regulate co-stimulatory molecules and activate a T cell (Gallucci & Matzinger,
2001). In the absence of co-stimulation, antigen presentation leads to the development of tolerance 
to that antigen, which ensures that on repeated exposure an immune response will not be induced 
(for review see Parkin et al., 2001).
Danger signals can be of many forms including pathogenic, inducible and intracellular molecules.
These include PAMPs which are molecules found on all bacteria, viruses and other pathogens which 
bind to toll like receptors (TLRs) found on antigen presenting cells (Amati et al., 2006). TLRs are type 
one membrane glycoproteins which have binding sites for PAMPs. There are 10 types of TLRs in
humans (TLR 1-10) which have varying affinities for different pathogenic molecules including bacterial 
and viral deoxyribonucleic acid (DNA), and cell surface molecules (Lee & Iwasaki, 2007). Binding of a 
PAMP to a TLR provides an indication to the body that a dangerous pathogen is present and that an 
immune response is required.
Intracellular danger signals include molecules that are normally found at high intracellular 
concentrations, but low extracellular concentrations. This means that when a cell releases these 
molecules, the change in extracellular concentration is recognised and can be detected by receptors 
on APCs. Cells release these contents due to death by necrosis, cell damage or mechanical stress, 
indicating to the body that a danger is present. To be an intracellular danger signal a molecule must 
be quick to be released or generated, come from a pool of intracellular molecules and have a low 
extracellular concentration in the steady state. They must also be easily broken down once in the 
extracellular space to terminate the response quickly once the pathogen has been removed and to 
eliminate tissue damage (Di Virgilio, 2005). These molecules include heat shock proteins, human DNA 
sequences and nucleotides (Matzinger, 1994). Inducible danger signals include inducible cytokines, 
which are molecules that are secreted by a cell to change the behaviour of another cell via paracrine, 
autocrine and endocrine routes (Parkin et al., 2001). Table 1.1 shows the main cytokines of interest, 
including type 1 IFNs which are secreted in response to viral infection of a cell, and indicate to 
surrounding cells that an infection is present (Parkin et al., 2001). As well as danger signals, some 
allergens, such as Der p 1 from the house dust mite, contain their own properties that activate APCs. 
Derpl contains proteolytic enzymes that directly activate dendritic cells, inducing an immune 
response (Lambrecht & Hammad, 2002). Environmental factors can also act as danger signals or cause 
the release of danger signals, as they contaminate normally innocuous antigens. These include 
pollutants and cigarette smoke which damage epithelial cells, causing the release of cytokines that 
activate dendritic cells. Innocuous antigens can also be contaminated with bacterial products leading
to an unwanted immune response. This has been shown by the contamination of ovalbumin (OVA; an 
innocuous antigen) with a low dose of bacterial lipopolysaccharide (LPS) which induces a T helper cell 
mediated asthmatic immune response in mice on inhalation, whereas inhalation with OVA alone had 
no effect (Piggott, 2005). Therefore, many different molecules can act as danger signals to indicate 
whether or not an antigen is dangerous to the body. To recognise these signals, dendritic cells express 
multiple receptors including P2 receptors for nucleotides, TLRs and cytokine receptors (Matzinger,
2002).
Evidence that danger signals are vital for dendritic cell maturation has been shown by exposing 
immature monocyte-derived dendritic cells (moDCs) which had not been activated by danger signals 
previously, to necrotic cells which led to an increase in the maturation markers CD80, CD8 6 , HLA 
(human leukocyte antigen; the human MHC molecule) and CD40 on the dendritic cell, indicating the 
maturation and potential T cell stimulatory capacity of these mature dendritic cells. Exposure to 
apoptotic cells, on the other hand had no effect on the DCs, indicating that a substance from the 
necrotic cells caused DC maturation, and this substance is, therefore acting as a danger signal (Sauter 
& Albert, 2000). Activation of T cells by mature DCs results in clonal expansion of the T cell, to 
produce effector cells which are released into the blood and eradicate invading organisms. These 
effector cells are either T helper 1 (Thl) cells (CD4+ cells which activate cytotoxic T cells), T helper 2 
(Th2) cells (CD4+ cells which activate B cell responses) or in the case of viral infection, CD8 + cytotoxic T 
cells which eliminate virus infected cells directly (Parkin et al., 2001).
The danger model explains the gaps in the self/non-self model, in that it explains why a healthy foetus 
is not rejected, as although the antigens from the foetus are 'foreign', the foetus is healthy so not 
releasing danger signals; and why mutated tumour cells are only rejected once the tumour causes 
damage to surrounding tissues causing danger signals to be released. It can also explain why
transplants are rejected, as they cannot be performed without some ischemia to the tissue, and 
surgery which causes tissue damage to the patient, releasing danger signals and activating the 
immune system (Matzinger, 2002).
Therefore, it is clear that the study of danger signals is vital for the development of future 
pharmacotherapies for numerous immune diseases ranging from asthma and allergies, where 
immune responses occur to innocuous antigens, to autoimmunity where danger signals activating 
dendritic cells may cause immune reactions against the body's own tissues (Gallucci et al., 2001). The 
ability to block danger signals or to manipulate them would be a vital tool in our fight against disease. 
For example, injecting a tumour with danger signals, or causing it repeated damage could activate the 
immune system to clear the tumour without the need for cytotoxic drugs. This was demonstrated in 
1898 by Coley, who found that virus-infected tumours were able to evoke an immune response in the 
body, while similar uninfected tumours could not (Coley, 1898). Also, current immunosuppressant 
treatments for transplants act by blocking signal one (MHOTCR interaction). This prevents the patient 
from becoming tolerant to the antigen and therefore must be taken for life. However, if signal two 
(co-stimulation) was blocked, the APC could become tolerant to the new tissue, and drugs would only 
be required for a few months post-surgery (Matzinger, 1994). This has been shown by the 
simultaneous blockade of CD40 and CD28 in the MHOTCR complex, which prevented clonal 
expansion of T cells promoting long term skin graft survival in mice (Larsen et al., 1996), and by the 
injection of monoclonal antibodies against both CD80 and CD8 6  in mice which suppressed the T cell 
proliferative responses to allogeneic pancreatic islet transplantation (Lenschow et al., 1995). It is clear 
from these early studies that researching the events surrounding danger signal activation of DCs is 
vital.
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1.2. Dendritic cells
Dendritic cells (DCs) were first identified by Steinman in 1973 who observed a population of adherent 
cells from mouse spleen with properties distinct from mononuclear phagocytes, granulocytes and 
lymphocytes (Steinman & Cohn, 1973). They were named DCs due to their cytoplasm being arranged 
in pseudopods of various width, length and number producing a dendritic or stellate shape. DCs are 
large cells containing dense granules, with a large nucleus and were observed to constantly extend 
and retract their dendrites in culture (Steinman et al., 1973). The main properties of these cells noted 
by Steinman were that they survive only 12—16 hours in cytokine-free media and they do not express 
lymphocyte markers (Steinman & Cohn, 1974a). Irradiation of mice reduced the number of spleen 
DCs, but adoptive transfer of bone marrow into these mice caused the DCs to recover within 1-2 
weeks, indicating that DCs originate from precursors in the bone marrow (Steinman et al., 1974b). 
Since their discovery, DCs have been found to be important cells in initiating the immune response, 
and they continue to be studied in depth. DCs are derived from CD34+ haematopoietic progenitor 
cells in the bone marrow (Galy et al., 1995). Progenitor cells produce circulating DC precursors that 
home to the blood and tissues, where they differentiate into specific dendritic cell subsets (Sato & 
Fujita, 2007).
Dendritic cells are the main APCs of the immune system (Rossi & Young, 2005). An APC is an immune 
cell that is capable of phagocytosing an antigen, processing it, and presenting it on the cell surface 
bound to a MHC molecule which can be presented to T cells. These include monocytes, macrophages, 
and most importantly DCs (Savina & Amigorena, 2007).
There are multiple subsets of DCs, not all of which are fully characterised and understood. The main 
subsets of interest include myeloid DCs (mDC; myeloid refers to any cell that is not a lymphocyte and 
originates in the bone marrow) which are found in the blood and tissues, make up approximately 1 %
of peripheral blood mononuclear cells, and respond to extracellular pathogens including bacteria; 
plasmacytoid DCs (pDC; plasmacytoid refers to their shape being plasma cell-like) which are also 
found in the blood and tissues, make up 0.3% of peripheral blood mononuclear cells and respond to 
intracellular pathogens including viruses; Langerhans's cells (named after their discoverer) which are 
found in all layers of the skin and function to protect against pathogens entering the body via this 
route (Kimber et al., 1998; Sato et al., 2007). In the laboratory, the main type of DC studied are 
monocyte-derived DCs which are cultured from CD14+monocytes isolated from peripheral blood and 
cultured for 7-9 days with granulocyte-macrophage colony stimulating factor (GM-CSF) and 
interleukin-4 (IL-4) which induces monocyte differentiation into DCs. DCs produced by this technique 
have the same phenotype and morphology as mDCs, can stimulate T cells, release similar cytokines as 
mDCs, and monocytes are easier to isolate from blood with high yields (Sallusto & Lanzavecchia, 
1994). The use of moDCs counteracts the problems of very low yields of mDCs that can be isolated 
(due to 1% peripheral blood mononuclear cells being mDCs), however inherently the phenotype of 
moDCs may not be exactly the same as mDCs due to their different lineages.
Immature DCs (which have not been activated by an antigen/danger signal) are located specifically at 
the sites of pathogen entry to the body, allowing all antigens that enter the body to be captured and 
presented to lymphocytes. DCs are, therefore, found lining the respiratory tract, gastrointestinal tract 
and genitourinary tract where they function as sentinels, constantly extending dendrites into the 
lumen of the tract and the extracellular space to phagocytose antigens or pathogens present 
(Steinman & Banchereau, 2007). DC turnover in the tissues can be rapid with a half-life of two days 
due to their constant trafficking to the lymph node to present antigens to T cells. In the lymph node 
they have a half-life of two days before cell death (Steinman et al., 2003).
DCs are also located in the thymus. Here they are involved in deleting self-reactive T lymphocytes by 
taking up antigen from apoptotic cells and presenting it to naïve T cells without the presence of a co­
stimulatory signal. This induces tolerance to the antigen so that an unwanted immune response does 
not occur (Steinman et al., 2003).
DCs are highly phagocytic, due to the need to take up and present antigen to T cells, and they express 
multiple receptors for phagocytosis catering for a wide range of molecules. These receptors include C- 
type (calcium dependent) lectins that recognise mannosyl residues on pathogens, and FCy receptors 
that recognise immune complexes such as opsonised bacteria (Steinman & Hemmi, 2006). These 
receptors ensure that all encountered antigens are phagocytosed and presented to lymphocytes to 
either induce an immune response, or induce tolerance to that antigen. While immature DCs are 
highly phagocytic, mature DCs lose this ability to phagocytose indicating a change in cell function after 
maturation (Sauter et al., 2000). Once phagocytosed, an antigen is processed and binds to an MHC 
molecule which is then presented as a complex on the cell surface (as shown in figure 1.1). DCs retain 
the MHC:antigen complex for more than 100 hours, which allows time for migration to the lymph 
node and presentation of antigen to lymphocytes. This is a longer time than other APCs indicating the 
importance of DCs in the induction of the immune response (Moser & Murphy, 2000).
As mentioned previously, for an immune response to occur, two signals are required to activate a 
lymphocyte. Signal one is the MHC:TCR complex, and signal two provides co-stimulation (Matzinger,
2002). Signal two is induced by danger signals binding to their receptors on DCs. The type of danger 
signal received also determines the type of immune response induced. There are three main T cells 
which produce an immune response. Viral infection leads to the activation of CD8 + T cells by pDCs, 
which bind to the target cell expressing the antigen of interest, and release perforins which cause cell 
lysis, and granzymes which induce caspase activation to cause apoptosis of the infected cell. CD4+ T
cell responses can be divided into T h l and Th2 responses. T h l responses, such as those that are 
produced by LPS, are aimed at extracellular pathogens and are cell-mediated. T h l cells secrete IL-2, 
which induces T cell proliferation, and the secretion of IL-12 and interferon-y (IFNy) which activate 
macrophages to phagocytose bacteria (Chen, 2006). Th2 responses are antibody-mediated responses, 
as Th2 cells secrete IL-4, IL-5 and IL-10 which aid B cell proliferation, antibody class switching from 
immunoglobulin M (IgM) to IgG, IgE or IgA responses, and eosinophil growth (as shown in table 1.1). 
This type of response is aimed at some bacteria, multicellular parasites and helminths, and is also 
involved in autoimmune responses and in asthma (Parkin et al., 2001).
1.3. Purinergic receptors and ATP
Evidence suggests that extracellular nucleotides act as danger signals on DCs. Nucleotides are purines 
or pyrimidines that are important in many cellular functions, including energy release, and as 
neurotransmitters (Burnstock, 2007).
The concept of purines as extracellular signalling molecules was instigated by Drury and Szent-Gyorgyi 
in 1929, who showed that adenosine and adenosine ^monophosphate (AMP) extracted from heart 
muscle had pronounced biological effects including heart block, arterial dilatation, lowered blood 
pressure and inhibition of intestinal contraction (Drury & Szent-Gyorgyi, 1929). Since this time, work 
on ATP has continued, leading to Burnstock in 1972 suggesting that ATP is a neurotransmitter 
(Burnstock, 1972) and in 1978 proposing distinct receptors for adenosine and nucleotides (Burnstock, 
1978). Burnstock proposed that PI receptors recognise adenosine, and P2 receptors recognise 
nucleotides. This nomenclature is now accepted by the International Union of Basic and Clinical 
Pharmacology (IUPHAR) (Abbracchio et al., 2006). Burnstock also proposed that PI and P2 receptors 
mediate the physiological effects of these compounds including in secretory exocrine and endocrine 
cells, and as co-transmitters in the central and peripheral nervous systems (Abbracchio & Burnstock,
1998). Burnstock suggested rules of classification into PI and P2 receptors. These were: 1) Relative 
potencies for ATP, adenosine 5'diphosphate (ADP), AMP and adenosine. 2) Selective actions of 
antagonists -  methylxanthines which antagonise adenosine, not ATP. 3) Modulation of adenylate 
cyclase with resultant changes in intracellular cAMP levels by adenosine, not ATP. 4) Induction of 
prostaglandin E synthesis by ATP but not adenosine (Burnstock, 1978).
Since this initial work, 19 purinergic receptors have been cloned, and a number of receptors were 
proposed, but discounted due to their identification as other receptor types (as reviewed in 
Abbracchio et al., 1998). It was also noted that there are two main types of P2 receptors, originally 
described due to their vasodilatation or vasoconstriction properties, but later distinguishable from 
their structure and electrophysiological properties. These are fast ionotropic P2X receptors, and slow 
metabotropic P2Y receptors (Ralevic & Burnstock, 1998).
1.4. Adenosine 5'triphosphate
ATP belongs to the purine family, and is made of an adenine base, a ribose sugar, and a chain of three 
phosphates (for chemical structure see Fig. 1.2). ATP is the main energy source in all cells, where it is 
produced in mitochondria by oxidative phosphorylation. ATP is then broken down by hydrolysis of its 
high energy phosphate bonds, releasing energy that is used for cellular processes (Bodin & Burnstock, 
2001). ATP is stored within areas of the cytoplasm, where its concentration ranges between 150 and 
1000 pM (Abbracchio et al., 2006). ATP is a small solute of 650 Daltons (Da) and has 2 to 4 negative 
charges depending on the pH and Ca2+ and Mg2+ ion concentrations of the microenvironment. This 
means it cannot enter or exit cells without a specific transporter -  exocytosis during 
neurotransmission; release from cells during damage and necrosis (Burnstock, 2006a). In the 
extracellular space, ATP is readily diffusible, and has a resting concentration of 0.5-10 nM (Abbracchio 
et al., 2006). Levels of ATP in the extracellular space are controlled tightly by a balance between ATP
release from cells, catabolism and inter-conversion of nucleotides, and nucleotide breakdown by 
ecto-nucleotidases (Abbracchio et a i, 1998).
Nucleotide release can occur via numerous mechanisms. In neurones, mast cells and platelets, ATP is 
released from vesicles in response to stimuli (Bodin et a i, 2001). ATP-binding cassette transporters 
are found on many cell types and form transmembrane pumps which transport ATP as well as amino 
acids and other molecules across the cell membrane. Cell lysis of damaged or apoptotic cells causes 
the release of all cellular contents into the extracellular space, including ATP (Bodin et a i, 2001). In 
1984, Born and Kratzer showed that puncture of rat and rabbit artery, or incisions of human skin 
causes the release of ATP from damaged cells, indicating a major source of ATP (Born & Kratzer,
1984). Mechanical stimulation can cause ATP release from cells, such as in the bladder, where bladder 
distension causes ATP release which acts at P2X3 receptors on sensory nerves to control bladder 
volume (Lazarowski et a i, 2003). There are multiple other mechanisms in which ATP can be released, 
not all of which are completely understood. Once in the extracellular space, ATP binds to P2 receptors 
found on multiple cell types where it has varying effects.
1.5. P2 receptors
P2 receptors bind purine nucleotides including ATP, ADP, uridine 5'triphosphate (UTP), uridine 
5'diphosphate (UDP), and the sugars UDP-glucose, and UDP-galactose (Burnstock, 2006b). They are 
divided into P2Y G protein coupled receptors, and P2X ligand-gated ion channels.
1.5.1. P2Y receptors
P2Y receptors are G protein-coupled receptors, of which there are 8  types -  P2Yi, 2,4, e, n, 12, is, 14. P2Y 
receptors have seven membrane spanning domains with short extracellular N and C termini. P2Y 
receptors are 328-379 amino acids in length, and have molecular weights of 41-53 kDa after
glycosylation. Table 1.2 shows the properties of P2Y receptors including their functions, most 
commonly used agonists and antagonists, and locations in the body. In immune cells, low doses of 
ATP (10 pM) cause rapid, short increases in intracellular calcium from intracellular stores, likely to be 
due to activation of P2Y receptors (Berchtold et al., 1999). As can be seen in table 1.2, P2Y receptors 
couple to various G proteins. Activation of G a q/n  results in the activation of phospholipase C (PLC), 
which hydrolyses phosphatidylinositol 4, 5-bisphosphate (PIP2) to form diacylglycerol (DAG) and 
inositol triphosphate (IP3) which increases intracellular calcium. DAG also activates protein kinase C 
(PKC) which activates proteins inside the cell. Activation of Gj/0 inhibits adenylate cyclase activity 
leading to reduced cyclic AMP (cAMP) production which reduces protein kinase A (PKA) activity. This 
results in reduced phosphorylation of target proteins. P2Yn couples to Gq which activates PLC leading 
to an increase in intracellular calcium, as well as to Gs which activates adenylate cyclase, increasing 
target protein phosphorylation (Abbracchio et al., 2006).
1.5.2. P2X receptors
P2X receptors are nucleotide-gated ion channels, of which there are 7 types -  P2X1, 2, 3, 4, 5, 6 , 7. 
They range from 379 to 595 amino acids in length. P2X receptors consist of two transmembrane 
domains separated by a bulky cysteine-rich extracellular loop containing six glycosylation sites and 
they are thought to be trimeric (North, 2002). ATP binds to the extracellular loop which evokes a 
conformational change in the structure of the ion channel resulting in the opening of the pore. This 
allows Na+ and Ca2+ into the cell, depolarising the cell membrane and activating Ca2+-sensitive 
intracellular processes. The P2X receptors show varying opening times (ms to longer) which 
determine the cellular effects induced (Girdler & Khakh, 2004). Properties of P2X receptors can be 
seen in table 1.3, including their functions, most commonly used agonists and antagonists, and 
locations in the body. Activation of immune cells by high doses of ATP (100-1000 pM) caused
prolonged increases in calcium due to extracellular sources (Berchtold et al., 1999). This is likely to be 
due to P2X receptor activation.
P2X7 is an important receptor as it mediates cell death via apoptosis. It is found on many cell types, 
principally immune cells, where high concentrations of ATP are cytotoxic and thus lead to cell death. 
This may also play a role in thymic T cell selection, in brain remodelling following trauma and 
ischemia, in cancer and in autoimmunity (Abbracchio et al., 2006). ATP acting on P2X7 is a potent 
stimulus for the release of IL-1(3 from DCs, however it cannot cause this alone, as a bacterial product 
must first initiate the transcription of the IL-1(3 gene, leading to cytoplasmic accumulation of pro-IL-lp 
which, due to ATP is matured and released (Koeppen et al., 2011).
As well as the homomeric receptors shown in table 1.3, P2X receptors can form heteromeric 
receptors such as the P2X2/3 receptor found on sensory nerve terminals. The P2Xl/5receptor, P2X4/6 
receptor and P2X2/6 receptor have been identified by co-expressing them in xenopus oocytes, and it 
is believed that they are endogenous. However, these receptors prove difficult to study as they 
display properties of the individual receptors making it difficult to identify and analyse them (North,
2002 ).
The study of P2X and P2Y receptors in complicated by their formation of heterodimers and 
heterotrimers, and due to the overlapping of receptor agonists. This also makes the creation of 
specific agonists and antagonists difficult, as most molecules tested show promiscuity, affecting 
multiple receptors, or multiple enzymes involved in the control of nucleotide levels in the 
extracellular space (Jacobson et al., 2009).
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1.6. PI receptors
Adenosine is a nucleoside that has multiple roles within the body. It binds to PI receptors, of which 
there are four types -  A i, A 2a, A2b, and A3 which are G protein-coupled receptors (Abbracchio &
Ceruti, 2007). The A i receptor couples to G i/o, the A2A receptor couples to Gs, the A2B receptor couples 
to Gs and can also couple to Gq, and the A3 receptor couples to Gi/0. As with nucleotides, 
concentrations of adenosine in the extracellular space increase under cell stress and inflammation, 
both due to its release from cells and due to its formation from the breakdown of extracellular 
adenine nucleotides (Kumar & Sharma, 2009). Adenosine is anti-inflammatory and promotes tissue 
protection and repair via the modulation of the production and release of pro-inflammatory cytokines 
(Abbracchio et al., 2007). When studying the purinergic receptors care must be taken to account for 
the effects of adenosine as well as nucleotides, as adenine nucleotides are broken down to adenosine 
as described below.
1.7. Ecto-nucleotidases
Ecto-nucleotidases are enzymes that hydrolyse extracellular nucleotides to generate other 
nucleotides or nucleosides that activate adenosine receptors (Dwyer et al. 2007). During the resting 
state, ecto-nucleotidases are involved in keeping extracellular levels of ATP low, as small amounts 
may be secreted from cells or neurones. Therefore they are vital in preventing receptor 
desensitisation (Mizumoto et a i, 2002).
There are multiple families of ecto-nucleotidases which are involved in this process. The main family 
of interest in the immune system is the E-NTDPase family (ecto-nucleotide 5'triphosphate 
diphosphohydrolases). This is a family of 8  enzymes (E-NTDPase 1-8) that are found either on the cell 
surface (1, 2, 3 and 8 ), intracellular and secreted (5 and 6 ), or intracellular and not secreted (4 and 7) 
(Yegutkin, 2008). They hydrolyse ATP and ADP to form AMP (Zimmermann, 2000). E-NTDPase 1 is
more commonly known as CD39 and is found on all immune cells. It is vital for purinergic signalling, as 
shown in CD39 null mice that have suppressed IgG responses to antigens and impaired B cell memory 
responses, indicating that CD39 contributes to the affinity maturation of antibodies and facilitates B 
cell differentiation (Dwyer et al., 2007). Other enzymes involved in the breakdown of ATP include the 
E-NPP family, consisting of three members that have alkaline phosphodiesterase and nucleotide 
pyrophosphatase activity, and so hydrolyse ATP to AMP (Zimmermann, 2000).
CD73 is another vital ecto-5'nucleotidase in the immune system that converts AMP to adenosine 
(Zimmermann, 2000). It is often used as a maturation marker for T and B cells due to its expression on 
these cells and it is also found on T regulatory cells, indicating a role for these cells in the dampening 
of the immune response (Deaglio et al., 2007). The result of nucleotide breakdown by CD39 and CD73 
is the accumulation of adenosine in the extracellular space. Adenosine is considered to be anti­
inflammatory, so this is beneficial in reducing the severity of the immune response to nucleotides 
(Cristalli et al., 2001). CD39 and CD73 on epithelial cells can be inhibited in vitro by cell activation, 
which delays the hydrolysis of ATP. This results in the prolongation of the effect of ATP on immune 
cells, thus promoting an immune response (Robson et al., 1997; Kalsi et al., 2002)
As well as enzymes that break down nucleotides, enzymes that convert them to other forms are also 
found in the extracellular space, and are important in receptor activation. These include adenylate 
kinase which catalyses reversible phosphoryl transfers, such as converting ATP and AMP to two ADP 
molecules, or adenosine kinase which converts adenosine to AMP thus controlling adenosine levels 
in the extracellular space (Bours et al., 2006). However, adenosine can also be removed from the 
extracellular space via adenosine deaminase, which breaks adenosine down to inosine. This enzyme 
has wide expression including on lymphocytes and DCs where it acts to stop DCs from being 
suppressed by adenosine (Yegutkin, 2008). Deficiencies in adenosine deaminase lead to severe
combined immunodeficiency syndrome, where reduced T and B cell numbers leads to increased risk 
of infection and immune suppression (Bours et al., 2006).
It is also important for cells to take up adenosine from the extracellular space to prevent receptor 
desensitisation and for nucleotide biosynthesis. The SLC28 family consisting of concentrative 
nucleoside transporters 1-3 (CNT), transport nucleosides back into the cell, while the SLC29 family 
consisting of equilibrative nucleoside transporters 1-4 (ENT), plays a similar role (Baldwin et al., 2004; 
Gray et al., 2004). These molecules are especially important in the lung, where ATP is secreted by 
epithelial cells and is involved in the regulation of mucociliary clearance, which means that the 
breakdown products of ATP must be removed by cells in order to control this response (Lazarowski et 
al., 2 0 1 1 ).
It can be seen, therefore, that enzymes that control nucleotide and nucleoside levels control 
purinergic signalling. In the resting state the degrading enzymes dominate as there is not enough 
substrate for the regenerating enzymes, although this changes during inflammation (Yegutkin 2008).
1.8. P2 receptors and dendritic cells
Due to the importance of DCs in the immune system, and the identification of P2 receptors on DCs, 
there has been much interest in the role of extracellular nucleotides, specifically ATP on DCs. 
Immature moDCs show spontaneous oscillations in Ca2+ concentration within the cell, which appears 
to be due to IP3 mediated release of calcium from intracellular stores and from the influx of calcium 
across the plasma membrane. Although it is not clear exactly what effect this has, it appears to 
regulate the activation of the transcription factor nuclear factor of activated T cells (NFAT) which 
keeps the cell in an immature state (Vukcevic et al., 2010). On the maturation of DCs, these 
oscillations are lost, although the mechanisms behind this are unclear. This has been shown with 
Escherichia coll, which causes an increase in calcium concentration in the cell. This increase in
intracellular calcium concentration causes the exocytosis of secretary vesicles containing cytokines 
such as IL-1|3, as well as downstream effects on transcription factors that result in changes to marker 
expression of the cell surface, and cytokine production (Shumilina et al., 2011). This has also been 
shown with LPS which binds to TLR-4 and requires CD14 signalling to activate the transcription factor 
NFkB which regulates pro-inflammatory gene transcription leading to DC maturation (Bohnenkamp et 
al., 2007). Activation of P2 receptors causes changes in intracellular calcium concentrations, which 
may lead to similar effects on their maturation state.
To determine the effect of extracellular nucleotides on DCs, most of the studies carried out have 
focused on using moDCs. However, caution must be taken when analysing data from this cell type as 
it is not clear whether these cells are the same as mDCs (Zhou & Tedder, 1996). The studies reviewed 
in the following section all use moDCs.
1.9. Expression of P2 receptors on dendritic cells
moDCs express messenger ribonucleic acid (mRNA) for P2X1 4,s,i receptors and P2Yi,2,4, e, n  receptors 
regardless of their maturation state (Berchtold et al., 1999; Zhang et al., 2002). They also express 
P2 Yi4 mRNA while immature, but not when mature (Skelton et al., 2003). While these groups did not- 
test for mRNA of P2X2; 3j6 and P2Yi2, 13, it is possible that dendritic cells also express these receptors.
Mice deficient in both the P2Yi and P2Y2 receptors (double knockouts) showed no survival to lung 
infection with Pseudomonas aeruginosa, whereas 85% of wild type mice survived. This indicates a 
crucial role for P2 receptors in immunity against various pathogens (Geary et al., 2005).
1.10. Does ATP act as a danger signal in monocyte derived dendritic cells?
Multiple groups have attempted to provide evidence as to whether extracellular nucleotides, 
specifically ATP, act as danger signals on DCs. Some of the measures used to explore this are the
expression of co-stimulatory markers on moDCs, analysis of cytokine release from moDCs, and the 
capacity of moDCs to stimulate T cell proliferation. These will be discussed below.
1.10.1. Co-stimulatory marker expression on moDCs
The main action of a danger signal is to cause a DC to mature, thus up-regulating co-stimulatory 
markers on the cell surface. It is known that LPS, which activates TLR 4 and acts as a danger signal, up- 
regulates CD80, CD83, CD8 6 , HLA-DR (human MHC II) and CD54 (ICAM-1) on moDCs (Corinti eto i ,  
2001). LPS can, therefore, be used as a positive control to compare to the effects of nucleotides. Table 
1.4 indicates the effects of incubating nucleotides with moDCs and measuring maturation markers by 
flow cytometry. These experiments show that ATP at varying concentrations caused an increase in the 
cell surface expression of the co-stimulatory markers HLA-DR, CD80, CD83, CD8 6  and CD54 on moDCs, 
and the authors suggest that this indicates that ATP has caused the cells to undergo maturation as 
they are expressing co-stimulatory molecules so are able to activate lymphocytes. Nonetheless there 
are a number of discrepancies between these experiments. A variety of moDC isolation protocols 
have been used which could affect results. The first is incubating adherent peripheral blood 
mononuclear cells with GM-CSF and IL-4 to differentiate moDCs (Berchtold et al., 1999; Schnurr et al., 
2000; Wilkin et al., 2001; Marteau et al., 2004). One problem with this method is that cells other than 
monocytes adhere to plastic, including macrophages and B cells. This means that contamination of 
the monocyte/DC population may occur affecting the microenvironment in culture, thus altering 
results. The second protocol is CD14+ cell isolation, where CD14+ monocytes are isolated using 
magnetic separation, then incubated with GM-CSF and IL-4 to differentiate them into moDCs. This 
ensures that 95% of isolated cells are monocytes, so that once differentiated the majority of cells are 
moDCs (la Sala et al., 2001; la Sala, 2002). This is a more reliable method of isolation, and comparison 
between the two protocols may be misleading.
Another limitation to these studies is that there is a lack of statistical analysis performed on the 
results. For example, in one study, the mean fluorescence values of CD80, CD83 and CD8 6  increase by 
10% from 5% expression in control samples, to 15% expression in ATP treated moDCs (Berchtold et 
al., 1999). However it is unclear whether this increase in expression is a significant result, and how 
many cells are expressing this marker, which can be interpreted from the flow cytometry results. This 
leads to doubts as to the reliability of the claims made by the authors that these markers are 
increasing, as statistical significance may not be reached. Another limitation to these studies is that 
only 'one representative experiment' from five experiments is shown. It is possible that the 
'representative experiment' may not represent the results of multiple subjects, indicating that this n 
number is not sufficient to back up the results presented. Due to a wide genetic pool in humans, it is 
important to account for baseline variations in results, meaning that one subject's response may not 
reflect that of others.
None of these published studies provide statistically conclusive evidence of the effect of ATP and LPS 
on moDCs, although an indication of the effects can be seen. A more thorough statistical analysis of 
the results is required to provide convincing evidence of an effect.
1.10.2. Mobilisation of intracellular calcium by nucleotides in moDCs
Another indicator that a molecule acts as a danger signal is that it mobilises intracellular calcium by 
activating its receptor. Low concentrations of ATP (10 pM) caused a rapid, short increase in cytosolic 
calcium from intracellular calcium stores in immature moDCs (Liu et al., 1999; Idzko et al., 2002). A 
similar calcium increase occurred in moDCs matured with cytokines (Berchtold et al., 1999). Higher 
concentrations of ATP (100-1000 pM) cause a prolonged peak in calcium concentration which was 
due to the influx of extracellular calcium, shown by the fact that a calcium chelator blocked the 
increase in calcium concentration (Berchtold etal., 1999).
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Other nucleotides including UTP and UDP-glucose also caused calcium mobilisation in immature 
moDCs, indicating that multiple P2 receptors are functional on moDCs (Liu et al., 1999; Skelton et al.,
2003). These results indicate that nucleotides activate receptors on moDCs, however it is impossible 
at this stage to identify which receptors are responsible.
1.10.3. Cytokine release by nucleotide stimulated moDCs
Once a DC has matured due to danger signal activation, it releases cytokines. The specific cytokines 
released will determine the immune response produced, by dictating the type of T cells that are 
activated, and other cellular events (Ferrari et al., 2000)
As shown in table 1.5, multiple groups have studied this response in moDCs. Conflicting results are 
seen as regard to IL-12 release from moDCs. IL-12 is a Th l promoting cytokine, that consists of two 
subunits -  p40 and p35 which make up the p70 molecule which activates the IL-12 receptor (Cooper 
et al., 2007). LPS increased both p40 and p70 subunits on moDCs, which would lead to a T h l cell 
mediated immune response (la Sala et al., 2001; Wilkin et al., 2001; Marteau et al., 2004). At high 
concentrations (1 mM), ATP increased IL-12 release by moDCs, but at lower concentrations (50-500 
pM) while one group showed an increase in IL-12 release (Schnurr et al., 2000), another showed no 
effect (Marteau et al., 2004). ATPyS caused a similar effect to ATP indicating that its breakdown 
products are not responsible for this effect, as ATPyS is a non-hydrolysable analogue of ATP. When 
used in combination with LPS, 1 mM ATP further increased IL-12, but at low concentrations ATP either 
inhibited IL-12 or no effect was seen. As with the flow cytometry experiments, these results are 
conflicting due to the lack of statistical analysis of results. It is therefore unclear whether these 
results represent the mean of multiple subjects, or a specific response in one subject and a solid 
conclusion cannot be drawn due to human variation.
{ 42 )
IL-10 release has been studied by La Sala et al. (2001), who showed that LPS induced a low nM release 
of IL-10, while ATP alone had no effect, and in combination with LPS, ATP caused no change in its 
release. Another group showed that ATPyS acted in synergy with LPS to further increase IL-10 release 
(Marteau et al., 2004). IL-10 is an anti-inflammatory, B cell promoting cytokine. The action of ATPyS 
suggests that the P2Yu receptor may be involved in this response as ATPyS is its most potent agonist, 
although it also acts on other receptor subtypes so this is not a clear conclusion. Again there is a lack 
of statistical support of this data.
One group also studied further cytokines, showing that ATP inhibited LPS induced tumour necrosis 
factor a (TNFa), IL- 6  and IL-1(3 release (la Sala et al., 2001). Again no statistics were performed on the 
data, but these data suggest that ATP may be inhibitory to T h l cytokines and favour a Th2 response.
A specific P2Yn agonist NF546 has been shown to stimulate IL- 8  release by moDCs, but not IL-12p70 
which indicates that this receptor may not be responsible for the all cytokines released by moDCs 
(Meis et al., 2010).
1.10.4. ATP as a chemoattractant for monocyte derived dendritic cells
Immune cell migration is tightly controlled by chemokines which are secreted proteins of 8-10 kDa 
that are produced by cells and recruit immune cells along a concentration gradient in the extracellular 
space (Janetopoulos & Firtel, 2008). There are four groups of chemokines, named based on the 
position of their first two cysteines -  C, CC, CXC and CX3C. Chemokine receptors are G protein coupled 
receptors, and are found on the cell surface of immune cells (Myrtek & Idzko, 2007). Other molecules 
including danger signals can act in a similar way to chemokines but on different receptors, and recruit 
immune cells to the site of infection. ATP may act as a chemoattractant on immature DC, as it caused 
actin polymerisation and the reorientation of dendrites in immature moDCs and cells migrated 
towards the high ATP gradient (Liu et al., 1999).
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Mature DCs lose this ability to migrate towards ATP, indicating that cells are attracted to the site of 
inflammation where there is a high concentration of ATP present, but once a DC matures it loses the 
attraction to ATP so that it can migrate away from the high ATP gradient to the lymph node (Idzko et 
al., 2002). Other nucleotides including ADP and UTP are also capable of acting as chemokines for 
moDCs, indicating that multiple P2 receptors are involved in this process (Liu et al., 1999).
Immature DCs migrate towards chemokine receptor type 5 (CCR5) ligands, which are present at the 
inflammatory site, but do not migrate towards the CCR7 ligands chemokine ligand 19 (CCL19) and 
CCL21 which are present at the lymph node. This induces the attraction of immature moDCs to the 
site of infection, however mature DCs migrate towards the CCR7 ligands allowing their entry to the 
lymph node (Marsland et al., 2005). ATP-matured DCs lose their ability to migrate to CCR5 ligands, 
and instead gain the ability to migrate towards CCR7 ligands. This is also the case with LPS-matured 
DCs, indicating that the cells are mature. DCs are therefore able to migrate away from the site of 
inflammation once matured and are able to migrate towards the lymph node for T cell presentation 
(Idzko et al., 2002; Schnurr et al., 2003).
1.10.5. Uptake of antigen by moDCs
Another process which is modified during DC maturation is the ability to take up antigen. Immature 
DCs phagocytose antigen, whereas mature-DCs are no longer able to do this. As can be seen in table
1.6, DCs matured with ATP show reduced capacity to take up bovine serum albumin (BSA) over time, 
which is the same effect as LPS-matured DCs indicating that maturation has occurred (la Sala et al., 
2001). This was confirmed by incubation of moDCs with ATPyS for 48 hours, producing an initial 
increase in d ext ran uptake, but over 48 hours this decreased and this was suggested to be due to the 
maturation of DCs (Schnurr et al., 2000).
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1.10.6. Activation of T cells by ATP-matured monocyte derived dendritic cells
Once a DC is matured, it enters the lymph node and migrates to the T cell zone where it presents its 
MHC:antigen complex to naïve T cells. Once the T cell with the corresponding TCR binds to the DC, 
antigen recognition occurs (Parkin et al., 2001). As mentioned earlier, if the DC is not fully matured, 
co-stimulation will not be provided, and the T cell will not become activated (see figure 1.1). Once 
activated, the naïve T cell will mature, and undergo clonal expansion and proliferation, producing 
multiple copies of itself, so that the cells can migrate back to the infected area and recognise the 
antigen to mount an immune response (Parkin et al., 2001). Therefore, another property of a danger 
signal is to induce DCs to cause T cell activation and proliferation. As shown in table 1.6, LPS-matured 
DCs induced a statistically significant increase in the proliferation of T cells, which is mirrored by ATP- 
matured DCs, and the two act in synergy together to further increase this effect (Schnurr et al., 2000; 
la Sala et al., 2001). Conversely another group disagreed with these results, showing that ATP- 
matured DCs decreased the proliferation of CD3+, CD4+ and CD8 + T cells compared to control 
(Marteau et al., 2004). It is unclear why there is a discrepancy in these results, however it could be 
due to different concentrations of ATP being used, or due to differing protocols. Further study may 
be required to confirm this result.
1.10.7. Adenosine receptors and moDCs
Care must be taken when analysing the effect of nucleotides on moDCs, as they are rapidly broken 
down to adenosine (Abbracchio et al., 2007). Adenosine is released from cells under stress, and is also 
formed in the extracellular space by the breakdown of ATP by the enzymes CD73 and CD39 (Kumar et 
al., 2009). Immature moDCs express functional A i and A 3 receptors, and low levels of A 2a receptors; 
while mature moDCs down-regulate A i and A3 receptors and up-regulate A 2a receptors, indicating 
different roles for these receptors in the function of DCs (Panther et al., 2001).
In immature DCs, adenosine caused rapid calcium mobilisation and actin polymerisation via Ai and A3 
receptors, but this response was lost in LPS-matured DCs due to receptor down-regulation. Adenosine 
acts as a chemoattractant to immature DCs, while in LPS-matured DCs it inhibited the production of 
IL-12 and TNFa, and increased IL-10 release, suggesting skewing of the immune response to an anti­
inflammatory Th2 response (Panther et a i, 2001). Adenosine also up-regulated antigen uptake in 
immature DCs, and caused them to mature, up-regulating CD80, CD8 6 , MHC I and HLA in synergy with 
LPS, although the lack of statistics in this study leads to questionable validity of these results (Panther 
et a i, 2003). Overall these studies suggest that adenosine recruits DCs to the site of infection, and 
then inhibits the severity of the immune response by reducing cytokine release.
1.10.8. Conclusion
Overall, these studies suggest that ATP and other nucleotides induce DCs to either mature, or enter a 
state similar to maturation. However the techniques used in these studies vary and the lack of 
statistics in some cases makes studies difficult to interpret. It is widely believed that ATP acts as a 
danger signal, yet complete proof of this is not currently available. Also, the work carried out has 
studied moDCs. Although these cells in appearance resemble mDCs, and act in a similar way, they 
may not be the same as blood-derived mDCs, and so the effects being seen may not represent the 
true effect in the body. These experiments should, therefore be repeated on blood-derived DC 
subsets to confirm these moDC experiments and confirm the theory that ATP acts as a danger signal 
in the immune system.
1.11. Myeloid dendritic cells
mDCs can be isolated directly from human blood using the BDCA-1 (blood dendritic cell antigen-1) 
antibody, a molecule specific for mDCs. There are no studies published thus far indicating the effect of 
ATP on these cells which may be due to the assumption that mDCs are the same cells as moDCs,
however this may not be the case. For example, while mDCs isolated directly from blood were shown 
to express similar co-stimulatory markers to moDCs, mDCs showed an increased activation of tetanus 
toxin specific T cells and a Th l cytokine environment, compared to moDCs which showed a lower T 
cell response (Osugi et al., 2002). This suggests that there are differences between the two cell types, 
and that further study of mDCs is required.
1.12. Plasmacytoid dendritic cells
Plasmacytoid DCs were first identified in 1958 by Lennert and Remmele, who observed cells similar to 
plasma cells but lacking B cell and plasma cell markers that were located in the T cell zone of the 
lymph node (Lennert & Remmele, 1958). They were named T associated plasma cells, which was later 
changed to plasmacytoid T cells. Continuing study of this cell type showed that during viral infection, 
these cells secrete high amounts of IFNcx and IFN(3, and they were identified to be a subset of 
dendritic cell, and thus are now accepted as plasmacytoid DCs (Asselin-Paturel & Trinchieri, 2005). 
They have been identified in the blood, tissues, lymph node and mucosal associated lymphoid tissue 
(Colonna et al., 2004).
pDCs arise from a lymphoid lineage of CD34+CD10+ haematopoietic stem cells, which differs from the 
CD34+CD10" lineage that gives rise to mDCs. The lymphoid stem cells also produce T lymphocytes, B 
cells and NK cells depending on the cytokine stimulation received (Galy et al., 1995). pDCs develop 
fully in the bone marrow, and are released into the blood from which they are recruited to tissues on 
infection (for review see Villadangos & Young, 2008).
pDCs make up around 0.4% of peripheral blood mononuclear cells, so are a very small subset of 
immune cells (Fanning et al., 2006). They have a round morphology, large nucleus and abundant 
endoplasmic reticulum (Asselin-Paturel et al., 2005). When matured using IL-3 and CD40 ligand, they 
take on a more dendritic cell morphology and function (Grouard et al., 1997). pDCs do not express the
extracellular TLRs (TLR 1, 2, 4, 5, 6 ) so do not respond to LPS and other bacterial products, but express 
the intracellular TLRs (TLR 3, 7, 8  and 9). TLR 3 responds to double stranded RNA, TLR 7 responds to 
single stranded RNA, TLR 8  to oligonucleotides, and TLR 9 to CpG rich DNA from bacteria, and viral 
DNA, meaning that pDCs are able to respond to intracellular pathogens including viruses and some 
bacteria (Barchet et al., 2005). TLR activation causes pDCs to release type 1 IFNs (IFNa and IFN(3) of 
which they release around 3-10 pg/cell which is 10-100 fold more than is released by mDCs 
(Fitzgerald-Bocarsly et al., 2008). IFNa/(3 act by enhancing the toxicity of NK cells and CD8 + T cells to 
destroy viral infected cells. pDCs also secrete IL-12 which induces IFNy release by CD8 + T cells to 
promote pathogen clearance (Asselin-Paturel et al., 2005). As with mDCs, pDCs must be activated to 
be able to stimulate T cell proliferation. On maturation, pDCs enhance antigen presentation and up- 
regulate MHC, CD80, CD8 6  and CD40 but to a lesser extent than mDCs (Barchet et al., 2005). This 
means that pDCs are not as effective in antigen capture, processing, and presentation as mDCs, and 
are poor activators of T cells, but on the other hand their role appears to be modulation of the 
immune response at the site of infection, rather than trafficking antigen to the lymph node 
(Villadangos et al., 2008).
pDCs express BDCA-2 and BDCA-4 which are molecules not expressed on other cell types (Dzionek et 
al., 2000). BDCA-2 is a C-type lectin transmembrane glycoprotein of 213 amino acids. It is a signalling 
receptor that may internalise antigen for presentation (Dzionek et al., 2001). BDCA-4 is expressed 
only by CD54+ T cells in tonsils and pDCs and is a vascular endothelial growth factor receptor. It is 
expressed on mDCs and monocytes after 12-24 hours of culture (Dzionek et al., 2002). While anti- 
BDCA-2 antibodies inhibit IFNa/[3 secretion by pDCs, anti-BDCA-4 antibodies do not, therefore this 
receptor is used in their isolation (Colonna et al., 2004).
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pDCs express L-selectin which aids entry to the lymph nodes where they reside in the T cell zone near 
high endothelial venules (Celia et al., 1999). pDCs cluster here during infection and can also be found 
in certain disease locations, such as skin lesions in psoriasis and the nasal mucosa during allergic 
reactions and in the vicinity of tumours (Schnurr et al., 2004). In vitro, pDCs require IL-3 to survive in 
culture (Olweus et al., 1997).
Imidazoquinoline molecules (resiquimod and imiquimod) are potent inducers of IFNa on pDCs. These 
are low molecular weight, synthetic compounds that have broad anti-viral and anti-tumour activity in 
animal models. They act via TLR 7 (Gibson et al., 2002). Resiquimod and imiquimod induce cytokine 
secretion on pDCs, and this is abrogated in TLR 7 knockout mice. Human cultured pDCs produce IFNa 
in response to these molecules, whereas peripheral blood mononuclear cells depleted of pDCs do not 
produce IFNa. They increase survival of pDCs in culture by 20-30%, as does IL-3. Resiquimod also 
increases CD80, CD8 6 , CD40 and CCR7 on pDCs suggesting that it stimulates pDCs to mature (Gibson 
et al., 2002). These molecules can, therefore induce pDC maturation and be used as positive controls 
in their study, in a similar way that LPS is used for mDC.
1.12.1. P2 receptors and plasmacytoid dendritic cells
Immature pDCs express mRNA for P2Y4/ 6, u, is, u  with no detected mRNA for P2Y2, n, while mature 
pDCs down-regulate mRNA for P2Yi2, is, u  but not P2Y4j 6. This resulted in pDCs being sensitive to UDP, 
UTP and UDP-glucose and to a lesser extent ADP and ATP as shown by nucleotide ability to mobilise 
intracellular calcium. ATP, UDP, UTP and UDP-glucose induced the maturation of pDCs by increasing 
the cell surface expression of the co-stimulatory markers CD8 6 , CD83, HLA-DR and CCR7; however no 
statistical analysis was presented to support these results (Shin et al., 2008). Nucleotides alone were 
unable to induce IFNa secretion from pDCs, while ATP, UTP, UDP and UDP-glucose inhibited CpG 
oligodeoxynucleotide (ODN; aTLR 9 agonist)-induced IFNa release indicating a role of nucleotides in
the induction of tolerance to allergen, or in dampening the response against viruses (Shin et al.,
2008).
1.12.2. PI receptors and plasmacytoid dendritic cells
In immature pDCs, adenosine acted as a chemoattractant via the A1 receptor, recruiting pDCs to the 
area of high concentration, but this response is lost in mature pDCs. Adenosine also decreased IL-6 , IL- 
12 and TNFa production to CpG ODN indicating an anti-inflammatory effect, possibly via the Ai 
receptor (Panther et al., 2001).
1.13. P2 receptors on other immune cell subtypes
Other immune cells also express P2 receptors, including mast cells (where they modulate cytokine 
and histamine release), lymphocytes (where they induce mitogenesis), and platelets (where they 
induce platelet aggregation) (for review see Junger, 2011). The presence of P2 receptors on other 
immune cells further complicates the DC story, as extracellular ATP can have effects on other immune 
cells, altering the effects of DCs.
Neutrophils express P2Y^ 2,4, e, n, m and P2X1, 4, 5, 7and release ATP and adenosine on cell activation. 
In neutrophils, ATP stimulates neutrophil adhesion to endothelial cells, mediating their entry to 
inflamed tissues (Bours et al., 2006). ATP is also chemotactic for neutrophils, attracting them to the 
site of infection. ATP stimulates phagocytosis, degranulation and oxidative burst aiding in neutrophil 
mediated killing of pathogens, and delays their apoptosis to ensure cell survival (Bours et al., 2006; 
Kukulski et al., 2009).
Monocytes and macrophages also express P2Y and P2X receptors, expression levels of which change 
depending on cell activation state (Bours et al., 2006). ATP alters cytokine secretion from monocytes 
(Piccini et al., 2008). In murine macrophages, ATP, as well as ADP, UTP and UDP have been shown to
increase phagocytosis of latex beads to varying degrees, and ATP and a,(3-methylene ATP increased 
adhesion of apoptotic but not viable cells to macrophages both in vivo and in vitro. This indicates that 
nucleotides released from apoptotic cells may increase the ability of macrophages to phagocytose 
(Marques-da-Silva et al., 2011). In the thymus, apoptotic T cells secrete ATP, which attracts 
monocytes and macrophages to clear them (Elliott et al., 2009).
1.14. Asthma
Asthma is an inflammatory disease of the respiratory tract, affecting 10% of adults and even more 
children in the western world. In developing countries, the incidence is lower but increasing, either 
due to increased awareness and diagnosis or due to increased disease (Pearce et al., 2007). Asthma 
often first presents in childhood and continues into adult life (Barnes, 2008b). There are varying 
severities of disease, and people respond differently to treatments making it a complicated disease to 
treat (Holgate, 2008).
The lungs are an organ where gas exchange occurs, bringing oxygen into the body and removing 
waste carbon dioxide. The lung has a surface area of 150 m2 and a volume of 350 litres of air per hour 
at rest. This large capacity, and the fragile exchange surface provides a huge challenge to the immune 
system; as well as inhaling air, pollutants, allergens, and pathogens are also inhaled, meaning that a 
strong immune defence is required to protect the body from harm (von Gamier & Nicod, 2009). 
Nonetheless the lungs have multiple mechanisms to protect against infection. The first of these is in 
the upper airways, where the mucosal surface is made of ciliated epithelial cells interspersed with 
goblet cells. The goblet cells provide mucus which is sticky and traps allergens, bacteria and pollutants 
and prevents them from entering the lower, more delicate alveoli (Simpson et al., 2008). Epithelial 
cells lining the upper respiratory tract provide lubrication by activating gated ion channels such as the 
CFTR (cystic fibrosis transmembrane conductance regulator) which transports Cl" ions across the cell
membrane to release water (Okada et al., 2006). They are ciliated, creating a mucociliary escalator 
which traps particulates and transports them to the throat where they can be swallowed (von Gamier 
et al., 2009). ATP is released from epithelial cells and kept at a basal level of 1-10 nM by ecto- 
nucleotidase. ATP at this concentration is able to activate CFTR channels to ensure lubrication occurs, 
but this is below the concentration threshold for P2Y2 receptor activation. However under mechanical 
stress such as heavy breathing and coughing, ATP release is increased to 100-1000 pM which activates 
P2Y2 receptors. This promotes Cl" secretion via calcium activated Cl" channels, which in turn increases 
mucus release and increases ciliary beat frequency, thus aiding increased lung activity (Okada et al., 
2006). This has also been shown in vitro by changes in surface tension caused by air bubbles, which 
caused the dispersion of surfactant over the epithelial surface, flattening the cells and causing ATP 
release (Ramsingh et al., 2011).
The next form of immune protection in the lungs is the dense network of DCs located underneath the 
epithelium. These are mainly mDCs with a few pDCs interspersed (von Gamier et al., 2009). These DCs 
constantly extend their dendrites through the epithelial junction into the lumen of the respiratory 
tract to sample antigens that are present. These antigens are internalised and processed and are 
presented to T cells in the draining lymph nodes (Burchell et al., 2010). There are around 500-1000 
DCs per mm2 of epithelium (Stumbles et al., 2003a). The airway epithelium may also act as a sieve, 
allowing small molecular weight antigens to enter the lymph so that they can access DCs found in the 
lymph node. However, it is not known whether this is sufficient to fully activate DCs (Hammad & 
Lambrecht, 2008). Other immune cells are also found below the epithelium, including macrophages 
which phagocytose and destroy the majority of particulates and pathogens that enter the upper 
respiratory tract, and memory T cells which can activate an immune response if triggered by DCs. The 
cell content of bronchiolar lavage fluid consists of 80% macrophages and 20% DCs and T cells 
indicating the proportions of these cell types found in the upper airways (von Gamier et al., 2009). In
the lower respiratory tract, the lung parenchyma consists of smaller bronchioles, alveoli and a 
vascular supply. DCs are found here lining the bronchioles, and also in the alveolar space along with T 
cells and macrophages. Macrophages phagocytose particulates, while DCs take up any antigens 
present and, depending on the environment induce tolerance or an immune response. W ithout an 
immune response, DCs have a turn-over of two days in the lung due to their constant trafficking to 
the lymph nodes (Holt, 2001). In asthmatics, circulating mDCs are reduced between 3 and 24 hours 
after allergen challenge and start appearing in airways 5-6 hours after allergen challenge indicating 
that mDCs are recruited to the lungs on allergen challenge; however there is no change in pDC levels 
(Farrell et al., 2007).
1.15. Tolerance and sensitisation to inhaled allergen
There is a very complex interaction between mDCs, pDCs, T cells and T regulatory cells (T regs) in the 
lung which determines the immunological outcome of any allergen (for review see Burchell et al., 
2010). In the steady state, mDCs phagocytose, process and present antigen on their surface and 
migrate to the lymph nodes to present to T cells. Nevertheless without signal two (co-stimulation) 
which would indicate danger, no immune response is generated. In fact, tolerance is generated to 
these antigens. For example, immunisation of naïve mice with OVA caused them to become tolerant 
to subsequent immunisation with OVA plus the adjuvant alum, and inhibited an asthmatic reaction 
occurring. Some T cell proliferation occurred, however this was not sufficient to reach the threshold 
required for prolonged survival and they were deleted (Hammad et al., 2008). Tolerance is generated 
to all innocuous allergens in normal subjects.
Tolerance is induced to these allergens due to a number of possible mechanisms. pDCs appear to play 
a major role in inducing tolerance, as injection of Flt3 ligand (which induces pDC differentiation), into 
sensitised mice blocked the features of asthma (Edwan et al., 2004), while the removal of pDCs from
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naïve mice (using the anti-gr-1  antibody) following exposure to a harmless antigen led to the 
development of asthma symptoms (De Heer et al., 2004). It is unclear how pDCs induce tolerance, but 
evidence suggests that this may be due to pDC expression of indoleamine 2,3-dioxygenase which 
inhibits T cell proliferation (Kool et al., 2009).
T regs are also vital in inducing tolerance to inhaled antigen. pDCs may act by inducing T reg 
formation. T regs dampen the immune response by suppressing the function of CD4+ and CD8 + T cells, 
B cells, macrophages and DCs by secreting anti-inflammatory cytokines such as 11-10 (Chen, 2006). 
Depletion of T regs in mice led to DCs becoming mature as shown by an increase in the co-stimulatory 
markers CD80, CD8 6  and MHC II and increased T cell stimulatory capacity. This indicates that T regs 
are vital in preventing DCs from becoming activated to innocuous allergens which may have low 
stimulatory capacity (Lambrecht & Hammad, 2009).
It is clear that IL-10, secreted in low levels by immature DCs suppresses their maturation, as 
neutralisation of IL-10 caused some spontaneous maturation of DCs in vitro. This also led to Th l 
responses in LPS-matured DCs showing that IL-10 skews the response to a Th2 response, or inhibits a 
response completely (Corinti et al., 2001). Macrophages in the lung may inhibit DC:T cell interactions 
by secreting IL-10 which can be overcome by activated epithelial cells releasing pro-inflammatory 
mediators in response to danger signals. DCs have also been shown to release IL-10, and IL-10- 
expressing DCs are found in the draining lymph nodes of the lung 24 hours after allergen challenge 
indicating that T regs are being activated. IL-10 knockout mice do not produce tolerance to OVA after 
the adoptive transfer of OVA-DCs, whereas wild type mice do, again indicating that T regs are vital for 
tolerance formation (Akbari et al., 2001).
Genetics may also play a role in the susceptibility to generating tolerance or sensitisation to an 
allergen. For example, polymorphisms in the IL-12 gene are linked to childhood asthma (Stumbles et
al., 2003b), while genes that regulate the function of the epithelial barrier in the lung are also related 
to asthma. These polymorphisms may determine if a person is susceptible to sensitivity to innocuous 
allergens (Hammad et al., 2008).
To initiate an allergic reaction, such as allergic asthma, the body fails to induce tolerance to a certain 
allergen, meaning that an immune response is induced instead. In developed countries 30% of the 
population is atopic (susceptible to allergy), but only 1 0 -1 2 % of the population have asthma, 
suggesting that sensitisation to allergens and the IgE response generated is only a risk factor for 
asthma development. The complete events in asthma induction are unclear (Hammad et al., 2008).
1.16. Asthma development
Non-allergic asthma constitutes one third of asthma cases. It has prolonged onset and is associated 
with increased neutrophils and no increase in IgE antibodies. The pathology of this type of asthma is 
relatively unclear, although it could be induced by the inhalation of certain endotoxins or viruses 
(Simpson et al., 2008).
Allergic asthma accounts for two thirds of cases and is eosinophilic. It is a chronic inflammation of the 
respiratory tract caused by a complex interaction between many immunological mediators produced 
by immune cells and structural cells (Verstraelen et al., 2008). As can be seen in figure 1.3, the first 
contact with an allergen leads to sensitisation due to the lack of tolerance. It is unclear why an 
individual will become sensitised to certain allergens and not others, and why sensitisation occurs. 
Multiple factors may determine the immunological outcome of exposure to an allergen including 
contamination of allergen with pollutants, viruses, bacteria, or by the allergen itself activating DCs 
(Lambrecht et al., 2009). Therefore, the allergen is taken up by a DC, which matures and migrates to 
the draining lymph nodes where it activates T cells to induce a Th2 response against this allergen. The 
mature DC secretes IL- 6  to suppress T regs and allows an immune response to be generated
(Lambrecht et a i, 2009). Th2 cells become activated, and proliferate, releasing cytokines such as IL-4, 
IL-5 and IL-13 which induce B cells to secrete IgE antibodies specific to the allergen present, which 
activates mast cells and causes an asthmatic response. These antibodies remain in the blood and are 
available to create a quicker immune response on re-exposure to the allergen. Alongside this, IgE 
secreting plasma cells and memory T cells specific for the allergen of interest are formed, which reside 
in the lung tissue and are activated on re-exposure to the allergen (Holgate, 2008). Re-exposure to the 
allergen via inhalation then initiates the early asthmatic reaction. Specific IgE bound to Fc receptors 
on mast cells and basophils bind to the allergen, opsonising it. This binding causes mast cells and 
basophils to release various pro-inflammatory mediators. These include histamine, which is stored in 
granules in the cytoplasm of mast cells and binds to HI, H2, H3 and H4 receptors. H I receptors are 
found on smooth muscle where ligation causes bronchoconstriction, vasodilatation of blood vessels 
and mucus secretion (Barnes, 2008b). Leukotrienes are released, including C4, D4 and E4 which are 
synthesised and released by mast cells, macrophages and epithelial cells, and are 1 0 0 0  times more 
potent at causing bronchoconstriction than histamine. They also cause airway oedema, and 
neutrophil recruitment to the airways. Prostaglandin D2 is released which also causes 
bronchoconstriction, and the pro-inflammatory cytokines IL-4, IL-5, IL-13, TNFa, IL-1(3 and IL-6  are 
released (see table 1.1). The symptoms of the early phase response range from mild rhinitis to 
bronchoconstriction and in severe cases anaphylactic shock. Symptoms include bronchospasm, mucus 
secretion and inflammatory infiltrate formation (Verstraelen et al., 2008).
The late asthmatic reaction occurs 4 to 6  hours after allergen inhalation, is longer and more severe. It 
occurs due to DCs taking up the inhaled allergen migrating to the lymph nodes and presenting it to T 
cells causing their activation, and the activation of memory T cells which are recruited to the lungs 
and induce a Th2 response (Holgate, 2008). In humans, allergen challenge led to a decrease in mDCs 
in the blood, and an increase in mDCs in the lung. This is due to the recruitment of mDCs to the lungs
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Figure 1.3 -  A schematic diagram of asthma initiation.
For sensitisation to occur, an allergen binds to an ARC which becomes activated due to a danger 
signal. This ARC migrates to the lymph node to activate T cells, which proliferate and release 
mediators which activate B cells to secrete IgE. On re-exposure to the allergen, IgE binds the allergen, 
and activates mast cells to release mediators such as histamine and bradykinin, producing the early 
asthmatic reaction. These mediators, and DC activation leads to the activation of other immune cell 
types resulting in the late phase reaction. Damage caused by this immune response leads to airway 
remodelling (adapted from Verstraelen et a!., 2008).
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caused by chemokines released by resident DCs and other cell types. pDC numbers do not change 
(Upham et al., 2002; Lambrecht et al., 2009). Conversely, in mouse models of asthma the number of 
pDCs in the lungs increased on allergen challenge, which could be due to species differences or 
experimental procedure (Kool et al., 2009). Activated Th2 cells release a number of pro-inflammatory 
cytokines and chemokines that attract immune cells to the lung. Eosinophils, mast cells, basophils, 
macrophages and T cells release mediators that cause bronchoconstriction, increase vascular 
permeability, induce airway hyper-responsiveness and mucus hyper-secretion making it difficult to 
breathe. This has been shown by adoptive transfer of antigen specific Th2 cells into naïve mice, which 
caused eosinophilia and airway hyper-responsiveness to allergen challenge. This indicates that these 
cells are the initiators of the asthmatic response (Afshar et al., 2008). T h l cells are also involved in 
asthma, although it is unclear what role they play here, as there are no changes in T h l cell numbers in 
asthmatics, while Th2 cells and their cytokines are increased at baseline in asthmatics, and further 
increase on allergen challenge (Afshar et al., 2008). After many years of repeated asthma attacks, 
damage caused to the lungs results in a decline in lung function due to airway remodelling which 
includes airway wall thickening, fibrosis, goblet cell and squamous cell metaplasia (replacement of 
one cell type by another), cell hypertrophy, cartilage breakdown, angiogenesis due to vascular 
endothelial growth factor secretion from epithelial cells and basement membrane thickening due to 
collagen deposition under the epithelium (Barnes, 2008b; Verstraelen et al., 2008).
In humans, the levels of peripheral blood DC subsets is increased in asthmatics compared to healthy 
controls; mDCs from 0.35 to 0.59%, and pDCs from 0.22 to 0.32%. This may indicate why some 
patients are atopic although this is not clear (Spears etal., 2011).
1.17. ATP and asthma
Evidence suggests that ATP plays an important role in the pathogenesis of asthma. It is thought that 
ATP acts as a danger signal for DCs, inducing their maturation, thus it may be involved in allergic 
sensitisation and in enhancing the immune response to an inhaled allergen.
There are few studies on the effects of ATP in human lungs due to the ethics and health problems 
associated with inducing asthmatic responses in humans; however the few that have been carried out 
suggest that ATP is linked to asthma. Aerosolised ATP caused asthmatics but not healthy people to 
experience a fall in FEVi (forced expiratory volume in 1 second) indicating a decline in lung function, 
and AMP had the same effect in 90% of patients (Basoglu et al., 2005). ATP also caused cough in 40% 
of patients by causing throat irritation (Basoglu et al., 2005). These effects have been found to be due 
to adenosine, formed from the breakdown of ATP or AMP, acting via the Ai receptor (Blackburn, 
2007).
Allergen challenge in asthmatics caused an increase in ATP in the bronchiolar lavage fluid indicating its 
release during asthma attacks (Idzko et al., 2007). In vitro, ATP and adenosine have been shown to 
enhance histamine release from lung mast cells, which would induce bronchospasm (Basoglu et al., 
2005). Overall it is clear that studying the effects of ATP and its breakdown products in lung tissue and 
in asthmatic patients would be beneficial in the study of asthma.
Mouse models of allergic airway inflammation are used to study asthma as they are easier to perform 
then human studies, and similar symptoms to the human asthmatic response is induced. However, 
this model is not the same as human asthma, and care must be taken when relating these studies to 
the human disease due to species and disease differences. Mice sensitised to OVA, and then 
challenged 10 days later with aerosolised OVA develop asthma-like symptoms including increased 
number of eosinophils, neutrophils, lymphocytes and macrophages in the bronchiolar lavage fluid, as
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occurs in human asthmatics. This was associated with an increase in ATP concentration, again 
corresponding to results seen in humans (Idzko et al., 2007). This asthmatic response could be 
reduced by administration of apyrase (an enzyme that breaks down ATP), or the P2 antagonists 
suramin or PPADS (pyridoxalphosphate-6-azophenyl-2,,4,-disulphonic acid) prior to allergen 
challenge, indicating that ATP acting via P2 receptors enhances the asthmatic reaction. When ATPyS 
was given with the OVA aerosol, a large increase in pro-inflammatory cytokines and immune cells was 
observed in the bronchiolar lavage fluid, again indicating that P2 receptor activation exacerbates the 
immune response in allergic sensitisation (Idzko et al., 2007). These results are supported by the 
adoptive transfer of ATPyS-matured DCs to the airway of naïve mice which caused a large increase in 
the allergic response compared to OVA-matured DCs. ATP may, therefore, act as a danger signal in 
the lungs, promoting sensitisation to inhaled allergen (Idzko et al., 2007).
Few studies have looked into individual P2 receptor involvement due to the complexities of cell types 
involved in asthma, and the challenge of finding selective agonists and antagonists for the P2 
receptors. It has been shown that the P2Y6 receptor is increased on airway epithelia during allergic 
airway inflammation in mice, and that blocking this receptor, or using P2Y6"/" mice reduced the 
symptoms of inflammation, indicating a role for this receptor and its agonist UDP in this disease 
model (Vieira et al., 2011).
1.18. Other effects of DCs or ATP in the lung
Increasing focus is being put on the effect of smoking on lung immunology, and purinergics. In murine 
studies, mice exposed to cigarette smoke long term showed a decrease in the numbers of mDCs in the 
lungs compared to controls, accompanied by a decreased CD8 + T cell response to viral infection 
(Robbins et al., 2004). In virus-infected pDC, cigarette smoke extract inhibited IFNa, IL-1(3 and IL-10 
release and decreased TLR 7 expression in these cells (Castro et al., 2011). This indicates that cigarette
smoking alters DC related immunity, which could play an important role in the damaging effects of 
smoking, such as CORD development (Mortaz et al., 2009a). It is also clear that ATP is involved in the 
immune response to smoking, as shown by the exposure of mice to acute doses of cigarette smoke 
which increased ATP levels and neutrophil, and macrophage numbers in the bronchiolar lavage fluid. 
This was reduced after prior treatment with apyrase, or the P2 antagonists suramin and PPADS (Cicko 
et al., 2010). This indicates that ATP accumulates in the airways after smoke-induced lung damage, 
which is another indicator for ATP acting as a danger signal in the lungs.
1.19. Conclusion
It is clear from multiple studies that ATP is implicated in the asthmatic immune response. However, 
due to difficulties in human and mouse studies of asthma, elucidating the cells and receptors involved 
in this response is a difficult process.
1.20. Thesis hypothesis and aims
Evidence suggests that extracellular nucleotides act as danger signals to activate the immune system, 
and that dendritic cells are the target cells for these responses. However, the full effect of nucleotides 
in the immune response remains unclear. The hypothesis of this thesis is that extracellular ATP acts as 
a danger signal in both human blood and lung dendritic cells via activation of P2 receptors.
The aim of this thesis is to confirm the effects of extracellular nucleotides as danger signals on 
dendritic cells from human peripheral blood, and to extend this to study the effects of nucleotides on 
human lung tissue. Specific aims are:
a) To study the effects of extracellular nucleotides on co-stimulatory marker expression on 
monocyte-derived DCs, compared to myeloid DCs and plasmacytoid DCs isolated directly from 
human blood, by flow cytometry.
b) To study the effects of extracellular nucleotides on cytokine release by monocyte-derived DCs 
compared to myeloid DCs and plasmacytoid DCs, by MSD cytokine assay.
c) To study the effects of extracellular nucleotides on human lung parenchyma from post­
mortem patients using MSD cytokine assay to measure cytokine release.
d) To study the role of myeloid DCs and plasmacytoid DCs in the lung response to extracellular 
nucleotides by isolating these cells from human lung parenchyma and measuring cytokine 
release by MSD cytokine assay.
Chapter 2 -  Materials and Methods
2.1. Isolation of peripheral blood mononuclear cells from human blood, buff y coat or 
lymphocyte cone
Solution preparation
Sterile phosphate buffer saline (PBS; GIBCO) plus 2 mM ethylenediaminetracetic acid (EDTA; Sigma 
Aldrich) was prepared and stored at room temperature for use in dilutions of blood samples.
Human volunteers were used in these experiments due to the limitations in relating animal 
experiments to humans. The use of human blood was approved by the University of Surrey ethics 
committee (see appendix). Volunteers were recruited from the University of Surrey and were chosen 
randomly. Informed consent was gained prior to blood taking (see appendix).
In some experiments, blood (45ml) was collected from healthy volunteers by venepuncture, into 5 ml 
sodium citrate 0.4% w /v (Invitrogen) to prevent coagulation. Blood was diluted 1:2 with sterile PBS 
plus 2 mM EDTA at room temperature.
In other experiments, buffy coat, a blood bag containing leukocytes and platelets separated from 
whole blood, was obtained from the National Blood Service (UK) and used due to the increased 
number of cells obtainable compared to 45 ml of whole blood. Buffy coat was transferred from blood 
bags into 50 ml Falcon tubes, and diluted 1:5 with sterile PBS plus 2 mM EDTA at room temperature. 
Alternatively, leukocyte cones, a concentrated form of buffy coat isolated using a different procedure 
(Dietz et al., 2006) were obtained from the National Blood Service. These were used as the National
Procedure
Blood Service changed their technique and buffy coats were no longer available. Blood was 
transferred from the leukocyte cone into a 50 ml Falcon tube, and diluted 1:5 with sterile PBS plus 2 
mM EDTA at room temperature.
Peripheral mononuclear cells (PBMC) were isolated from diluted blood/buffy coat/leukocyte cone by 
density gradient centrifugation using Histopaque-1077 (Sigma Aldrich), according to the 
manufacturer's instructions. In brief, 35 ml of diluted blood was layered onto 15 ml of Histopaque- 
1077 in a 50 ml Falcon tube, and centrifuged at 400 g for 30 minutes at 20°C without brake. The 
interface layer was removed using a Pasteur pipette and transferred into a sterile Falcon tube, while 
the remaining layers were discarded. The interface was made up to 50 ml with PBS plus 2 mM EDTA 
and centrifuged at 300 g for 10 minutes. The supernatant was discarded. If red blood cells were 
present, the interface pellet was made up to 50ml with PBS plus 2 mM EDTA, and centrifuged at 200 g 
for 10 minutes. The supernatant was discarded, and the mononuclear cell pellet was re-suspended in 
1 ml MACS buffer (see below) and viable cells were counted using 0.4% v/v trypan blue (Sigma 
Aldrich) exclusion in a haemocytometer.
2.2. Isolation of dendritic cell subsets
Solution preparation
MACS buffer was prepared containing PBS plus 0.5% bovine serum albumin (BSA; GIBCO) and 2 mM 
EDTA and stored at 4°C for use in cell isolations.
Tissue culture media was used for all cell cultures. 50 ml of media was removed from a 500 ml bottle 
of advanced RPMI (GIBCO), and 50 ml fetal calf serum (FCS; GIBCO), 100 U/ml penicillin, 2mM 
glutamine, 100pg/ml streptomycin (GIBCO) and 5 ml fungizone (Invitrogen) was added to the bottle 
and mixed.
IL-3, IL-4 and GM-CSF cytokines (Sigma Aldrich) were prepared individually to stock concentrations of 
10 pg/ml with sterile PBS plus 1% BSA. 20 pi aliquots were stored at -4°C.
LPS from Escherichia coli 026:B6 (Sigma Aldrich) was prepared to a stock concentration of 1 mg/ml 
with sterile PBS and stored in 100 pi aliquots at -4°C.
Resiquimod (obtained as a gift from GSK) was prepared to a stock concentration of 10 mM with sterile 
PBS and stored in 100 pi aliquots at -4°C.
ATP disodium salt and ATPyS tetralithium salt (Sigma Aldrich) were prepared to a stock concentration 
of 10 mM with distilled water and stored in 1 ml aliquots at -4°C. From this 10 mM stock, aliquots of 2 
mM and 0.2 mM solutions were prepared and stored at -4°C.
In all experiments, LPS 10 pg/ml was used. Initial pilot experiments using lung parenchyma indicated 
that this concentration elicited a submaximal release of cytokines compared to higher and lower 
concentrations of LPS (data not shown). This matched the concentration of LPS used in the literature, 
allowing comparison between methods (La Sala et al. 2001, Marteau et al. 2004). Pilot experiments 
also indicated that 2 pM resiquimod was an appropriate concentration due to similar reasons (data 
not shown). This concentration has been shown to induce IFNa release from human pDCs, and was 
similar to the 3 pM concentration used in future experiments by the same group (Gibson et al. 2002).
MACS technology
DC subtypes were isolated using positive cell isolation MACS technology from Miltenyi Biotech 
(Germany). This technique involved incubating a single cell suspension with 50 nm magnetic 
microbeads that are conjugated to an antibody specific for a cell surface molecule expressed by the 
cell of interest, for example CD14. The antibody will bind to the CD14 molecule on the cell surface, so 
only be bound to cells expressing CD14. This suspension is then passed over a MACS column, which
contains a matrix of ferromagnetic spheres, placed in a magnetic field. The spaces between the 
spheres are larger than immune cells, so the cells pass through the column and while non-labelled 
CD14" cells are eluted, CD14+ cells bound to a microbead are held in the column by the magnetic field. 
Removal of the column from the magnetic field allows the CD14+ cells to be flushed out of the column 
using MACS buffer, resulting in a pure sample of monocytes.
Two types of MACS separation columns were used in these experiments. The MidiMACS separator 
was used to isolate CD14+ monocytes as these cells are abundant in the PBMC solution. This separator 
used small columns for cell separation. The SuperMACS separator was used to isolate mDCs and pDCs, 
as these cells are rare in the PBMC solution. This separator is much larger than the MidiMACS 
columns, which allows for increased purities of rare cell populations to be isolated. Both systems use 
a magnet of an appropriate size to ensure cell isolation occurs.
The SuperMACS columns could be used for up to 10 isolations. For this reason, they were stored in 
70% ethanol to prevent rusting of the column. To begin an isolation, the column had to be prepared. 
The ethanol was drained from the column and 2 x 50 ml distilled water was back-flushed through the 
column to remove any traces of ethanol. 50 ml of PBS was then back-flushed through to the column 
to remove water, and then 150 ml PBS was allowed to run through the column. Immediately before 
use, 75 ml of 4°C MACS buffer was run through the column, and a blunt ended needle was inserted 
onto the bottom of a 3 way tap attached to the bottom of the column. This allowed for a controlled 
amount of cell suspension to be passed through the column at a time. The cell suspension was then 
passed through the column as described below. After use, the column was back-flushed twice with 50 
ml distilled water to remove all buffers, and then 150 ml distilled water was passed through the 
column. The column was then back-flushed with 75 ml of 70% ethanol and stored at room 
temperature.
Isolation o f CD14+ monocytes and differentiation to moDCs
CD14+ microbeads (Miltenyi Biotech) were used to isolate monocytes from PBMC according to 
manufacturer's instructions. In brief, PBMC were centrifuged at 300 g for 10 minutes, and the 
supernatant discarded. Cells were re-suspended in MACS buffer at 107 cells per 80pl, and incubated 
with CD14 microbeads at 107 cells per 20 pi for 15 minutes in the fridge. 2 ml MACS buffer per 107 
cells was added to the cells, and they were centrifuged at 300 g for 10 minutes. The supernatant was 
discarded, and cells re-suspended in 500 pi buffer. An LS column (suitable for separation of up to 108 
cells; Miltenyi Biotech) was placed in the magnetic field of a midiMACS separator, and 2 ml MACS 
buffer was passed through the column and collected in a 50ml Falcon tube. The cell suspension was 
then passed through the column, followed by 3 x 3 ml MACS buffer, which was added after each 
previous addition had emptied from the reservoir. Eluted cells (unlabelled cells) were collected in the 
Falcon tube and either stained for flow cytometry as required, or discarded. The LS column was then 
removed from the magnet, and placed over a fresh Falcon tube. 5 ml MACS buffer was pipetted into 
the column reservoir and immediately pushed through the column using the plunger, removing all 
CD14+ labelled cells from the column. The separation step was repeated using another LS column to 
ensure greater purity of cells. The eluted CD14+ monocytes were made up to 50 ml with MACS buffer, 
and centrifuged at 300 g for 10 minutes, then re-suspended in 1 ml tissue culture media and viable 
cells were counted using 0.4% trypan blue exclusion in a haemocytometer.
Monocytes were plated at 0.5xl06 cells per well in a 24 well tissue culture plate plus 1 ml tissue 
culture media and incubated overnight at 37°C in a 5% C02 atmosphere. The next morning 1 ml tissue 
culture media was removed from each well by aspiration and replaced with 1 ml fresh tissue culture 
media containing 0.2 ng/ml IL-4 and 30 ng/ml GM-CSF. Cells were incubated at 37°C in a 5% C02 
atmosphere for 6  days. This would induce the differentiation of monocytes to moDCs. Every 2 days,
0.5 ml media was removed from each well and replaced with fresh tissue culture media containing 0.2 
ng/ml IL-4 and 30 ng/ml GM-CSF.
On day 7, moDCs were stimulated with ATP at 10,100 or 500 pM (by addition of 50 pi of appropriate 
stock solution) and/or LPS (10 pi of stock solution) at 3 wells per treatment, with distilled water used 
as a control so that a final volume of 60 pi was added to each well, and cells were incubated for a 
further 48 hours. On day 9, moDCs in the triplicate treatment wells were scraped and transferred to a 
sterile FACS tube (BD bioscience) on ice (max 3 wells per tube), and cells were stained for flow 
cytometry (see section 2.3)
Isolation o f plasmacytoid dendritic cells and culture
pDCs were isolated using CD304 (BDCA-4/neuopilin-l) microbead kit (Miltenyi Biotech) according to 
manufacturer's instructions. In brief, PBMC were centrifuged at 300 g for 10 minutes, and the 
supernatant discarded. Cells were re-suspended in MACS buffer at 108 cells per 300 pi, and incubated 
with FcR blocking reagent at 108 cells per 100 pi, plus CD304 (BDCA-4) microbeads at 108 cells per 100 
pi for 15 minutes in the fridge. 10 ml MACS buffer was added to the cells, and they were centrifuged 
at 300 g for 10 minutes. The supernatant was aspirated, and cells re-suspended in 500 pi buffer. A 
SuperMACS separator was used for this isolation. A SuperMACS D column (for the separation of up to 
109 cells) was placed in the magnetic field of a MACS separator, prepared as stated above. The cell 
suspension was then passed through the column, followed by 150 ml MACS buffer, and the eluted 
cells were collected in three Falcon tubes and set aside for mDC isolation, or stained for flow 
cytometry as required. To remove labelled cells from the column, the column was removed from the 
magnet, and back-flushed with 150 ml MACs buffer which was transferred into three Falcon tubes. 
The cells were centrifuged at 300 g for 10 minutes, then re-suspended in 1 ml tissue culture media 
and viable cells were counted using 0.4% trypan blue exclusion in a haemocytometer.
pDC were plated at 2x l04cells per well in 200 [x\ tissue culture media and incubated overnight at 37°C 
in a 5% CO2 atmosphere to settle. The next morning 200 pi tissue culture media was removed from 
each well by aspiration and replaced with 200 pi fresh tissue culture media containing 20 ng/ml IL-3. 
pDC were then stimulated with nucleotides at 10,100 and 500 pM (by addition of 10 pi of appropriate 
stock solution) and/or resiquimod (2 pi of stock solution) at 3 wells per treatment, with distilled water 
used as a control to a maximum volume of 12 pi per well and cells incubated for 48 hours. On day 3, 
pDC wells treated in triplicates were scraped and transferred to a sterile FACS tube on ice (max 3 
wells per tube), and stained for flow cytometry (see section 2.3)
Isolation o f myeloid dendritic cells and culture
mDCs were isolated using the CDlc (BDCA-1)+ Dendritic cell isolation kit (Miltenyi Biotech) according 
to manufacturer's instructions. In brief, PBMC were centrifuged at 300 g for 10 minutes, and 
supernatant was discarded. Cells were re-suspended in MACS buffer at 108 cells per 200 pi, and 
incubated with FcR blocking reagent at 108 cells per 10 pi, plus CD19 microbeads at 108 cells per 100 
pi, plus CDlc (BDCA-l)-biotin at 108 cells per 100 pi for 15 minutes in the fridge. This ensured that 
CD19+ B cells were removed from the cell suspension, as these cells also express the CDlc marker. 2 
ml MACS buffer was added to the cells, and they were centrifuged at 300 g for 10 minutes. The 
supernatant was aspirated, and cells re-suspended in 5 ml MACS buffer. A SuperMACS separator was 
used for this isolation. A SuperMACS D column (for the separation of up to 109 cells) was placed in the 
magnetic field of a MACS separator, prepared as stated above. The cell suspension was then passed 
through the column, followed by 150 ml MACS buffer, and the eluted cells were collected in three 
Falcon tubes. The Falcon tubes were centrifuged at 300 g for 10 minutes and the supernatant 
discarded. To remove labelled cells from the column, the column was removed from the magnet and 
back-flushed with 150 ml MACs buffer and this solution was discarded. The column was placed back
in the magnetic field. Eluted cells which were depleted of B cells were then re-suspended in 400 pi 
buffer, and incubated with lOOpI anti-biotin microbeads for 15 minutes in the fridge. These 
microbeads bind to the CDlc biotin antibody already bound to the mDCs. 2 ml MACS buffer was 
added to the cells, and they were centrifuged at 300 g for 10 minutes. The supernatant was discarded 
and cells re-suspended in 5 ml MACs buffer. The cell suspension was then passed through the column, 
followed by 150 ml MACS buffer. Eluted cells (unlabelled cells) were collected in three Falcon tube 
discarded or set aside for staining for flow cytometry if required. The D column was then removed 
from the magnet, and labelled cells were removed by back-flushing the column with 150 ml MACS 
buffer, which was transferred into three Falcon tubes. The cells were centrifuged at 300 g for 10 
minutes, then re-suspended in 1 ml tissue culture media and viable cells were counted using 0.4% 
trypan blue exclusion in a haemocytometer.
mDC were plated at 2x l04 cells per well in a 96 well tissue culture plate plus 200 pi tissue culture 
media and incubated overnight at 37°C in a 5% C02 atmosphere to settle. The next morning 200 pi 
tissue culture media was removed from each well by aspiration and replaced with 2 0 0  pi fresh tissue 
culture media containing 0.2 ng/ml IL-4 and 30 ng/ml GM-CSF. mDC were then stimulated with 
nucleotides at 10,100 and 500 pM (by addition of 10 pi of appropriate stock solution) and/or LPS (10 
pi of stock solution) at 3 wells per treatment, with distilled water used as a control to a maximum 
volume of 12pl and cells incubated for 48 hours. On day 3, mDCs in wells treated in triplicate were 
scraped and transferred to a sterile FACS tubes on ice (max 3 wells per tube), and stained for flow 
cytometry (see section 2.3).
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2.3. Flow cytometry
Solution preparation
Staining buffer was made using 500 ml PBS plus 1% g BSA and 0.05% NaN3 (Sigma Aldrich). Wash 
buffer was made using 500 ml PBS plus 0.5% BSA and 0.05% NaN3. 1% paraformadehyde was made 
by diluting 37% paraformaldehye (Sigma Aldrich) with distilled water.
Protocol
Tubes containing treated cells (containing approximately 1.5xl06 moDCs, or 6x l0 4 mDCs or pDCs) 
were centrifuged at 400 g for 5 minutes at 4°C. 200 pi of supernatant was removed and frozen at - 
80°C for future cytokine analysis. Any remaining supernatant was discarded and cells re-suspended in 
1 ml staining buffer. 10 pi natural human serum (Millipore) was added, and the tubes were incubated 
for 10 minutes on ice. This serum contains immunoglobulin which binds to Fc receptors on immune 
cells and blocks non-specific binding of the antibodies. Cells were then washed by centrifugation at 
400 g for 5 minutes at 4°C, then re-suspended in the appropriate volume of staining buffer for the 
antibody combinations required (see below).
Antibody combinations were prepared in sterile FACS tubes as shown in tables 2.1-2.3. The rationale 
behind the choice of antibodies used can be seen in the gating strategies below. 2 pl of each antibody 
was added to each tube. 1 0 0  pi cells were then added to corresponding antibody tubes, and tubes 
were incubated on ice for 30 minutes in the dark. Cells were washed by centrifugation with 2 ml wash 
buffer at 400 g for 5 minutes at 4°C. Cells were re-suspended in 300 pi 1% paraformaldehyde in PBS 
and stored in the dark for a maximum of 2  weeks.
Flow cytometry was carried out on a FACS Canto flow cytometer (BD Biosciences) using FACSDiva 
software and analysed using Flowjo software (Treestar).
Mouse anti-human CDllc-FITC, rat anti-human HLA-DR-RPE, mouse anti-human CD80-RPE, mouse 
anti-human CD83-RPE, mouse anti-human CD8 6 -RPE, mouse anti-human CD209-RPE, mouse anti­
human CD14-RPE, mouse IgGl-FITC, mouse IGgl-APC, mouse IgG-l-RPE and rat IgGla-RPE were from 
AbD Serotec. Mouse anti-human CD123-APC, mouse anti-human CDlc-PerCP, mouse IgGla-PerCP, 
mouse anti-human CD80-PE-Cy7, mouse anti-human CD83-PerCP-Cy5.5, mouse anti-human CD209- 
PerCP-Cy5.5, mouse lgGl-PE-Cy7 and mouse lgGl-PerCP-Cy5.5 were from BioLegend. Mouse anti­
human CD303-RPE, mouse anti-human CD304-RPE, mouse anti-human CD141-RPE, mouse anti­
human CD3-APC, mouse anti-human CD4-RPE, mouse anti-human CD8 -RPE, and mouse anti-human 
CD19-RPE were from Miltenyi Biotech.
Antibody combinations for moDCs -  co-stimulatory markers:
Tube 1 CDllc-FITC CD123-APC HLA-DR-RPE
Tube 2 CDllc-FITC CD123-APC CD80-RPE
Tube 3 CDllc-FITC CD123-APC CD83-RPE
Tube 4 CDllc-FITC CD123-APC CD8 6 -RPE
Tube 5 CDllc-FITC CD123-APC CD209-RPE
Tube 6 CDllc-FITC CD123-APC CD14-RPE
Controls:
Control tube 1 Mouse IgGl-FITC Mouse IgGl-APC Rat lgG2a-RPE
Control tube 2 Mouse IgGl-FITC Mouse IgGl-APC Mouse IgGl-RPE
Control tube 3 CDllc-FITC CD123-APC Rat lgG2a-RPE
Control tube 4 CDllc-FITC CD123-APC Mouse IgGl-RPE
Control tube 5 Unstained Unstained Unstained
Table 2.1 -The antibody combinations used to stuc y co-stimulatory marker expression on moDCs.
Antibody combinations for mDC and pDC -  co-stimulatory mar cers:
Tube 1 CDllc-FITC CD123-APC HLA-DR-RPE CD80-PE-Cy7 CD83-PerCP-Cy5.5
Tube 2 CDllc-FITC CD123-APC CD8 6 -RPE No stain CD209-PerCP-Cy5.5
Controls:
Control tube 1 Mouse
IgGl-FITC
Mouse IgGl- 
APC
Rat lgG2a-RPE Mouse IgGl- 
PE-Cy7
Mouse IgGl-PerCP- 
Cy5.5
Control tube 2 Mouse
IgGl-FITC
CD123-APC HLA-DR-RPE CD80-PE-Cy7 CD83-PerCP-Cy5.5
Control tube 3 CDllc-FITC Mouse IgGl- 
APC
HLA-DR-RPE CD80-PE-Cy7 CD83-PerCP-Cy5.5
Control tube 4 CDllc-FITC CD123-APC Rat lgG2a-RPE CD80-PE-Cy7 CD83-PerCP-Cy5.5
Control tube 5 CDllc-FITC CD123-APC HLA-DR-RPE Mouse IgGl- 
PE-Cy7
CD83-PerCP-Cy5.5
Control tube 6 CDllc-FITC CD123-APC HLA-DR-RPE CD80-PE-Cy7 Mouse IgGl-PerCP- 
Cy5.5
Control tube 7 Unstained Unstained Unstained Unstained Unstained
Table 2.2 - The antibody combinations used to study co-stimulatory marker expression on mDCs 
and pDCs.
Antibody combinations for the identification of leukocytes and B cells:
Tube 1 CDllc-FITC CD3-RPE CD4-Alexa 647
Tube 2 CDllc-FITC CD3-RPE CD8 -Alexa 647
Tube 3 CDllc-FITC CD3-RPE CD19-Alexa 647
Controls:
Control tube 1 Mouse IgGl-FITC Mouse lgG2a-RPE Mouse IgGl-Alexa 647
Control tube 2 CDllc-FITC CD3-RPE Mouse IgGl-Alexa 647
Control tube 3 CDllc-FITC Mouse lgG2a-RPE CD4-Alexa 647
Control tube 4 Mouse IgGl-FITC CD3-RPE CD4-Alexa 647
Control tube 5 Unstained Unstained Unstained
Table 2.3 - The antibody combinations used to identify leukocytes and B ce Is.
Flow cytometric gating strategies
Analysis o f freshly isolated CD14+ monocytes
In order to confirm that the products of CD14+ monocyte isolation were monocytes, a sample of 
PBMC, isolated monocytes, and the eluted cell sample were analysed on flow cytometry. 10,000 total 
events were captured per tube. Fig. 2.1 A shows the PBMC sample containing both monocytes and 
lymphocytes. Fig 2.1 B shows the freshly isolated monocyte population. The forward vs side scatter 
plot shows that the cells were monocytes and that there was a lack of lymphocytes present in the 
population. Fig. 2.1 C shows the eluted cell population which contained lymphocytes only. This 
confirmed that the monocyte isolation process worked, and that the kit could be used for future 
isolations.
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Figure 2.1 -  Forward vs. side scatter plots to confirm the isolation of monocytes from PBMC.
CD14+ monocytes were isolated from PBMC, and a sample was taken for flow cytometry for 
confirmation. A shows the plot of PBMC indicating the presence of both monocytes and lymphocytes. 
B shows CD14+ monocytes after isolation. C shows the eluted lymphocytes.
Co-stimulotory marker expression on moDCs
This gating strategy was used to analyse the expression of co-stimulatory markers on moDCs, using 
the antibody labelling strategy in table 2.1. 10,000 total events were captured per tube. Samples were 
analysed based on their forward vs side scatter properties (Fig 2.2 A). The moDC population was gated 
to exclude small cells that are likely to consist of cell debris and dead cells. This produced around 75% 
of the cell population consisting of moDCs. It is known that moDCs are C D llc+ and CD123 (Osugi et 
al., 2002). To ensure that the cells analysed were moDCs, the gated moDCs were then gated based on 
their expression of these receptors. Isotype controls were used to determine the location of the
 (  77 )--------------------------------------------------------
Lymphocytes 
91.0 :
250K
2DÛK
'' Monocytes 
9 # %  ' 78.2Mononuclear cells 
13.4
Lymphocytes. 
70.9 '
positive gates by ensuring that the controls were excluded from the gates (Fig. 2.2 E, F, and G). The 
moDC population was gated on C D llc+ cells (Fig. 2.2 B). From the C D llc+ gate, cells were gated on 
their expression of CD123, to ensure cells were negative for CD123 (Fig 2.2 C). From the CD123" gate, 
cells were gated on their expression of the RPE antibody (HLA-DR, CD80, CD83, CD8 6 , CD209 or CD14, 
Fig 2.2 D). This ensured that the cells of interest were C D llc+ CD123' moDCs, and allowed for both 
the percentage of cells positive for the RPE antibody and the mean fluorescence intensity (MFI) of this 
antibody to be calculated.
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Figure 2.2 -The flow cytometric gating strategy for the analysis of moDC marker expression.
A = forward vs side scatter plot. B = C D llc  expression. C = CD123 expression. D = RPE expression. E, F, 
G = isotype controls
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Myeloid DC expression o f co-stimulatory markers
This gating strategy was used to analyse the expression of co-stimulatory markers on mDCs using the 
antibody combinations in table 2.2.10,000 total events were captured per tube. Samples were 
analysed based on their forward vs side scatter properties (Fig 2.3 A). The mDC population was gated 
to exclude small cells that are likely to consist of cell debris and dead cells. It is known that mDCs are 
C D llc+ and CD123" (Dzionek et al., 2000). To ensure that the cells analysed were mDCs, the gated 
mDCs were then gated based on their expression of these receptors. Isotype controls were used to 
determine the location of the positive gates by ensuring that the controls were excluded from the 
gates (Fig. 2.3 F, G, H, I). The mDC population was gated to C D llc* cells (Fig 2.3 B). From the CD llc* 
gate, cells were gated on their expression of CD123, to ensure cells were negative for CD123 (Fig 2.3 
C). From the CD123 gate, cells were gated on their expression of the RPE antibody (HLA-DR or CD8 6 , 
Fig. 2.3 D), PerCP-Cy5.5 antibody (CD80 or CD209, Fig 2.3 E) or the PE-Cy7 (CD83, not shown). This 
ensured that the cells of interest were C D llc* CD123 mDCs, and allowed for both the percentage of 
cells positive for the co-stimulatory marker antibodies and the mean fluorescence intensity of this 
antibody to be calculated.
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Figure 2.3 -The flow cytometric gating strategy for the analysis of mDC marker expression.
The gating strategy for mDC expression of co-stimulatory markers. Either 5 colour flow cytometry was 
used to determine HLA-DR, CD80 or CD83, or 4 colour flow cytometry to determine CD8 6  and CD209, 
as shown here. A = forward vs side scatter plot. B = C D llc  expression. C = CD123 expression. D = RPE 
expression. E = Cy5.5 expression. F, G, H, I = isotype controls.
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Plosmacytoid DC expression o f co-stimulatory markers
This gating strategy was used to analyse the expression of co-stimulatory markers on pDCs using the 
antibody in table 2.2. 10,000 total events were captured per tube. Samples were analysed based on 
their forward vs side scatter properties (Fig 2.4 A). The pDC population was gated to exclude small 
cells that are likely to consist of cell debris and dead cells. It is known that pDCs are CD llc" and 
CD123+ (Dzionek et al., 2000). To ensure that the cells analysed were pDCs, the gated pDCs were then 
gated based on their expression of these receptors. Isotype controls were used to determine the 
location of the positive gates by ensuring that the controls were excluded from the gates (Fig 2.4 F, G, 
H, I). The pDC population was gated on its negative expression of C D llc  (Fig 2.4 B). From the CDllc" 
gate, cells were gated on their expression of CD123, to ensure cells were positive for CD123 (Fig 2.4 
C). From the CD123+ gate, cells were gated on their expression of the RPE antibody (HLA-DR or CD8 6 , 
Fig 2.4 D), PerCP-Cy5.5 antibody (CD80 or CD209, Fig 2.4 E) or the PE-Cy7 (CD83, not shown). This 
ensured that the cells of interest were CDllc" CD123+ pDCs, and allowed for both the percentage of 
cells positive for the co-stimulatory marker antibodies and the mean fluorescence intensity of this 
antibody to be calculated.
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Figure 2.4 -The flow cytometric gating strategy for the analysis of pDC marker expression.
A = forward vs side scatter plot. B = C D llc  expression. C = CD123 expression. D = RPE expression. E = 
Cy5.5 expression. F, G, H, I = isotype controls
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Detection o f lymphocytes and B cells in a sample
To determine the percentage of contaminating cells in a sample, the following gating strategy was 
used using the antibody protocol in table 2.3. This allowed for the percentage of CD4+ T cells, CD8 + T 
cells and CD19+ B cells to be analysed. 10,000 total events were captured per tube. Samples were 
analysed based on their forward vs side scatter plots (Fig 2.5 A). From the lymphocyte gate, cells were 
analysed based on their expression of CD3 and CD4. CD4+ or CD8 + T cells and CD19+ B cells are located 
in the Q3 quadrant of the plot, as shown in this example to contain 41% CD4+ T cells (Fig. 2.5 B), 48.7% 
CD8 + T cells (Fig. 2.5 C) and 6.55% CD19+ B cells (Fig 2.5 D). Isotype controls were used to determine 
the location of the positive gates by ensuring that the controls were excluded from the gates (Fig 2.5
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Figure 2.5 - The flow cytometric gating strategy for the analysis of lymphocytes and B cells
A = forward vs side scatter plot of lymphocytes. B = CD3 and CD4 expression to determine CD4+ 
lymphocytes. C =CD3 and CDS expression to determine CD8 + lymphocytes. D =CD3 and CD19 
expression to determine B cells. E, F = isotype controls.
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2.4. Cytokine analysis
MSD Technology
Cytokine levels in supernatants were analysed using MSD cytokine immunoassays (Mesoscale), 
according to manufacturer's instructions. This technology is similar to an ELISA, however the plate is 
coated with 'spots' of capture antibodies immobilised on a working electrode, with each spot specific 
for a single cytokine. The cell culture sample is added which binds to the capture antibody, followed 
by a detection antibody labelled with the SULFO-TAG reagent as shown in figure 2.6. A tris-based 
'read' buffer is added which provides the appropriate chemical environment for the electrode, and 
the plate is read on an MSD SECTOR instrument. A voltage is applied to the electrode, causing the 
label bound to the electrode surface to emit light, allowing the concentration of cytokine present in 
the sample to be calculated. This allows for multiple cytokines to be analysed in one sample, as each 
cytokine 'spot' is stimulated separately.
Labeled-Ab
cytokine
Capture-Ab
Working 
Electrode /4 7 7 7 7 7 7 7
Figure 2.6 -  A diagram of the MSD multi-spot plate (taken from www.mesoscale.com)
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Types o f MSD assay used 
The assays used were as follows:
• Pro-inflammatory 7 plex assay -  IFNy, IL-1(3, IL-6 , IL-8 , IL-10, IL-12p70, TNFa
• Custom IPS 4plex assay -  11-1(3, TNFa, IFNy, IL-17
• Single spot IL- 6  assay -  IL- 6
• Single spot IL- 8  assay -  IL- 8
• Custom 10 plex assay -  IL-1(3, IL-10, IL-12p70, IL-13, IL-2, IL-4, IL-5, TNFa, BSA x2
• Custom IL-17 4 plex assay -  GM-CSF, IL-17, Eotaxin 3, BSA
• Cytokine panel 13 -  IL-12p40, l-TAC, IFNa2a, BSA
The limit of detection for the individual cytokines included in the assays were as follows; IFNa 1.4 
pg/ml; IFNy 1.5 pg/ml; IL-1(3 0.3 pg/ml, IL-2 1.4 pg/ml, IL-4 5.3 pg/ml, IL-5 0.7 pg/ml, IL- 6  0.9 pg/ml, IL- 
8  0.3 pg/ml, IL-10 9.1 pg/ml, IL-12p70 2.8 pg/ml, IL-13 3.4 pg/ml, IL-17 0.4 pg/ml, TNFa 0.7 pg/ml.
Procedure
In brief, samples were defrosted to room temperature. If IFNy was included in the assay, 150 pi of 1% 
blocker B solution in PBS was added to each well, or if IL-12 p40 was included in the assay, 0.1% 
blocker B was added to each well, and plates incubated at room temperature with vigorous shaking 
for one hour. Plates were washed using a solution of 0.05% tween plus PBS using an automatic plate 
washer. The 1 pg/ml antibody standards were diluted to prepare an 8  point calibration curve. To do 
this, 3 pi of standard was added to 297 pi tissue culture media, and then seven 1:4 dilutions were 
made, with the final dilution containing 300 pi tissue culture media as a blank. 25 pi of the standard 
curve or sample was added to the appropriate well of the MSD plate, and this was incubated at room 
temperature with vigorous shaking for 2 hours. The detection antibody was diluted from 50 x stock
solution to 1 x solution by mixing 60 |il antibody with 2.94 ml diluent 100. 25 [i\ of diluted detection 
antibody was added to each well, and plates incubated for 1 hour at room temperature with vigorous 
shaking. Plates were washed using an automatic plate washer, and 150 pi per well of 2x read buffer 
diluted in distilled water was added to the plates. Plates were read within 30 minutes of the addition 
of read buffer on the MSD SECTOR instrument.
2.5. Haematoxylin and eosin staining
Preparation o f cell monolayer on cover slips
Cover slips were immersed in 70% ethanol solution for 5 minutes. They were then dried by 
individually tipping on their sides. Cover slips were then placed in 6  well plates at 1 cover slip per well 
and 100 pi poly-lysine (Sigma Aldrich) added to the centre of each cover slip. The plate was incubated 
at 37°C with the plate lid removed for 1 hour. Cover slips were washed twice with PBS to remove 
excess poly-lysine and then dried by incubating at 37°C with the lid removed for 1 hour. Plates were 
then sterilised under UV light for 10 minutes.
Ix lO 4 cells in 200 pi tissue culture media was added to the centre of each cover slip, and plates 
incubated for 2 hours at 37°C in a 5% C02 atmosphere to allow adherence. 3 ml media containing 
relevant cytokines was then added to each well, and cells were treated as in section 2 .2 .
Haematoxylin and eosin staining
After 48 hours of treatment, media was removed from the 6  well plate and 2 ml ice cold methanol 
(Sigma Aldrich) was added and incubated for 5 minutes to fix the cells. Cover slips were removed from 
the plates and placed on a 6  well plate lid. Haematoxylin (Vector) was added for 1 minute, and then 
the slide was rinsed in two separate beakers of distilled water to remove stain. Eosin (Vector) was 
then added for 1 minute, and then the slide was rinsed in two beakers of distilled water. The slide was
dehydrated in 70% ethanol for 30 seconds, then 85% ethanol for 30 seconds, then 100% ethanol for 
30 seconds. The cover slip was mounted to a slide using DPX mounting media (Fluka) and left to dry. 
Images of slides were taken using a Leica DMLB microscope with JVC camera, using Leica QWin V3 
software.
2.6. Mixed leukocyte reaction
moDC were isolated as described in section 2.1-2. moDCs were plated in 96 well plates at Ix lO 4 
cells/well, O.SxlO4 cells/well, 0.25xl04 cells/well and 0.125xl04cells/well in 200 pi tissue culture 
media containing 0.2 ng/ml IL-4 and 30 ng/ml GM-CSF. Cells were incubated at 37°C in a 5% C02 
atmosphere for 7 days. Every 2 days 100 pi media was removed and 100 pi fresh media and cytokines 
were added. On day 7 cells were stimulated with nucleotides and/or EPS, with distilled water used for 
controls.
On day 9, CD4+ T lymphocytes were isolated. To do this, blood was taken from a different donor to 
the donor who provided the moDCs and the protocol for the isolation of PBMC was followed. The 
resulting mononuclear cell pellet was used to isolate T cells using the CD4+ T cell isolation kit (Miltenyi 
Biotech) according to manufacturer's instructions. In brief, PBMC were centrifuged at 300 g for 10 
minutes, and supernatant aspirated. Cells were re-suspended in MACS buffer at 107 cells per 40 pi, 
and incubated with anti-biotin cocktail at 107 cells per lOpI for 10 minutes in the fridge. MACs buffer 
at 107 cells per 30 pi, plus anti-biotin microbeads at 107 cells per 20 pi was then added to the cell 
suspension and this was incubated for 15 minutes in the fridge. 2 ml MACS buffer was added to the 
cells, and they were centrifuged at 300 g for 10 minutes. The supernatant was aspirated, and the cells 
re-suspended in 500 pi buffer. An LS column was placed in the magnetic field of a midiMACS 
separator, and 2 ml MACS buffer was passed through the column and collected in a 50ml Falcon tube. 
The cell suspension was then passed through the column, followed by 3 x 3 ml MACS buffer, which
was added after each previous addition had emptied from the reservoir. Eluted cells (unlabelled CD4+ 
T cells) were collected in the Falcon tube and the LS column discarded. The CD4+T cells were made up 
to 50 ml with MACS buffer, and centrifuged at 300 g for 10 minutes, then re-suspended in 1ml tissue 
culture media and viable cells were counted using 0.4% trypan blue exclusion in a haemocytometer.
200 pi media was removed from the moDC wells, and T cells were added at 2x l0 5cells/well in 200 pi 
fresh tissue culture media. Treatments were added again to the appropriate wells, and cells were 
incubated for 5 days at 37°C with 5% C02.
On day 14, the non-adherent T cells were removed from culture by aspiration of 200 pi media and 
transferred to eppendorfs (1 well per eppendorf). Tubes were centrifuged at 300 g for 5 minutes. 100 
pi of supernatant was transferred to fresh eppendorf tubes, and stored for future analysis. The 
remaining cell pellet was analysed for number of T cells using the CYQUANT direct cell proliferation 
assay (Invitrogen) according to manufacturer's instructions. This assay includes a nucleic acid dye 
which measures DNA content to give an accurate estimation of cell number. In brief, a solution of 
CYQUANT GR solution was made up consisting of 19 ml distilled water plus 1 ml lysis buffer, plus 50 pi 
dye for one 96 well plate. 400 pi CYQUANT GR solution was added to each eppendorf containing T 
cells, the tube was vortexed, then 200 pi of the solution was added to the correct well of a black 96 
well clear bottom plate, in duplicate. To create a standard curve, Ix lO 6 T cells were collected from 
control wells. 1 ml CYQUANT GR solution was added to these cells, the tube was vortexed and an 8  
point standard curve created by diluting 1:2 per point, with a blank consisting of CYQUANT GR 
solution only. The plate was incubated for 30 minutes in the dark, and then read on a SpectraMAX 
Gemini XS fluorescent microplate reader at 515 nm wavelength using Softmax Pro software.
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2.7. Lung parenchyma
Solution preparation
Lung-tissue culture media was prepared. 50 ml of media was removed from a 500 ml bottle of RPMI 
without phenol red (GIBCO), and 0.1% BSA, 100 U/ml penicillin, 2mM glutamine, 100pg/ml 
streptomycin was added to the bottle and mixed.
ATP disodium salt, ATPyS tetralithium salt, ADP disodium salt, DTP trisodium salt hydrate, AMP 
disodium salt, a,(3-methyleneATP lithium salt, 2methylthioATP tetrasodium salt hydrate, P1P4DiATP 
ammonium salt and BzATP triethyleamonium salt (Sigma Aldrich) were made up to 500 mM stock 
concentrations using distilled water and stored as 20 pi aliquots at -4°C. Stock solutions were diluted 
using distilled water to produce final concentrations within the well of 1000, 330,112, 37,12 and 4 
pM.
Apyrase from potato (>200 units/mg protein, Sigma Aldrich) was made up to stock concentration 
using distilled water and stored 20 pi at -4°C. Stock solutions were diluted using distilled water to 
produce final concentrations within the well of 36, 12, 4, 1.3, 0.44 and 1.4 units/ml.
Adenosine deaminase (from bovine spleen >200 units/mg protein, Sigma Aldrich) was made up to 
stock concentration using distilled water and stored 20 pi at -4°C. Stock solutions were diluted using 
distilled water to produce final concentrations within the well of 25, 8.3, 2.7, 0.92, 0.31 and 0.1 
units/ml.
Adenosine (>99%, Sigma Aldrich) was made up to stock concentration using distilled water and stored 
at -4°C. Stock solutions were diluted using distilled water to produce final concentrations within the 
well of 70, 23.3, 7.7, 2.6, 0.86 and 0.28 pM.
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IPS was prepared to a stock concentration of 1 mg/ml with sterile PBS and stored in 100 pi aliquots at 
-4°C. 10 pg/ml was used in all samples. I/I/We lung parenchyma
Human lungs from brain dead donors which were not suitable for transplantation were obtained from 
the National Disease Research Interchange (Philadelphia), a not-for-profit tissue procurement 
organisation based in the USA, under the US Uniform Anatomical Gifts Act. Consent for research was 
obtained from the next of kin. Ethics approval was obtained by GlaxoSmithKline. Information received 
about the donor included age, sex, race, height, weight, medical history, consumption of alcohol, 
cigarettes and drugs, time on a ventilator, and cause of death.
Lung parenchyma was dissected away from bronchial tissue. A 5 cm piece of lung was taken, and the 
outer layer of the parenchyma was removed using scissors, along with any fibrous tissue and large 
airways. The piece was placed in a Petri dish with 5 ml of lung-tissue culture media, and chopped 
finely using scissors. The suspension was then filtered through a 1 mm square sieve into a sterile Petri 
dish. The filtered fragments were transferred into a fresh, pre-weighed Falcon tube. The residual 
tissue was further chopped using scissors, and filtered once more. These fragments were added to the 
pre-weighed Falcon tube and made up to 50ml with lung-tissue culture media. The tube was 
centrifuged at 800 rpm for 2  minutes, and the supernatant was poured away, leaving the pellet of 
fragments. The fragments were made up to 50ml with fresh lung-tissue culture media and the 
centrifugation process was repeated 2-4 times until the supernatant was clear. A final centrifugation 
of 1300 rpm for 5 minutes was then carried out, after which the supernatant was removed. The tube 
containing the fragment pellet was then weighed, and fragment weight calculated. The fragments 
were re-suspended in fresh lung-tissue culture media to 0.04 g/ml and transferred into a wide necked 
sample pot.
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Nucleotides were made up in distilled water to the appropriate concentrations and 1.4 pi of 
nucleotide solution was pipetted into the corresponding well of a 48 well tissue culture plate.
A magnetic stirrer was used to mix the lung suspension, and 0.7 ml of homogenate was pipetted into 
each well, with care taken to ensure all wells had approximately the same amount of tissue. 1 0  pi of 
IPS was then added to the corresponding wells (the two treatments were added separately to avoid 
cross-contamination), and the plates incubated at 37°C for 24 hours. After 24 hours, 200 pi 
supernatant was removed from each well and stored at -80°C for further analysis.
mDC and pDC isolation from lung parenchyma
A 2 inch piece of lung tissue was prepared as stated above, to gain a Falcon tube of lung fragments. 50 
ml of digestion media consisting of lung-tissue culture media plus 0.02mg/ml DNAse (Invitrogen) plus 
lm g/m l collagenase (Invitrogen) was added to the tube. This was incubated for 30 minutes at 37°C in 
a 5% C02 atmosphere. The tissue was washed by centrifugation, and incubated in fresh digestion 
media for 15 minutes at 37°C in a 5% C02 atmosphere. The tissue was washed and re-suspended in 
PBS + 10 mM EDTA, and incubated for 5 minutes at room temperature on a shaker. Fragments were 
then passed through a 70 pm strainer into a fresh Falcon tube, and then passed through a 40 pm 
strainer to ensure a single cell suspension was obtained. This suspension (35ml) was layered over 
15ml Histopaque-1077, and this was centrifuged at 400 g for 30 minutes at 20°C without brake. The 
interface layer was used to isolate pDCs using the BDCA-4 kit (Miltenyi Biotech), using a SuperMACS 
according to manufacturer's instructions (see section 2.2). The unlabelled cell fraction was set aside 
for mDC isolation. The eluted pDC fraction was counted using an automated cell counter.
The unlabelled cell fraction was centrifuged at 1300 rpm for 5 minutes, and then mDC were isolated 
using the BDCA-1 kit (Miltenyi Biotech) according to manufacturer's instructions (see section 2.2). The 
eluted mDC fraction was counted using an automated cell counter.
mDC and pDC were plated at 2x l04 cells per well in 200 pi lung-tissue culture media, in 96 well plates 
and stimulated with nucleotides (0.3 pi per well) plus or minus LPS (2 pi per well, for mDCs) or 
resiquimod (4 pi per well for pDCs). Plates were incubated at 37°C in a 5% C02 atmosphere for 48 
hours. At 24 hours and 48 hours, 100 pi supernatant was removed and stored at -80°C for future 
analysis of cytokine content via MSD immunoassay (see section 2.4).
2.8. Statistics
In chapter 3, the raw data was analysed. This was done by a paired t-test between control and 
LPS/resiquimod, one way repeated measures ANOVA between control and nucleotide concentrations, 
and one way repeated measured ANOVA between LPS/resiquimod and nucleotide concentrations 
plus LPS/resiquimod. A post hoc Dunnett's test between treatments and the relevant control was 
performed to identify differences between treatments.
In chapter 4, LPS experiments were analysed by paired t-test between LPS and untreated control. For 
other experiments the normalised data was analysed to account for human variation. Data was 
normalised by subtracting the non-treated control value from the treatment value, and then dividing 
by the LPS/resiquimod control value. Statistical analysis was carried out using a one way repeated 
measures ANOVA, with a post hoc Dunnett's test between treatments and LPS control to identify 
differences between treatments.
Chapter 3 - The effect of extracellular nucleotides in blood dendritic cell
subtypes
3.1. Introduction
It is hypothesised that extracellular ATP acts as a danger signal in human DCs. Activation of a DC by a 
danger signal leads to multiple downstream events. Firstly, co-stimulatory markers are up-regulated 
on the DC surface. These molecules bind to corresponding molecules on the surface of naïve T cells, 
and together this provides co-stimulation to fully activate T cells together with antigen presentation 
by the DC (as shown in figure 1.1). Alongside this, cytokines are released by the DC which determines 
the type of T cell response generated, i.e. IL-12 release promotes a T h l cell response, whereas IL-4 
promotes a Th2 cell response. The effect of danger signals on DCs has been shown using multiple 
molecules including CD40L, which is expressed on activated platelets at the site of tissue injury, and 
the pro-inflammatory cytokine IL-1(3. CD40L induces the maturation of moDCs which would ensure 
that any pathogens encountered are removed by the immune system (Caux et al., 1994). IL-1(3 is an 
inducible danger signal that induces IL-12 release from moDCs, skewing the immune response to a 
Th l response (Wesa & Galy, 2001).
The suggestion that extracellular ATP may act as a danger signal on human DCs has been widely 
accepted, due to evidence that extracellular ATP causes changes in DCs associated with their 
maturation. For example, ATP induced the uptake of particulates by immature moDCs, and over time 
this ability is reduced possibly due to the maturation of the moDCs which reduces their phagocytic 
capacity (Schnurr et al., 2000). ATP-matured DCs also induce the migration and proliferation of 
certain T cell subsets (la Sala, 2002). However, when cells are studied for their co-stimulatory marker 
expression and cytokine release, the evidence for ATP acting as a danger signal is less clear due to
variation in responses (Schnurr et al., 2000; la Sala et al., 2001; Marteau et al., 2004). It is necessary, 
therefore, to use statistically appropriate analysis to determine the true effects of ATP on moDCs.
The conflicting evidence offered by the current literature leads to questions about the exact effects of 
extracellular nucleotides acting as danger signals in the immune system. For this reason, the aim of 
this chapter was to elucidate the true effects of ATP on moDCs, as well as on mDCs and pDCs enriched 
from human peripheral blood. It is hypothesised that extracellular ATP will induce the maturation of 
DCs and induce a Th2 skewing of the immune response. In order to prove this hypothesis, a number 
of experimental techniques have been used.
In moDCs, the expression of co-stimulatory markers has been studied using multiple donors, and 
statistical tests have been applied to the results in order to determine whether ATP is able to mature 
moDCs. Cytokine secretion from these DCs has also been analysed, providing not only a statistical 
evidence of a result, but also extending the number of cytokines studied compared to that already 
published. The effects of stimulated moDCs on T cell proliferation have also been studied, in order to 
link the effects of nucleotides on moDCs alone with their effects on other cell types. LPS, a TLR 4 
agonist had been used as a positive control, as it is known that LPS induces the maturation of moDCs 
by up-regulating co-stimulatory molecules and inducing T h l cytokine secretion in these cells (Corinti 
et al., 2 0 0 1 ).
The next problem to address in this study was whether the effects seen in moDCs are the same to 
those seen in mDCs. It is believed that the two cell types are the same, as they have similar properties 
and act in similar ways; however this has not been demonstrated conclusively. For this reason, mDCs 
were enriched from the monocyte population, and the experiments repeated on this cell type. This 
will allow comparison with the effects of nucleotides on mDCs in the blood. In order to attempt to 
confirm that these effects are due to activation of a P2 receptor, the non-hydrolysable form of ATP,
ATPyS was used in this study. ATP is rapidly broken down by ecto-nucleotidases to ADP, AMP and 
adenosine, which act on varying P2 and PI receptors (Yegutkin, 2008). It is possible therefore, that 
any effects seen with ATP are not due to its binding to ATP-specific P2 receptors, but instead to its 
breakdown products. ATPyS, however, is not broken down in culture, and so results seen with this 
compound will represent effects of the ATP-specific P2 receptors.
To complete the study of DCs and ATP, the effects on pDCs have also been studied. This is because 
there are few studies on the effects of nucleotides on this cell type, and as they play an important 
anti-viral role in the body it is important to determine what effect ATP has on them. Resiquimod was 
used in these studies in place of LPS, as pDCs lack the extracellular TLRs (including TLR 4 which binds 
LPS), so an intracellular TLR agonist was required. Resiquimod has been shown to induce large 
amounts of IFNa secretion from pDCs, but may also increase co-stimulatory marker expression on 
these cells, indicating that it may induce their maturation (Gibson et al., 2002).
3.2. Methods
3.2.1. Cell isolation
MoDCs were isolated from human peripheral blood as described in section 2.1. In brief, blood was 
taken from volunteers by venepuncture, and PBMCs were isolated by density gradient centrifugation 
using Histopaque-1077. The PBMC layer was used to isolate monocytes, using the CD14+ monocyte 
isolation kit as detailed in section 2.2. Isolated CD14+ cells were plated at 5x10s cells per well of a 48 
well plate in advanced RPMI media containing 30 ng/ml GM-CSF and 0.2 ng/ml IL-4. Plates were 
incubated at 37°C in a 5% C02 atmosphere for 7 days, with half of the media and cytokines changed 
every 48 hours. After 7 days, cells were stimulated as in section 2.2.
mDCs were isolated from leukocyte cones as detailed in section 2.1. In brief, leukocyte cones were 
received from the National Blood Service, and PBMCs were isolated by density gradient centrifugation 
using Histopaque-1077. The PBMC layer was used to isolate mDCs, using the BDCA-1 isolation kit as 
detailed in section 2.2. Isolated BDCA-1+ cells were plated at 2x10* cells per well of a 96 well plate in 
media containing 30 ng/ml G-CSF and 0.2 ng/ml IL-4. Plates were incubated at 37°C in a 5% CO2 
atmosphere overnight. The next morning, media was removed and replaced with fresh media 
containing cytokines, and cells were stimulated as in section 2 .2 .
pDCs were isolated from leukocyte cones as detailed in section 2.1. In brief, leukocyte cones were 
received from the National Blood Service, and PBMCs were isolated by density gradient centrifugation 
using Histopaque-1077. The PBMC layer was used to isolate pDCs, using the BDCA-4 isolation kit as 
detailed in section 2.2. Isolated BDCA-4+ cells were plated at 2x10* cells per well of a 96 well plate in 
media containing 2 ng/ml IL-3. Plates were incubated at 37°C in a 5% C02 atmosphere overnight. The 
next morning, media was removed and replaced with fresh media containing cytokines, and cells 
were stimulated as in section 2 .2 .
3.2.2. Cell stimulation
moDCs and mDCs were stimulated with vehicle (distilled water), ATP or ATPyS at 10, 100 and 500 pM, 
LPS 10 pg/ml, ATP plus LPS or ATPyS plus LPS. pDCs were stimulated with vehicle, ATP or ATPyS at 10, 
100 and 500 pM, resiquimod 2 pM, ATP plus resiquimod or ATPyS plus resiquimod. Cells were 
incubated at 37°C in a 5% C02 atmosphere for 48 hours.
3.2.3. Haematoxylin and eosin staining
For H&E staining, moDCs were plated on cover slips, in 6  well plates. Media was removed from the 
wells and 2 ml of ice cold methanol added and incubated for 5 minutes to fix cells. Cover slips were
then removed from wells and placed on plate lid. Haematoxylin was added for 1 minute, the slide was 
rinsed in two separate beakers of distilled water to remove the stain. Eosin was then added for 1 
minute, and then the slide was rinsed in two beakers of distilled water. The slide was dehydrated in 
70% ethanol for 30 seconds, then 85% ethanol for 30 seconds, then 100% ethanol for 30 seconds. The 
cover slip was mounted to a slide using DPX mounting media and left to dry. Images of slides taken 
using a Leica microscope with Leica QWin software, as described in section 2.5.
3.2.4. Flow cytometry
After 48 hours, cells were prepared for flow cytometry as stated in section 2.4. moDCs were stained 
using the 3 colour protocol as shown in table 2.1. mDCs and pDCs were stained using the 4 and 5 
colour staining protocol as shown in table 2.2. Flow cytometry was performed using a BD FACS Canto 
II with FACSDiva software, and results analysed using Flowjo software.
3.2.5. Cytokine analysis
Supernatants from DCs were removed prior to flow cytometry, or from T cell cultures prior to 
CYQUANT assay and stored at -80°C. Cytokine levels in supernatants were analysed using MSD 
immunoassay as detailed in section 2.4
3.2.6. T cell proliferation
moDCs were isolated as previously described, and plated to give DC:T cell ratios of 1:20, 1:40, 1:80 
and 1:160 as described in section 2.6. Cells were incubated with nucleotides in the presence or 
absence of IPS as previously described. On day 9, blood was taken from a different donor, and PBMCs 
were isolated using density gradient centrifugation. CD4+ T cells were then isolated using the CD4+ 
isolation kit as described in section 2.6. Media was then removed from moDCs cultures, and replaced 
with media containing 2x l0 5 cells per well. Cells were re-stimulated with treatments, and incubated
for 5 days to allow T cell proliferation. After 5 days, cells were analysed for T cell numbers using the 
CYQUANT assay as described in section 2.6.
3.2.7. Statistical analysis
Results from all studies were analysed for statistical significance using Graphpad Prism software 
(Graphpad software Inc.). In order to compare cells stimulated with LPS or resiquimod against control 
cells, a paired t-test was used. In order to compare cells stimulated with nucleotides against control 
cells, a one way repeated measures ANOVA with post-hoc Dunnett's test was used. In order to 
compare cells treated with LPS/resiquimod plus nucleotides against cells treated with 
LPS/resiquimod, a one way repeated measures ANOVA with post-hoc Dunnett's test was used. Results 
from all treatments were presented on one graph for ease of comparison.
3.3. Results
3.3.1. Monocyte-derived dendritic cells
3.3.1.1. Haematoxylin and eosin staining
Pictures taken of moDCs stained with H&E show the dendritic-like structure of moDCs. There were no 
obvious differences noted between treatments (Fig. 3.1).
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Figure 3.1 - Haematoxylin and eosin staining of moDCs.
MoDCs from human blood were stimulated for 48 hours at 37°C with ATP 10 in the presence or 
absence of LPS (10 pg/ml). Cells were stained with H&E and pictures taken. A represents control cells, 
B represents LPS-treated cells, C represents ATP 10 pM treated cells, and D represents cells treated 
with ATP 10 pM and LPS, all at x 100 magnification.
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3.3.1.2. Co-stimulatory marker expression
48 hour stimulation of moDCs with ATP at 10,100 and 500 pM concentrations had no significant 
effect on the percentage of moDCs expressing the co-stimulatory markers HLA-DR, CD80, CD83, CD8 6 , 
CD209 or CD14 compared to untreated control cells (p>0.05, one way repeated measures ANOVA, Fig.
3.2 A-F).
LPS (10 pg/ml) caused a significant increase in the percentage of cells positive for HLA-DR (p<0.01, Fig
3.2 A), CD80 (p<0.05. Fig 3.2 B), CD83 (p<0.05, Fig 3.2 C), CD8 6  (p<0.05, Fig 3.2 D) and CD14 (p<0.05, 
Fig 3.2 F) compared to untreated control, but no significant change was seen in the percentage of 
cells positive for CD209 (p>0.05, paired t-test, Fig. 3.2 E).
ATP in combination with LPS caused a significant decrease in the percentage of cells expressing HLA- 
DR (p<0.05 at 500 pM, Fig. 3.2 A), CD80 (p<0.05 at 10 and 100 pM and p<0.01 at 500 pM, Fig 3.2 B), 
CD8 6  (p<0.01 at 500 pM, Fig. 3.2 D), and in CD209 (p<0.005 at 500 pM, Dunnett's post hoc test, Fig.
3.2 E) compared to LPS alone. No significant change was seen with CD83 and CD14 (p>0.05, one way 
repeated measures ANOVA, Fig. 3.2 C, F).
ATP 500 pM caused a significant increase in the MFI of CD8 6  (p<0.05. Fig 3.3 D), and a decrease in the 
MFI of CD209 on moDCs compared to untreated control cells (p<0.05, Dunnett's post hoc test, Fig. 3.3 
E). There were no significant effects of ATP on the MFI of HLA-DR, CD80, CD83 or CD14 compared to 
control (p>0.05, one way repeated measures ANOVA, Fig. 3.3 A, B, C, F).
LPS caused a significant increase in the MFI of HLA-DR (p<0.05), CD8 6  (p<0.05) and CD14 (p<0.05, 
paired t-test, Fig. 3.3 A, D, F) compared to untreated control. There were no significant effects of LPS 
on the MFI of CD80, CD83 and CD209 (p>0.05, paired t-test, Fig. 3.3 B, C, E).
ATP in combination with LPS caused a significant decrease in the MFI of CD209 at 100 |-iM ATP 
(p<0.05) and 500 pM (p<0.01, Dunnett's post hoc test, Fig. 3.3 E) compared to LPS alone. No 
significant effects were seen with HLA-DR, CD80, CD83, CD209 or CD14 (p>0.05, one way repeated 
measures ANOVA, Fig. 3.3 A, B, C, E, F).
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Figure 3.2 - Effect of ATP in the presence or absence of LPS on cell surface expression of co-stimulatory 
markers on moDCs.
MoDCs from human blood were stimulated for 48 hours at 37°C with ATP (10,100 and 500 pM) in the presence 
or absence of LPS (10 pg/ml). Cells were analysed for cell surface markers using flow cytometry. Percentage of 
cells positive for HLA-DR (A), CD80 (B), CD83 (C), CD8 6  (D), CD209 (E) or CD14 (F) are shown, with 100% 
indicating the whole cell population. Values are expressed as mean ± SEM of 7 independent experiments 
analysed by one way repeated measures ANOVA between control and ATP, LPS and LPS+ATP with post hoc 
Dunnett's test, or by paired t-test between control and LPS. *p<0.05, **p<0.01, ***p<0.005.
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Figure 3.3 - Effect of ATP in the presence or absence of LPS on the mean fluorescence intensity of co­
stimulatory markers on moDCs.
MoDCs from human blood were stimulated for 48 hours at 37°C with ATP (10,100 and 500 pM) in the presence 
or absence of LPS (10 pg/ml). Cells were analysed for cell surface markers using flow cytometry. Mean 
fluorescence intensity (MFI) of HLA-DR (A), CD80 (B), CD83 (C), CD8 6  (D), CD209 (E) or CD14 (F) on the cell 
surface are shown. Values are expressed as mean ± SEM of 7 independent experiments analysed by one way 
repeated measures ANOVA between control and ATP, LPS and LPS+ATP with post hoc Dunnett's test, or by 
paired t-test between control and LPS. *p<0.05, **p<0.01.
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3.3.1.3. Cytokine release by moDCs
48 hour stimulation of moDCs with ATP at 10,100 and 500 \iW\ had no significant effect on the 
secretion of IFNy, IL-1(3, IL-6 , IL-8 , IL-10, IL-12p70 and TNFa compared to untreated control cells 
(p>0.05, one way repeated measures ANOVA, Fig 3.4 A-G).
LPS (10 pg/ml) caused a significant increase in the secretion of IFNy (p<0.05, Fig 3.4 A), IL-1(3 (p<0.05, 
Fig 3.4 C), TNFa (p<0.01, Fig 3.4 D), IL-6  (p<0.05, Fig 3.4 E), IL- 8  (p<0.05. Fig 3.4 F), and IL-10 (p<0.05, 
Fig 3.4 G) from moDCs compared to untreated control, whereas no effect was seen with IL-12p70 
(p>0.05, paired t-test, Fig. 3.4 B).
ATP had no significant effect on the secretion of IFNy (p>0.05, Fig 3.4 A) or IL-12p70 (p>0.05, Fig. 3.4 
B) induced by LPS compared to LPS alone. ATP dose-dependently inhibited LPS induced secretion of 
IL-1(3 (p<0.05 at 500 pM ATP, Fig. 3.4 C), TNFa (p<0.05 at 10 pM ATP, p<0.01 at 100 pM ATP, p<0.005 
at 500 pM ATP, Fig. 3.4 D), IL- 6  (p<0.05 at 100 pM ATP, pcO.Ol at 500 pM ATP, Fig. 3.4 E), IL-8  (p<0.01 
at 500 pM ATP, Fig. 3.4 F) and IL-10 (p<0.05 at 100 pM ATP, p<0.01 at 500 pM ATP, Dunnett's post 
hoc test, Fig. 3.4 G) compared to LPS alone.
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Figure 3.4 - Effect of ATP on the release of IFNy, IL-12p70, IL-ip, TNFa, IL-6 , IL-8  and IL-10 from moDCs 
incubated in the presence or absence of LPS.
MoDCs from human blood were stimulated for 48 hours at 37°C with ATP (10,100 and 500 p.M) in the presence 
or absence of LPS (10 pg/ml). The cytokines IFNy(A), IL-12p70 (B), IL-lp (C), TNFa (D), IL-6  (E), IL-8  (F) and IL-10 
(G) are shown. Values are expressed as mean ± SEM of 7 independent experiments analysed by one way 
repeated measures ANOVA between control and ATP, LPS and LPS+ATP with post hoc Dunnett's test, or by 
paired t-test between control and LPS. *p<0.05, **p<0.01, ***p<0.005.
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3.3.1.4. Mixed leukocyte assay
moDCs matured in the presence of 10,100 or 500 pM ATP had no effect on the proliferation of CD4+ T 
cells in vitro compared to untreated control cells at all of the DOT cell ratios used (p>0.05, one way 
repeated measures ANOVA, Fig. 3.5). LPS matured moDCs also had no significant effect of the 
proliferation of CD4+T cells compared to untreated control at all of the DOT cell ratios used (p>0.05, 
paired t-test, Fig. 3.5). When used in combination, LPS and all concentrations of ATP had no effect on 
the proliferation of CD4+ T cells compared to LPS alone at all of the DOT cell ratios used (p>0.05, one 
way repeated measures ANOVA, Fig. 3.5 A-D).
ATP, LPS or the two in combination had no effect on the release of IL-lp, IL-2, IL-4, IL-12, IL-13 and 
TNFa from CD4+ T cells stimulated with moDCs (p>0.05. Fig. 3.6 A-F). No effect was also seen for IL-10, 
IL-5, IL-6 , IL-8 , IL-17 and IFNy for any of the treatments used (p>0.05, data not shown).
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Figure 3.5 - The effect of ATP in the presence or absence of LPS on the T cell stimulatory capacity of 
moDCs.
moDCs from human blood were stimulated for 48 hours at 37°C with ATP (10, 100 and 500 ^M) in the 
presence or absence of LPS (10 pg/ml). After 48 hours, all media was removed and replaced with 
media containing T cells from a different donor at the corresponding DC:T cell ratio. Cells were re­
stimulated with ATP and/or LPS and incubated for 5 days at 37°C. On day 5, T cells were removed by 
aspiration and T cell number was analysed by CYQUANT live cell assay. Values are expressed as mean 
± SEM of 4 independent experiments analysed by one way repeated measures ANOVA between 
control and ATP, LPS and LPS+ATP with post hoc Dunnett's test, or by paired t-test between control 
and LPS.
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Figure 3.6 - The effect of ATP in the presence or absence of LPS on the release of cytokines from 
CD4+T cells.
moDCs from human blood were stimulated for 48 hours at 37°C with ATP (10, 100 and 500 pM) in the 
presence or absence of LPS (10 pg/ml). After 48 hours, all media was removed and replaced with 
media containing T cells from a different donor at 1:20 DOT cell ratio. Cells were re-stimulated with 
ATP and/or LPS and incubated for 5 days at 37°C. On day 5, supernatants were removed and analysed 
for cytokine release by MSD immunoassay. Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATP, LPS and 
LPS+ATP with post hoc Dunnett's test, or by paired t-test between control and LPS.
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3.3.2. Myeloid dendritic cells
3.3.2.1. Co-stimulatory marker expression
48 hour stimulation of mDCs with ATP at 10 (p<0.05), and 500 pM (p<0.05, Dunnett's post hoc test. 
Fig. 3.7 A) caused a significant increase in the number of cells expressing HLA-DR compared to 
untreated control. ATP caused a significant decrease in CD209 expression compared to control at 100 
pM (p<0.05, Dunnett's post hoc test, Fig. 3.7 E). No significant effects of ATP were seen with CD80, 
CD83 and CD8 6  (p>0.05, one way repeated measures ANOVA, Fig. 3.7 B, C, D).
48 hour stimulation of mDCs with ATPyS at 500 pM caused a significant increase in the percentage of 
cells positive for CD83 compared to untreated control (p<0.01, Dunnett's post hoc test, Fig. 3.8 C). 
There were no significant effects of ATPyS at 10,100 or 500 pM concentrations at the other markers 
analysed compared to non-treated control (p>0.05, one way repeated measures ANOVA, Fig. 3.8 A, B, 
D, E).
LPS (10 pg/ml) caused no significant changes in any of the markers analysed compared to untreated 
control (p>0.05, paired t-test, Fig. 3.7 and 3.8). There was an apparent decrease in CD209 expression 
caused by LPS, but this did not reach significance (p>0.05, Fig. 3.7 E and 3.8 E).
ATP in combination with LPS caused no significant changes to any of the markers compared to LPS 
alone (p>0.05, one way repeated measures ANOVA, Fig. 3.7 A-E). There was no significant effect of 
ATPyS in combination with LPS compared to LPS alone at any of the markers analysed (p>0.05, one 
way repeated measures ANOVA, Fig. 3.8 A-E).
ATP or ATPyS alone caused no significant change in the MFI of any of the co-stimulatory markers 
analysed compared to control (p>0.05, one way repeated measures ANOVA, Fig.3.9 A-E).
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LPS caused a significant decrease in the MFI of HLA-DR (p<0.05, Fig. 3.9 A and 3.10 A), and CD83 
(p<0.05, paired t-test, Fig. 3.9 A) compared to untreated control. No significant changes were 
observed for the other markers studied (p>0.05, Fig. 3.9 and 3.10 B-E).
ATP 500 pM in combination with LPS caused a significant increase in the MFI of CD8 6  compared to 
LPS alone (p<0.05, Dunnett's post hoc test. Fig. 3.9 D). ATP 10, 100 and 500 pM in combination with 
LPS caused no other changes to the expression of co-stimulatory markers compared to LPS alone 
(p>0.05, one way repeated measures ANOVA, Fig. 3.9 A, B, C, E, 3.10 B, C, D, E). There was no 
significant effect of ATPyS in combination with LPS on the expression of any of the markers tested 
(p>0.05, one way repeated measures ANOVA, Fig. 3.10 A-E).
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Figure 3.7 - Effect of ATP in the presence or absence of LPS on cell surface expression of co-stimulatory 
markers on myeloid DCs.
mDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATP (10,100 and 500 pM) in the presence 
or absence o f LPS (10 pg/m l). Cells were analysed fo r cell surface markers using flow  cytom etry. Percentage o f 
cells positive fo r HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) are shown, w ith  100% indicating the 
whole cell population. Values are expressed as mean ± SEM o f 4 independent experiments analysed by one 
way repeated measures ANOVA between control and ATP, LPS and LPS+ATP w ith  post hoc Dunnett's test, or by 
paired t-test between control and LPS. *p<0.05.
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Figure 3.8 - Effect of ATPyS in the presence or absence of LPS on cell surface expression of co-stimulatory 
markers on myeloid DCs.
mDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATPyS (10, 100 and 500 pM ) in the 
presence or absence o f LPS (10 pg/m l). Cells were analysed fo r cell surface markers using flow  cytom etry. 
Percentage o f cells positive fo r HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) are shown, w ith  100% 
indicating the whole cell population. Values are expressed as mean ± SEM o f 4 independent experim ents 
analysed by one way repeated measures ANOVA between control and ATP, LPS and LPS+ATP w ith  post hoc 
Dunnett's test, or by paired t-test between control and LPS. **p<0.01.
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Figure 3.9 - Effect of ATP in the presence or absence of LPS on the mean fluorescence intensity of co­
stimulatory markers on myeloid DCs.
mDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATP (10,100 and 500 pM) in the presence 
or absence o f LPS (10 pg/m l). Cells were analysed fo r cell surface markers using flow  cytom etry. Mean 
fluorescence intensity (MFI) o f HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) on the cell surface are 
shown. Values are expressed as mean ± SEM of 4 independent experiments analysed by one way repeated 
measures ANOVA between control and ATP, LPS and LPS+ATP w ith  post hoc Dunnett's test, or by paired t-tes t 
between control and LPS. *p<0.05.
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Figure 3.10 - Effect of ATPyS in the presence or absence of LPS on the mean fluorescence intensity of co­
stimulatory markers on myeloid DCs.
mDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATPyS (10, 100 and 500 pM) in the 
presence or absence o f LPS (10 pg/m l). Cells were analysed fo r cell surface markers using flo w  cytom etry.
Mean fluorescence intensity (MFI) o f HLA-DR (A), CD80 (B), CD83 (C), CD86 (0), or CD209 (E) on the cell surface 
are shown. Values are expressed as mean ± SEM o f 4 independent experiments analysed by one way repeated 
measures ANOVA between control and ATP, LPS and LPS+ATP w ith  post hoc Dunnett's test, or by paired t-tes t 
between control and LPS. **p<0.01.
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3.3.2.2. Cytokine release by mDCs
48 hour stimulation of mDCs with ATP at 100 and 500 pM caused a significant decrease in the 
secretion of IL-4 compared to untreated control (p<0.05 and p<0.01 respectively, Dunnett's post hoc 
test, Fig. 3.11 F). No other significant effects were seen with the other cytokines tested (p>0.05, Fig. 
3.11 and 3.12).
ATPyS caused a significant decrease in IL-4 secretion compared to untreated control at 10 pM 
(p<0.005), 100 pM (p<0.005) and 500 pM (p<0.005, Dunnett's post hoc test, Fig. 3.13 F). ATPyS 500 
pM also caused a significant decrease in IL-10 secretion from mDCs compared to control (p<0.05, 
Dunnett's post hoc test, Fig. 3.13 B). No other significant effects were seen with the other cytokines 
tested (p>0.05, Fig. 3.13 and 3.14).
LPS caused a significant decrease in IL-4 secretion compared to control (p<0.05, paired t-test, Fig. 3.11 
F and 3.13 F). No other significant effects were seen with the other cytokines tested (p>0.05, Fig. 3.11 
-3.14).
ATP in combination with LPS caused no further significant change in IL-4 release compared to LPS 
alone (p>0.05, Fig. 3.11 F), which was the same case for ATPyS in combination with LPS (p>0.05, one 
way repeated measures ANOVA, Fig. 3.14 F). ATPyS 500 pM in combination with LPS caused a 
significant decrease in IL-10 secretion compared to LPS alone (p<0.05, Dunnett's post hoc test, Fig. 
3.13). No significant effects of ATP/ATPyS in combination with LPS were seen with the secretion of the 
cytokines IL-1(3, IL-12p70, IL-13, IL-2, IL-5, TNFa, IFNy, and IL- 6  (p>0.05, Fig. 3.11 -  3.14). The values of 
IFNy and IL-5 were very low, which means that these results show variability.
The values for IL-8  were consistently above the upper limit of the assay sensitivity, making it 
impossible to analyse the results for this cytokine (data not shown).
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Figure 3.11 - Effect of ATP on the release of IL-ip, IL-10, IL-12p70, IL-13, IL-2 and IL-4 from mDCs incubated in 
the presence or absence of LPS.
mDCs from  human blood were stim ulated fo r 48 hours at 37°C w ith  ATP (10,100 and 500 pM) in the presence 
or absence o f LPS (10 pg/m l). Values are expressed as mean ± SEM o f 4 independent experiments analysed by 
one way repeated measures ANOVA between control and ATP, LPS and LPS+ATP w ith  post hoc Dunnett's test, 
or by paired t-test between control and LPS. *p<0.05, **p<0.01.
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Figure 3.12 - Effect of ATP on the release of IL-5, TNFa, IFNy, IL-17, and IL-6 from mDCs incubated in 
the presence or absence of LPS.
mDCs from human blood were stimulated for 48 hours at 37°C with ATP (10, 100 and 500 (iM) in the 
presence or absence of LPS (10 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATP, LPS and 
LPS+ATP with post hoc Dunnett's test, or by paired t-test between control and LPS.
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Figure 3.13 - Effect of ATPyS on the release of 11-1(3, IL-10, IL-12p70, IL-13, IL-2 and IL-4 from mDCs 
incubated in the presence or absence of LPS.
mDCs from human blood were stimulated for 48 hours at 37°C with ATPyS (10, 100 and 500 jiM) in 
the presence or absence of LPS (10 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATPyS, LPS and 
LPS+ATPyS with post hoc Dunnett's test, or by paired t-test between control and LPS. *p<0.05, 
**p<0 .0 1 .
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Figure 3.14 - Effect of ATPyS on the release of IL-5, TNFa, IFNy, IL-17, and IL-6 from mDCs incubated 
in the presence or absence of LPS.
mDCs from human blood were stimulated for 48 hours at 37°C with ATPyS (10, 100 and 500 |uM) in 
the presence or absence of LPS (10 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATPyS, LPS and 
LPS+ATPyS with post hoc Dunnett's test, or by paired t-test between control and LPS.
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3.3.3. Plasmacytoid dendritic cells 
3.3.3.1. Co-stimulatory marker expression
48 hour stimulation of pDCs with ATP caused a significant increase in the number of cells expressing 
CD209 (10pM p<0.05, 500 pM p<0.05, Dunnett's post hoc test, Fig. 3.15 E). No significant effect was 
found for ATP on any of the other markers measured (p>0.05, one way repeated measures ANOVA, 
Fig. 3.15). ATPyS caused a significant increase in the number of cells expressing CD209, at all 
concentrations (10 pM p<0.05,100 pM p<0.05, 500 pM p<0.01, Dunnett's post hoc test, Fig. 3.16 E). 
No significant effect was found for ATPyS on any of the other markers measured (p>0.05, one way 
repeated measured ANOVA, Fig. 3.16).
Resiquimod had no effect on the percentage of marker expression for all the markers tested (p>0.05, 
paired t-test, Fig. 3.15, 3.17).
ATP and ATPyS both decreased the percentage of cells expressing CD80 induced by resiquimod (ATP 
500 pM p<0.05, Fig. 3.15 B, ATPyS 100 pM p<0.05, 500 pM p<0.01, post hoc Dunnett's test, Fig. 3.16 
B). No effect was seen on any of the other markers tested (p>0.05, one way repeated measures 
ANOVA).
48 hour stimulation of pDCs with ATP caused no effect on the MFI of any of the markers tested (Fig. 
3.17, p>0.05, one way repeated measures ANOVA). ATPyS caused an increase in the MFI of CD209 on 
pDCs compared to control (p<0.05, post hoc Dunnett's test, Fig. 3.18 E). No significant effects were 
seen for ATPyS on the MFI of any of the other markers tested (p>0.05, one way repeated measures 
ANOVA, Fig 3.18).
Resiquimod alone caused a significant increase in the MFI of CD8 6  compared to control (p<0.05, Fig. 
3.17 D), but had no effect in the ATPyS experiment (p>0.05, paired t-test, Fig. 3.18 D). Resiquimod had 
no significant effect on the other markers (p>0.05, Fig. 3.17, 3.18).
ATP in combination with resiquimod caused a significant decrease in the MFI of CD80 at 100 pM 
(p<0.05) and 500 pM (p<0.01, Dunnett's post hoc test, Fig. 3.17 B) compared to resiquimod alone. 
ATPyS in combination with resiquimid caused a small but statistically significant decrease in the MFI 
of HLA-DR compared to LPS alone (p<0.05, lOOpM ATP, Fig 3.18 A), and in the MFI of CD83 at 10 pM 
(p<0.01) and 100 pM (p<0.005, Dunnett's post hoc test, Fig. 3.18 C) compared to resiquimod alone.
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Figure 3.15 - Effect of ATP in the presence or absence of resiquimod on cell surface expression of co­
stimulatory markers on plasmacytoid DCs.
pDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATP (10, 100 and 500 pM) in the presence 
or absence o f resiquimod (2 pM). Cells were analysed fo r cell surface markers using flo w  cytom etry. 
Percentage o f cells positive fo r HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) are shown, w ith  100% 
indicating the whole cell population. Values are expressed as mean ± SEM o f 4 independent experiments 
analysed by one way repeated measures ANOVA between control and ATP, resiquimod and resiquimod+ATP 
w ith  post hoc D unne tfs  test, or by paired t-test between control and resiquimod. *p<0.05.
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Figure 3.16 - Effect of ATPyS in the presence or absence of resiquimod on cell surface expression of co­
stimulatory markers on plasmacytoid DCs.
pDCs from  human blood were stim ulated fo r 48 hours at 37°C w ith  ATPyS (10,100 and 500 pM) in the 
presence or absence o f resiquimod (2 pM). Cells were analysed fo r cell surface markers using flow  cytom etry. 
Percentage o f cells positive fo r HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) are shown, w ith  100% 
indicating the whole cell population. Values are expressed as mean ± SEM o f 4 independent experiments 
analysed by one way repeated measures ANOVA between control and ATP, resiquimod and resiquimod+ATP 
w ith  post hoc Dunnett's test, or by paired t-tes t between control and resiquimod. *p<0.05, **p<0.01.
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Figure 3.17 - Effect of ATP in the presence or absence of resiquimod on the mean fluorescence intensity of 
co-stimulatory markers on plasmacytoid DCs.
pDCs from  human blood were stim ulated fo r 48 hours at 37°C w ith  ATP (10, 100 and 500 |iM ) in the presence 
or absence o f resiquimod (2 pM). Cells were analysed fo r cell surface markers using flow  cytom etry. Mean 
fluorescence intensity (MFI) o f HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) on the cell surface are 
shown. Values are expressed as mean ± SEM o f 4 independent experiments analysed by one way repeated 
measures ANOVA between control and ATP, resiquimod and resiquimod+ATP w ith  post hoc Dunnett's test, or 
by paired t-tes t between control and resiquimod. *p<0.05, **p<0.01.
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Figure 3.18 - Effect of ATPyS in the presence or absence of resiquimod on the mean fluorescence intensity of 
co-stimulatory markers on plasmacytoid DCs.
pDCs from  human blood were stimulated fo r 48 hours at 37°C w ith  ATPyS (10, 100 and 500 pM) in the 
presence or absence o f resiquimod (2 pM). Cells were analysed fo r cell surface markers using flow  cytom etry. 
Mean fluorescence intensity (MFI) o f HLA-DR (A), CD80 (B), CD83 (C), CD86 (D), or CD209 (E) on the cell surface 
are shown. Values are expressed as mean ± SEM o f 4 independent experiments analysed by one way repeated 
measures ANOVA between control and ATP, resiquimod and resiquimod+ATP w ith  post hoc Dunnett's test, or 
by paired t-tes t between contro l and resiquimod. *p<0.05, **p<0.01.
{ 127 )
3.3.3.2. Cytokine secretion by pDCs
48 hour stimulation of pDCs with ATP at 10 pM (p<0.01), lOOpM (p<0.005) and 500pM (p<0.005; Fig. 
3.20 E) caused a significant increase in IL- 6  secretion compared to untreated control. No significant 
effect was seen for ATP with the other cytokines tested (p>0.05, one way repeated measures ANOVA, 
Fig 3.19-2.22).
ATPyS 100 pM caused a significant increase in IL-10 secretion compared to untreated control (p<0.05, 
Dunnett's post hoc test, Fig. 3.21 C). IL-4 secretion was decreased by ATPyS at 10 pM (p<0.01), 100 
pM (p<0.01) and 500 pM (p<0.005, Dunnett's post hoc test, Fig. 3.22 A) compared to control. ATPyS 
also increased IL-6  secretion compared to control at 100 pM (p<0.01) and 500 pM ATPyS (p<0.05, 
Dunnett's post hoc test, Fig. 3.22 F).
Resiquimod had no significant effect compared to control for any of the cytokines tested (p>0.05, 
paired t-test, Fig. 3.19-3.22). Although resiquimod caused an apparent increase in the secretion of 
IFNa, IL-12p70, TNFa and IFNy, this did not reach statistical significance (p>0.05, paired t-test, Fig. 
3.19 A, D, Fig. 3.20 C, D).
In the presence of resiquimod, ATP inhibited the secretion of IFNy at 100 pM (p<0.05) and 500 pM 
(p<0.01, post hoc Dunnett's test, Fig. 3.20 D). No significant effects of ATP/ATPyS in combination with 
resiquimod were seen with the secretion of another of the other cytokines measured (IFNa, IL-1(3, IL- 
10, IL-12p70, IL-13, IL-4, IL-5, IL-17 and IL-6 , p>0.05, Fig. 3.19-3.22).
The values for IL- 8  were consistently above the limit of assay sensitivity, making it impossible to 
analyse the results from this cytokine (data not shown).
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Figure 3.19 - Effect of ATP on the release of IFNa, IL-ip, IL-10, IL-12p70, IL-13 and IL-2 from pDCs 
incubated in the presence or absence of resiquimod.
pDCs from human blood were stimulated for 48 hours at 37°C with ATP (10, 100 and 500 pM) in the 
presence or absence of resiquimod (2 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATP, resiquimod 
and resiquimod+ATP with post hoc Dunnett's test, or by paired t-test between control and 
resiquimod.
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Figure 3.20 - Effect of ATP on the release of IL-4, IL-5, IFNy, and IL-6 from pDCs incubated in the 
presence or absence of resiquimod.
pDCs from human blood were stimulated for 48 hours at 37°C with ATP (10, 100 and 500 pM) in the 
presence or absence of resiquimod (2 pg/ml). Supernatants were stored at -80°C until analysis using 
mesoscale Thl/Th2 10 plex MSD assay, or IL-6  single spot MSD assay. Values are expressed as mean ± 
SEM of 4 independent experiments analysed by one way repeated measures ANOVA between control 
and ATP, resiquimod and resiquimod+ATP with post hoc Dunnett's test, or by paired t-test between 
control and resiquimod. *p<0.05, **p<0.01, ***p<0.005.
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Figure 3.21 - Effect of ATPyS on the release of IFNa, IL-lp, IL-10, IL-12p70, IL-13 and IL-2 from pDCs 
incubated in the presence or absence of resiquimod.
pDCs from human blood were stimulated for 48 hours at 37°C with ATPyS (10, 100 and 500 pM) in the 
presence or absence of resiquimod (2 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATPyS, resiquimod 
and resiquimod+ATPyS with post hoc Dunnett's test, or by paired t-test between control and 
resiquimod. *p<0.05.
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Figure 3.22 - Effect of ATPyS on the release of IL-4, IL-5, TNFa, IFNy, and IL-6 from pDCs incubated in 
the presence or absence of resiquimod.
pDCs from human blood were stimulated for 48 hours at 37°C with ATPyS (10, 100 and 500 pM) in the 
presence or absence of resiquimod (2 pg/ml). Values are expressed as mean ± SEM of 4 independent 
experiments analysed by one way repeated measures ANOVA between control and ATPyS, resiquimod 
and resiquimod+ATPyS with post hoc Dunnett's test, or by paired t-test between control and 
resiquimod. *p<0.05, **p<0.01, ***p<0.005.
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3.4. Discussion
3.4.1. Monocyte derived dendritic cells
The aim of this study was to determine the effects of extracellular ATP on the maturation of moDCs, 
mDCs and pDCs isolated from human peripheral blood. Firstly, moDCs were studied in order to 
confirm the results presented in the literature and to extend these studies by applying statistical 
analysis to the results so that a reliable conclusion can be drawn.
The purity of moDCs isolated in these experiments was around 75% of the whole cell population. The 
remaining population consisted of cell debris and dead cells which are present probably due to the 9 
days of culture which will result in some cell death.
The concentration of ATP at the site of injury is estimated to be around 20 pM, however this 
concentration may increase during various inflammatory situations (Born et al., 1984). Therefore, to 
gain a thorough understanding of the range of responses to nucleotides, the concentrations of ATP 
used in these experiments were 10 pM, 100 pM and 500 pM. This provides coverage below the 
predicated concentration of ATP at the site of injury, and covered a larger range that may be present 
during inflammation. IPS was used in this study as it has been shown to induce the maturation of DCs 
and as it is a common molecule encountered by the body (Corinti et al., 2001). A concentration of 10 
pg/ml LPS was chosen as this is what had been used in other studies (la Sala et al., 2001). A 48 hour 
incubation period was chosen as pilot time course studies showed that this time point caused the 
most profound increase in co-stimulatory marker expression and cytokine release by LPS compared to 
earlier time points (data not shown). The published studies also used this time point, as it allows 
sufficient time for the effects of DNA transcription induced by treatments to be seen (la Sala et al., 
2001).
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Stimulation of moDCs with ATP alone caused no change in the expression of HLA-DR, while LPS caused 
an increase in HLA-DR expression which was inhibited by ATP at 500 pM. HLA-DR is the human MHC 
class II molecule involved in presenting antigens to T cells. An increase in HLA-DR expression as 
caused by LPS suggests that more MHC II molecules are being expressed, so an increased number of 
antigens are able to be presented to T cells. This result has also been shown using a number of 
inflammatory stimuli, which induced an increase in MHC II synthesis and expression, and increased 
the half-life of these molecules of the DC surface by 10 fold, leading to increased capacity to stimulate 
T cells (Celia et al., 1999). Inhibition of the increase in HLA-DR expression by ATP suggests that 
reduced antigen presentation will occur in LPS-matured DCs, therefore reducing the T cell stimulatory 
capacity of these cells. This confirms the results seen in the literature, where LPS induced an increase 
in the MFI of HLA-DR on moDCs, however ATP was not seen to inhibit this response (la Sala et al., 
2001). Another study showed that ATP alone was able to increase HLA-DR expression on moDCs, 
which is not seen in the present study (Schnurr et al., 2000). The variation reported is most likely due 
to variation in protocols, and the lack of statistical analysis of the previously published results.
Stimulation of moDCs with ATP caused no change in the expression of CD80. LPS caused an increase in 
the expression of CD80, which was dose-dependently inhibited by ATP. CD80 binds to CD28 on T cells, 
providing co-stimulation which induces T cell activation (as shown in figure 1.1). An increase in CD80 
expression induced by LPS suggests an increased ability of moDCs to co-stimulate T cells, whereas ATP 
inhibited this effect which may result in decreased T cell activation. This contrasts with the literature, 
where LPS-matured moDCs increased CD80 expression but ATP had no effect on this (la Sala et al.,
2001). In another study, ATP was shown to cause an increase in the MFI of CD80 (Berchtold et al., 
1999), however again a statistical analysis was not presented to support this effect.
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Stimulation of moDCs with ATP caused no change in the expression of CD83. LPS caused an increase in 
the expression of CD83, while ATP had no effect on this response. CD83 is a marker found on mature 
moDCs and it is believed to be involved in T cell activation; however its role in the immune response 
remains unclear (Schnurr et al., 2000). Many groups have shown that LPS induced an increase in CD83 
expression in moDCs; however while some groups suggest that ATP further increased CD83 
expression induced by LPS (Wilkin et al., 2001; Marteau et al., 2004), others did not find this result (la 
Sala, 2002). Again, the variation in response here may be due to lack of statistical analysis of results.
Stimulation of moDCs with ATP caused an increase in the MFI of CD8 6  at 500 pM. LPS also caused an 
increase in CD8 6  expression, which was inhibited by ATP. CD8 6  binds to CD28 on T cells, which 
provides co-stimulation which induces T cell activation (see figure 1.1). An increase in the MFI of CD8 6  
suggests that the same percentages of cells are expressing an increased amount of CD8 6 . ATP 
inhibited the increase in expression induced by LPS, suggesting an alteration of the level of 
maturation of cells and reduced co-stimulatory ability. In the published studies, both ATP and LPS 
were reported to increase the expression of CD8 6 , while ATP further increased CD8 6  expression 
induced by LPS (Schnurr et al., 2000; la Sala et al., 2001). This disagrees with the results presented in 
the current study, where ATP inhibited LPS-induced CD8 6  expression. The results presented in the 
current study are likely to be more representative as multiple donors were used, and statistical 
analysis was carried out.
Stimulation of moDCs with ATP caused a decrease in the MFI of CD209 at 500 pM. LPS caused no 
significant effect although a slight decrease in expression can be seen. ATP further decreased CD209 
expression in LPS-stimulated moDCs. CD209 is an adhesion molecule involved in DC:T cell binding, and 
in the adhesion of DCs to the endothelium. Its decrease indicates either reduced recruitment of DCs 
from the blood to the tissues due to decreased exiting of the blood vessel, or decreased DC binding to
T cells. There are currently no published studies on CD209 and ATP on moDCs, so this is the first 
report of a such an effect of ATP.
Stimulation of moDCs with ATP caused no change in the expression of CD14. LPS caused an increase in 
CD14 expression, while ATP had no effect on this. CD14 is an accessory molecule involved in the 
activation of TLR-4 by LPS, and so its increase in expression caused by LPS represents increased 
sensitivity to the agonist.
Overall these results suggest that ATP alone is able to affect the levels of CD209 and CD8 6  expression 
on moDCs which indicates that is modulates the maturation state of moDCs. LPS induced DC 
maturation, which supports the results documented in published studies. ATP inhibited some of the 
co-stimulatory markers induced by LPS, suggesting a reduction in maturation state of these cells 
which may reduce moDCs ability to provide co-stimulation to T cells. This is the opposite to the 
suggested role of ATP as a danger signal in moDCs.
In order to determine what effect this altered maturation state would have on moDCs ability to 
influence the immune response, the profile of cytokines released by moDCs was analysed. DCs release 
cytokines upon their maturation which determine not only the type of immune response produced 
(i.e. T h l or Th2), but the cytokines also recruit other immune cells to the site of inflammation (see 
table 1.1). LPS has been shown to induce a Thl-associated cytokine profile in moDCs (Golden et al., 
2008).
Stimulation of moDCs with ATP caused no change in the release of IFNy from these cells. LPS caused 
an increase in IFNy release while ATP had no effect on this. IFNy is a Th l cytokine that activates NK 
cells and macrophages, and promotes T h l cell proliferation. An increase in IFNy by LPS supports the 
idea that LPS is a T h l inducing cytokine.
Treatment of moDCs with ATP caused no change in the release of IL-12p70 by moDCs, which was the 
same for LPS and the two in combination. IL-12 is a T h l cell promoting cytokine that would be 
expected to increase when a T h l response is being induced. However, in this study low pg levels of IL- 
12 were detected which may suggest that a T h l response is not occurring, or that the presence of T 
cells is required for cells to release this cytokine. As ATP did not inhibit the increase in IFNy caused by 
LPS, these results suggest that a T h l response may be initiated, and not inhibited by ATP. However as 
IL-12 is not affected, this cannot be confirmed. Wilkin et al. has shown an increase in the expression 
of IL-12 p40 and p70 induced by LPS and also by ATP (Wilkin et al., 2001). In this study, both the p40 
and p70 subunits of IL-12 were detected within one assay, whereas in the present study only IL-12p70 
was detected. This may account for the low concentration of IL-12 detected in the current study, as a 
max of 10 pg/ml IL-12 p70 was detected in this study, compared to 10 ng/ml IL-12 p40 and p70 in 
other studies. This may also suggest that the effects seen by other groups are due to the p40 subunit 
(which is active as a homodimer) but not the p70 subunit (Cooper et al., 2007). However, La Sala et al. 
(2001) showed that LPS induced the release of 2 ng/ml IL-12 p70, which disagrees with this theory, 
and the results of the present study
Stimulation of moDCs with ATP alone caused no change to the release of IL-lp. LPS caused an 
increase in IL-lp release, and this was dose-dependently inhibited by ATP. IL-lp promotes T cell 
proliferation, so an increase in its release suggests that LPS is increasing T cell activation. IL-ip release 
is thought to require two signals. Signal one, which can come from TLR ligation, induces transcription 
of pro-IL-lp which is an inactive form of the cytokine. Signal two induces the activation of caspase-1, 
which cleaves pro-IL-lp and stimulates its release in granules from IL-ip containing cells (Dinarello,
2002). While LPS has been shown to increase transcription of the IL-ip gene, it leads to the release of 
only 10% of the cells IL-ip. ATP has been shown to act as signal two, inducing an increase in IL-ip 
release in cells that were pre-stimulated with LPS (Ferrari et al., 2006). However, in the present study.
LPS induced the release of 11-1(3, and this was inhibited by ATP. This effect was also shown in the 
literature (Ferrari et al., 2000; la Sala et al., 2001), although higher levels of IL-1(3 were detected. This 
may be partially due to increased cell numbers in the previous studies, but confirms the patterns of 
results seen in the current study. This inhibition by ATP does not follow the suggested role of ATP as a 
stimulator of IL-1(3 release, however it may be due to the fact that the concentration of ATP used here 
(500 pM) is not sufficient to activate P2X7 receptors, which are implicated in IL-1(3 release from 
macrophages, DCs and other immune cells (Ferrari et al., 2006). This inhibitory effect may, therefore, 
be due to activation of P2Y receptors on moDCs.
Stimulation of moDCs with ATP caused no change in TNFa release. LPS caused an increase in TNFa 
release which was inhibited back to control levels by ATP. TNFa activates macrophages and is a pro- 
inflammatory cytokine, which again matches the predicted T h l cytokine profile for LPS (Blanco et al., 
2008). Inhibition of TNFa secretion by ATP may result in reduced macrophage activation at the site of 
infection, reducing the severity of the immune response. A similar pattern of TNFa release was seen 
by another group, confirming this effect (la Sala et al., 2001).
Stimulation of moDCs with ATP caused no change in IL- 6  release. LPS caused an increase in IL-6  
secretion, which was dose-dependently inhibited by ATP. IL- 6  is a neutrophil-recruiting and activating 
cytokine which is also required to be secreted to overcome immune suppression by T regulatory cells 
(Kimura & Kishimoto, 2010). The increase in IL- 6  release by LPS suggests activation of the immune 
response, whereas ATP inhibited this which may prevent this immune response, or lead to increased T 
regulatory cell activation. Again, this is also shown by another group and confirms their results (la Sala 
et al., 2 0 0 1 ).
Stimulation of moDCs with ATP caused no change in IL-8  release. LPS increased IL-8  secretion which 
was inhibited by ATP. IL-8  is a neutrophil recruiting cytokine, which increases the number of these
cells present at the site of inflammation to kill the invading organism (Kukulski et al., 2009). LPS once 
again increased the secretion of this pro-inflammatory cytokine, while ATP inhibited this effect, which 
may result in reduced neutrophil recruitment to the infection site.
Stimulation of moDCs with ATP caused no change in IL-10 release. LPS increased IL-10 secretion which 
was dose-dependently inhibited by ATP. IL-10 is an anti-inflammatory cytokine that impairs IL-12 
secretion by immune cells (Yao et al., 2005). Here, LPS induced IL-10 release, which may be 
responsible for the low levels of IL-12 secreted by moDCs, however this is unlikely as inhibition of the 
LPS-induced release of IL-10 by ATP did not result in an increase in IL-12 secretion. Mature DCs lose 
sensitivity to the anti-inflammatory effects of IL-10, so this increase in release induced by LPS- 
matured cells may inhibit IL-12 release and prevent a T h l response in the absence of T cells. This has 
been shown previously, where LPS matured DC showed an increase in IL-10 secretion in moDCs 
(Corinti et al., 2001). This study also showed that neutralising IL-10 with a mAb enhanced the 
maturation and cytokine release of LPS-matured moDCs, showing that IL-10 is responsible for 
inhibiting DC maturation (Corinti et al., 2001). The increase in IL-10 in the present study caused by LPS 
may result in a reduced extent of maturation. The inhibition of LPS-induced IL-10 by ATP may suggest 
that the altered immune response induced by ATP does not require a damping signal.
Overall this shows that ATP alone had no effect on cytokine secretion by moDCs. LPS induced a pro- 
inflammatory Th l cytokine response, as shown by an increase in IL-1(3, TNFa, IFNy, IL-6 , IL-10 and IL-8 . 
It would be expected that an increase in IL-12 would be seen with LPS, as this would match the T h l 
immune response, however this was not seen. This may be due to the increase in IL-10 secretion, 
which may inhibit IL-12 release and suggests that the cells are not fully responding possibly due to the 
lack of T cells in the culture. To confirm this, analysis of IL-4 release would show whether a Th2 
response is induced rather than Thl, however this was not possible due to lack of availability of the IL-
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4 assay. ATP dose-dependently inhibited the release of pro-inflammatory cytokines from LPS-matured 
moDCs. This would result in reduced T cell activation, reduced recruitment of inflammatory cells 
including neutrophils and macrophages to the site of infection, and reduced maturation of immune 
cells.
The results in the present study confirm those of La Sala et al. (2001) who also showed that ATP 
inhibited LPS induced cytokine release, but disagrees with other studies who showed that ATP 
increased IL-12 and IL-10 release by LPS-matured DCs (Berchtold et al., 1999; Schnurr et al., 2000; 
Wilkin et al., 2001; Marteau et al., 2004). A possible explanation of this is variation in the tissue 
culture and isolation protocols used. The published studies that disagree with the results presented 
here cultured adherent PBMCs, which were then incubated with cytokines to differentiate into 
moDCs. However, in the current study, and in studies by La Sala et al. CD14+ monocytes were 
cultured. This protocol is superior to the use of adherent PBMCs as it ensures that other adherent 
mononuclear cells such as macrophages are removed from the culture, and cannot affect the moDCs 
or respond to the treatments. It is possible that these varied techniques could explain the differences 
between studies and show why the cytokine results from La Sala et al. (2001) agrees with the results 
presented here. La Sala et al. (2001) showed similar co-stimulatory marker results to the current 
study, however some conflicts are also seen. This may be due to differences in the flow cytometric 
protocol used. In the current study, moDCs were identified on the flow cytometer based on both the 
forward vs side scatter plots, and based on the cells being C D llc+ and CD123 (as described in section 
2.3). This ensured that any contaminating cells or cell debris was excluded from analysis, as these may 
alter the results. However, in the published studies it is unclear what moDC detection methods were 
employed. In the study by La Sala et al. (2001), cells were detected based on their expression of CDla 
and CD14. In other studies (Berchtold et al., 1999; Schnurr et al., 2000; Wilkin et al., 2001; Marteau et 
al., 2004) there is no description of the use of moDC specific markers to ensure that the cells analysed
were actually moDCs, although it is possible that these details were excluded from the papers. If the 
cell populations were not confirmed to be moDCs, other cells may affect flow cytometric results. 
Variations in the markers used to detect moDCs, such as the use of CDla and CD14 rather than C D llc  
and CD123 could mean that slightly different cell populations were analysed or excluded from 
analysis, leading to different results. This may be an important factor in explaining why the results in 
the current study differ to others, as when adherent moDCs are used, as it is likely that contaminating 
cells are present in the culture, so without the exclusion of these cells during flow cytometry incorrect 
conclusions may be drawn.
An important difference between the current study and others is the use of statistics and increased 
experimental numbers to verify that changes seen are statistically significant. This may also explain 
why there are differences in results compared to the published studies, and shows that the current 
study is more reliable.
In order to further examine the immune response induced by ATP, the ability of moDCs to stimulate 
CD4+ T cell proliferation was measured. Cytokine release from the T cells was also measured to 
determine the type of cells (Thl or Th2) induced to proliferate, which may answer the questions left 
by the previous cytokine experiment. Multiple DC:T cell ratios were studied, in order to detect the 
optimum ratio of cells that elicit a response.
No significant effects on T cell proliferation were seen with any of the treatments given and at any of 
the DOT cell ratios. It would be expected that LPS would cause an increase in the proliferation of T 
cells, as shown in the published studies (la Sala et al., 2001) however this was not the case in this 
experiment. The same study showed that ATP was able to induce T cell proliferation in naïve T 
lymphocytes. This was also seen by another group, where the effect was most distinct at the lower 
(1:20) DOT cell ratio (Schnurr etal., 2000).
The variation in results may be due to the different protocols that were used. In the published studies, 
[H] 3 thymidine incorporation was used, which measures DNA synthesis and thus cell proliferation. In 
the current study, the CYQUANT assay was used which uses a nucleic acid dye that concentrates in 
the nucleus of cells to determine cell number, and therefore measure cell proliferation. [H] 3 
thymidine could not be used in the present study due to the laboratory not being able to handle 
radioactivity, however the CYQUANT assay has been shown to provide an accurate measure of cell 
proliferation (Jones et al., 2001). The different protocols used may explain why there are different 
results obtained, as slightly different aspects of cell proliferation are being measured.
There were also no significant effects of any of the treatments on cytokine secretion from T cells 
induced by moDCs. LPS had little effect on cytokine secretion from T cells, which disagrees with the 
published studies that showed that LPS-matured moDCs stimulated an increase in IFNy release from 
co-cultured T cells, and a decrease in IL-4 secretion, suggesting a Th l skewing of the immune 
response by LPS (Schnurr et al., 2000). This group also showed that ATP inhibited LPS induced 
secretion of IFNy, and increased the secretion of IL-4 from T cells, suggesting Th2 skewing of the 
immune response by ATP. This was not seen in the present study, which may be due to different T cell 
isolation protocols. La Sala et al. (2001) showed that both LPS and ATP matured moDCs caused an 
increase T cell proliferation but that ATP had no effect on LPS-matured DCs. They also showed that 
ATP inhibited LPS-induced secretion of IFNy and increased the secretion of IL-4 and IL-10. However 
this group used a different T cell isolation protocol, which may explain the variation in responses.
The relevance of these findings are that ATP released during cell damage, stress or inflammation may 
have no effect on the maturation state of moDCs unless accompanied by another signal that activates 
DCs such as LPS. The presence of ATP alongside this signal results in a decreased maturation profile, 
causing changes in cytokine secretion that favour an anti-inflammatory or Th2 response. In the body
an invading pathogen may cause tissue damage leading to the release of ATP. This binds to P2 
receptors on DCs to negatively regulate the immune response, reduce the severity of the immune 
response, and reduce tissue damage (Kaufmann et al., 2005). This has also been seen in monocytes, 
which express P2 receptors and exhibit a similar response to that shown in moDCs, in reducing TNFa 
and increasing IL-10 release from these cells, thus reducing inflammation (Kaufmann et al., 2005). This 
statement requires further confirmation by improving the T cell proliferation study to determine the 
type of T cells induced by these cells. The use of flow cytometry to determine T cell number and 
phenotype may provide an alternative experimental procedure for this.
The results shown here do not support the hypothesis that ATP acts as a danger signal in DCs, as ATP 
alone has no effect, and it reduces the pro-inflammatory immune response to LPS. ATP is instead 
immuno-modulatory to the immune response induced by other stimuli.
3.4.2. Myeloid dendritic cells
The second aim of this study was to determine the effects of extracellular ATP on mDCs isolated from 
peripheral blood. This allows comparison to the results of moDCs to determine whether these cells 
are a valid representation of what occurs in vivo. It was not possible to obtain pure cultures of mDCs, 
but the cells were instead enriched from 1% PBMCs to 10% of the total cell population. Gating during 
flow cytometry allowed for only the mDC population to be analysed; however it must be taken into 
account that other immune cells are present in the culture and these cells may affect the results by 
responding to nucleotides themselves. Contaminating cells included 3% CD4+ lymphocytes, 3% CD8 + 
lymphocytes, 2% CD19+ B cells, and the remainder of the population consisted of unidentified cell 
types, and cell debris. Both lymphocytes and B cells express functional P2Y and P2X receptors (Wang 
et al., 2004). It is important, therefore to consider the effects of these cell types on the cell culture 
results as they may respond to nucleotides or LPS, and may also release cytokines and other
molecules into the media which may affect mDCs in the culture. Despite this, an enriched mDC 
population was studied. The non-hydrolysable form of ATP, ATPyS, was included in this study. This 
was to ensure that effects seen with ATP were due to activation of ATP-specific receptors, and not 
due to its breakdown products acting on other receptors. ATPyS is not rapidly broken down in culture, 
so will provide evidence of which receptor types are involved in the response.
Stimulation of mDCs with ATP caused an increase in HLA-DR expression, while ATPyS had no effect.
LPS decreased the expression of HLA-DR, while both ATP and ATPyS had no effect on this expression. 
The increase in HLA-DR by ATP suggests an increase in the antigen presentation ability of the cells, 
although this increase is small. LPS decreased expression of HLA-DR suggesting that cells are 
expressing less of this marker, which suggests lower antigen presentation.
Stimulation of mDCs with ATP, ATPyS, LPS or in combination caused no effect on CD80 expression.
This suggests no change in the co-stimulatory capacity of these cells induced by both ATP and LPS.
Stimulation of mDCs with ATP had no effect on CD83 expression, while ATPyS caused an increase in its 
expression. LPS decreased the MFI of CD83 and ATP/ATPyS had no effect on this response induced by 
LPS. CD83 is a marker of DC activation, so an increase by ATPyS suggests increased maturation of 
these cells, while a decrease caused by LPS suggests the cells are less mature when stimulated with 
LPS.
Stimulation of mDCs with ATP or ATPyS had no effect on CD8 6  expression, while LPS also had no 
effect. ATPyS had no effect on LPS induced CD8 6  expression, while ATP caused an increase in its 
expression. There is an apparent increase in CD8 6  expression due to ATP alone but this did not reach 
significance. This suggests that ATP induces the maturation of mDCs by increasing their ability to co­
stimulatory T cells.
Stimulation of mDCs with ATP alone caused a decrease in CD209 expression, which was also seen with 
ATPyS but it did not reach significance. LPS also decreased CD209 expression, but this also did not 
reach significance. ATP and ATPyS had no effect on LPS induced expression of CD209. This reduction 
in CD209 expression by ATP suggests decreased recruitment of cells from the blood to tissues/lymph, 
and a decrease in DC binding to T cells.
Overall this shows that ATP alone increased the maturation state of mDCs, inducing an increase in co­
stimulatory markers, however not all of the markers tested responded suggesting that this 
maturation is not compete. ATPyS had a different effect to ATP, which suggest that multiple receptors 
are involved. ATP acts on P2Yi; 2, 11, 12,13 and P2X receptors but is broken down quickly in culture to 
ADP and further to adenosine via ecto-nucleotidases found on the cell surface (Dwyer et al., 2007). 
The breakdown products have varying affinities for P2 and PI receptors, so the results seen with ATP 
may represent involvement of these receptors. ATPyS is not broken down rapidly, therefore most 
likely acts on the P2Y 1# 2, 11, 12,13 receptors and P2X receptors. It is clear that multiple receptors 
subtypes are involved in the response of mDCs to nucleotides. However further analysis using more 
specific nucleotides would be required to elucidate the actual receptors involved.
LPS had little effect on mDC maturation, which may suggest that mDCs do not react strongly to LPS 
due to reduced TLR-4 or CD14 expression, or that contaminating cells in the culture are affecting the 
response of mDCs to LPS. ATP increased LPS induced CD8 6  expression which may suggest increased 
co-stimulatory capacity of these cells, however there is also a small but not significant increase seen 
with ATPyS which suggests this may be due to activation of P2Y^ 2, 11, 12,13 receptors. Overall, this 
shows that ATP alone increased the maturation state of mDCs by increasing their co-stimulatory 
marker expression, however not all of the markers tested were affected so the cells may not be fully
mature. Partial maturation of mDCs may result in an altered immuno-stimulatory profile compared to 
fully mature cells.
As with moDCs, the profile of cytokine release from mDCs was analysed to determine the type of 
immune response that is induced by stimulated mDCs. The array of cytokines studied was extended in 
order to analyse a wider range of cytokines of interest as used in moDC experiments.
Stimulation of mDCs with ATP caused a decrease in IL-4 secretion which was mirrored by ATPyS. LPS 
decreased IL-4 secretion, while ATP and ATPyS had no effect on this although levels remain low as 
with ATP alone. IL-4 is a Th2 cytokine involved in B cell class switching and promoting Th2 cell 
proliferation (Yao et al., 2005). LPS is expected to decrease IL-4 release from DCs, as it is thought to be 
a T h l inducing cytokine so the response seen here matches this. The decrease in IL-4 release by ATP 
and ATPyS also suggests that a Th2 response is not being induced.
Stimulation of mDCs with ATPyS, but not ATP caused a decrease in IL-10 secretion. LPS had no effect 
on IL-10 secretion, while ATPyS reduced IL-10 secretion in the presence of LPS. IL-10 is an anti­
inflammatory cytokine that inhibits DC maturation, so a reduction in its secretion suggests that DCs 
are maturing, and that an immune response can be activated.
No significant effects were seen for any treatments on the release of IL-1(3, IL-12p70, IL-13, IL-2, IL-6 , 
TNFa, IFNy and IL-8 . The decrease in IL-4 secretion may suggest an increase in T h l response, however 
there was no change in IL-12 secretion which would verify this effect. The IL-12 concentration 
detected was very low which may mean that an increase in cell numbers may show an effect as more 
cells are available to secrete cytokines. Another factor that may have complicated this study is the 
contaminating cells. These may be activated by LPS or ATP, and so also release cytokines in response 
to these treatments. These cytokines would be detected in these assays, and may also either suppress
or activate mDCs, masking the results of the mDCs. This could, however, be more representative of 
the situation in vivo.
Overall, ATP partially increased the maturation state of mDCs and inhibited the release of anti­
inflammatory cytokines from these cells. However, this maturation may not be complete, as not all 
the co-stimulatory markers tested were affected by ATP and other pro-inflammatory cytokines 
showed no response. ATP may, therefore, act as a danger signal in mDCs, but full maturation requires 
another signal to occur.
It must be taken into account that the isolation of mDCs produced low cell purities, and 
contamination with other cell populations, and large amounts of dead cells. These dead cells are likely 
to be present due to the age of buffy coats once received. The high levels of baseline cytokines in 
these experiments indicate that the mDCs may already be activated due to the presence o f dead cells, 
and this may mask any effects of the treatments used. This is especially important as necrotic cells 
would release ATP into the culture media, which will activate P2 receptors prior to the treatments 
being added. To verify that the results in these experiments are due to the treatments added, and not 
due to the effect of necrotic cells on mDCs, increased yields and purities of cells are required. This 
may be obtained via FACS sorting, which separates cells based on their expression of multiple 
markers, and may lead to increased purities of cells. There are currently no reports in the literature on 
the effects of ATP on mDCs, so this is the first study to suggest an effect.
3.4.3. Plasmacytoid dendritic cells
The final aim of this study was to determine the effects of extracellular ATP on pDCs isolated from 
peripheral blood. This DC population comes from a lymphoid lineage and has a different structure and 
function to mDCs. pDCs are involved in the immune response against viruses and are involved in the
induction of tolerance. For this reason, it is possible that ATP acts as a danger signal for pDCs, so it is 
important to study this cell population alongside mDCs.
As with mDCs, pDCs could not be purified from PBMCs but were instead enriched from <0.5% PBMCs 
to 10% of the total cell population. Gating during flow cytometry meant that only pDCs were 
analysed, however it must be taken into account that other immune cells are present in the culture 
and may respond to nucleotides, thereby affecting the results. Contaminating cells included 3% CD4+ 
lymphocytes, 2% CD8 + lymphocytes and 3% CD19+ B cells and the remainder consisted of unidentified 
cell types and cell debris. Despite this, an enriched pDC population was studied. pDCs do not express 
TLR-4 which is ligated by LPS, therefore an appropriate stimulus was required. Resiquimod was used 
as it is a TLR7 agonist that has been shown to induce co-stimulatory marker expression, and an 
increase in cytokine secretion, including IFNa in pDCs (Gibson etal., 2002).
Stimulation of pDCs with ATP, ATPyS, resiquimod or in combination had no effect on HLA-DR 
expression. This suggests that the cell's ability to present antigen to T cells remains the same as in 
control cells. Shin et al. also showed that ATP stimulation of pDCs caused no increase on HLA-DR 
expression, supporting this result (Shin etal., 2008).
Stimulation of pDCs with ATP or ATPyS had no effect on the expression of CD80. Resiquimod had no 
effect, while ATP and ATPyS both inhibited CD80 expression in the presence of resiquimod to below 
control levels. This suggests that activation of P2Yi, 2, n, n, is or P2X receptors in the presence of 
resiquimod decreased the co-stimulatory capacity of pDCs. This disagrees with a study showing an 
increase in CD80 expression caused by reqisuimod (Gibson et al., 2002).
Stimulation of pDCs with ATP caused no effect on CD83 expression, while ATPyS caused a decrease in 
expression at 100 pM. Resiquimod had no effect on CD83 expression, and ATP/ATPyS had no effect on 
this. As CD83 is a maturation marker on DCs, this reduction caused by ATPyS may suggest a decrease
in the maturation state of these cells. Shin et al. (2008) suggested that ATP caused a moderate 
increase in CD83 expression by pDCs; however no statistical analysis was performed to confirm this.
Stimulation of pDCs with ATP or ATPyS caused no effect on CD8 6  expression, whereas resiquimod 
caused an increase in its expression. ATP or ATPyS caused no effect on resquimod-stimulated pDCs. 
This indicates that resiquimod treated pDCs have an increased ability to provide co-stimulation to T 
cells and confirms the findings of other groups that resiquimod increased CD8 6  expression in pDCs 
(Gibson et al., 2002). Shin et al (2008) showed that ATP caused a moderate increase in CD8 6 , however 
no statistical analysis was performed to confirm this.
Stimulation of pDCs with ATP and ATPyS caused an increase in CD209 expression. Resiquimod caused 
no effect while ATP and ATPyS also had no effect on resiquimod-stimulated pDCs. This may suggest 
that ATP stimulated pDCs have increased adhesion to endothelial cells, which would increase their 
recruitment to the tissues and increase T cell: DC binding. However, the increase in expression was 
from 1% to 3%, which is very low and unlikely to be physiologically relevant.
Overall, ATP and ATPyS were able to alter pDCs expression of maturation markers by decreasing the 
expression of HLA-DR and CD83 and increasing CD209 expression. Alongside resiquimod which caused 
an increase in CD80 and CD8 6  indicating a slightly increased maturation state; a further reduction in 
co-stimulatory marker expression of CD80 was caused by ATP and ATPyS. This suggests that while 
resiquimod induces the maturation of pDCs (although complete maturation was not seen), P2 
receptor activation caused a decline in the ability of pDCs to provide co-stimulation to T cells. The 
effects are likely to be due to activation of P2Yiz 2, n, is or P2X receptor activation (not to P2Yu as pDCs 
have not been shown to express this receptor) although as some markers were only affected by ATP, 
suggesting that other receptors that bind the breakdown products of ATP may also be involved.
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As with mDCs, the profile of cytokine release of pDCs was analysed to determine the type of immune 
response that may be induced by ATP. IFNcx was included in this study as it is known that pDCs release 
IFNot to aid in the clearance of viral infection (Barchet et al., 2005).
Stimulation of pDCs with ATPyS caused an increase in IL-10 release, showing a bell shaped response, 
as significance is lost at 500 pM. This may be due to receptor activation being different at a lower 
concentration of ATPyS compared to at a higher concentration. IL-10 is an anti-inflammatory cytokine, 
so an increase caused by ATPyS may indicate a reduction in an immune response. Resiquimod had no 
effect on IL-10 secretion, and ATP/ATPyS has no effect on this.
Stimulation of pDCs with ATPyS caused a decrease in IL-4 release, while a similar pattern is seen for 
ATP although this did not reach significance. Resiquimod also caused a reduction in IL-4 release, 
although this did not reach significance, and ATP/ATPyS did not affect this. Low concentrations of IL-4 
were detected here which are under the detection level of IL-4 in the assay (5.3 pg/ml), so this results 
may not be precise, and is likely to not be biologically relevant; however if the number of pDCs are 
increased in this culture then this may confirm the results found. IL-4 is a Th2 cytokine, so a decrease 
in its release suggests a reduction in inflammation.
Stimulation of pDCs with ATP or ATPyS caused an increase in IL-6  release, which was not seen with 
resiquimod. IL-6  inhibits the actions of T regulatory cells in suppressing the immune response (Kimura 
et al., 2010). Therefore an increase in IL- 6  release suggests an increase in the immune response, and 
increased neutrophil recruitment to the inflamed area.
Stimulation of pDCs with ATP or ATPyS caused no effect on IFNy release, while resiquimod caused an 
apparent increase however this did not reach significance. ATP dose-dependently inhibited the 
release of IFNy in the presence of resiquimod and a similar pattern was seen with ATPyS although this
did not reach significance. This may suggest a reduction in the T h l associated cytokine, leading to a 
lack of Th l response being initiated and reduced capacity to eradicate viruses.
There were no significant effects of any of the treatments on IFNot, IL-1(3, IL-12, IL-13, IL-2, IL-5 and 
TNFoc secretion from pDCs. Resiquimod caused an apparent increase in IFNot secretion from pDCs 
which was not affected by ATP or ATPyS. The large standard errors represent variation in subject's 
responses, as two subjects showed low 100 pg/ml IFNot release, while two subjects showed a 10 fold 
higher release. This is probably due to genetic variation, or the health status of the donors which was 
unknown. However, it is clear that resiquimod is able to activate pDCs to release large amounts of 
IFNot and that ATP is unable to affect this response. This confirms studies that showed an increase in 
IFNot caused by resiquimod (Gibson et al., 2002), however disagrees with another study that showed 
that ATP decreased IFNot release from pDCs stimulated with influenza virus (TLR-7 agonist) and ODN 
2216 (TLR 9 agonist) (Shin et al., 2008). The variation in response here may be due to specific effects 
on cells due to the stimulating pathogen, which means the immune response is specialised for the 
invading pathogen or that once again, low cell numbers and cell contamination was affecting the 
results seen. A similar activation pattern is also seen with IL-12, a T h l promoting cytokine, which does 
not reach significance due to a 10 fold difference in cytokine release between donors. Similarly TNFa 
shows the same pattern and this is not affected by ATP. Another group also showed that resiquimod 
is able to induce TNFa release from pDCs, confirming the results seen here (Gibson et al., 2002). The 
lack of statistical significance in this, and the mDC study may indicate that increased replicates of 
experiments, and using purer cell cultures may be required to show significant results. This is due to 
inter-individual variation between subjects, meaning that certain subjects may respond to a 
treatment differently to others. This may be due to genetic polymorphisms, the subject's health 
status and other factors which may influence their immune response at a certain time. This indicates
both the importance of carrying out statistical analysis of study results, and highlights that in human 
studies, increased experimental numbers may be required in order to represent the wider population.
Overall, these results suggest that P2 receptor activation on pDCs inhibits the pro-inflammatory 
cytokine secretion induced by resiquimod. ATP or ATPyS enhanced the secretion of anti-inflammatory 
cytokines, and had little effect on pro-inflammatory cytokines induced by resiquimod. ATP and ATPyS 
increased the secretion of IL-10 and IL-6 , and decreased the secretion of IL-4 which suggest that an 
immune response is being induced, however due to the lack of response of other cytokines, it is 
unclear what type of response is induced and to what extent. Resiquimod caused an increase in pro- 
inflammatory cytokines which would lead to the activation of CD8 + T cells and the activation of a 
response against viral infection. ATP or ATPyS only caused a decrease in IFNy induced by resiquimod, 
which suggests little effect on the overall cytokine profile induced by resiquimod. Overall, ATP may be 
modulatory on the immune response of pDCs, however it causes little effect on the response to 
resiquimod. It has been suggested by Shin et al. (2008) that nucleotides may inhibit the pro- 
inflammatory IFNa response of pDCs to TLR 7 and 9 stimuli, which acts to prevent tissue damage or 
autoimmunity (Shin et al., 2008), however this was not the effect seen in the present study.
As with mDCs, it must be taken into account that the isolation of pDCs produced low cell purities, and 
contamination with other cell populations, and large amounts of dead cells. These dead cells are likely 
to be present due to the age of buffy coats once received. The high levels of baseline cytokines in 
these experiments indicate that the pDCs may already be activated due to the presence of dead cells, 
and this may mask any effects of the treatments used. This is especially important as necrotic cells 
would release ATP into the culture media, which will activate P2 receptors prior to the treatments 
being added. To verify that the results in these experiments are due to the treatments added, and not 
due to the effect of necrotic cells on pDCs, these experiments should be repeated using increased cell
purities and numbers. As with mDCs, the use of FACS sorting may increase the purities of cells, which 
would allow further study of these cells. The results suggest that ATP is not a danger signal in pDCs 
but instead induces an inflammatory response.
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3.4.4. General discussion
MoDCs mDCs pDCs
ATP vs Control HLA-DR 4 HLA-DR (ATP) o  HLA-DR
CD80 CD80 o  CD80
CD83 4 CD83 (ATPyS) o  CD83
4 CD8 6 <>CD 8 6 ^ C D 8 6
t t  CD209 o  CD209 4 CD209
^  CD14 €044 €044
^  IFNy ^  IFNy ^  IFNy
o  IL-12p70 IL-12p70 IL-12p70
+ +  IL-1(B o  IL-1(B o  IL-ip
o  IL-6 o  IL-6 4 4 4  IL- 6
IL-8 IL-8 o  IL-8
IL- 1 0 t t  IL-lO(ATPyS) o  IL-10
^  TNFa ^  TNFa ^►TNFa
o  IL-13 ^  IL-13
^  IL-2 o  IL-
14-4 i t  IL- 4 4 IL-4 (ATPyS)
Ur^ ^  IL-5 O IL -5
IFNa ^  IFNa
IPS (moDC, mDC) 4 HLA-DR t  HLA-DR ^  HLA-DR
Resiquimod (pDC) vs 4 CD80 ^  CD80 ^  CD80
Control 4 CD83, 4 CD83 o  CD83
4 4  CD8 6 O C D 8 6 4 CD8 6
^  CD209 o C D 2 0 9 <+►€0209
4 4 CD14 €044 €044
4 4 |FNy O lF N y , O lF N y ,
+ +  IL-12p70 o  IL-12p70 <► IL-12p70
^ IL-1(3, o  IL-1(3 ^  IL-1(B
4 4  4 IL- 6 o  IL-6 <► IL-6
4 4  IL-8 , o  IL-8 <► IL-8
4 4 IL-10 IL-10 <► IL-10
4 4  4 TNFa, O T N F a TNFa
LL-4S ^  IL-13 ^  IL-13
44-2 o  IL-2 o  IL- 2
44-4 4 4 IL-4 +► |L-4
+4-5 O lL -5 O IL -5
+f+4a +f+4a ^  IFNa
Table continued on next page
MoDCs mDCs pDCs
LPS or Resiquimod + t  HLA-DR o  HLA-DR o  HLA-DR
ATP vs LPS/resiquimod t  CD80 CD80 t t  CD80
CD83 o  CD83 o  CD83
t  CD8 6 44  CD8 6  (ATP) O C D 8 6
t  CD209 o  CD209 O C D 209
o  CD14 €944 €944
o  IFNy o  IFNy, t t  IFNy (ATP)
IL-12p70 o  IL-12p70 o  IL-12p70
t  IL-ip o  IL-1(B o  IL-13
t  IL-6 o  IL-6 o  IL-6
t  IL-8 o  IL-8 o  IL-8
t  IL-10 t t  IL-10 (ATPyS) IL-10
1 1 1 TNFa, O T N F a O T N F a
ti=-43 IL-13 ^  IL-13
-H=-2 IL-2 o  IL-2
-Hz-4 O IL -4 IL-4
Wz-S o  IL-5 o  IL-5
IFNa IFNa
Table 3.1 - Summary of the effect of nucleotides and/or TLR agonists on cytokine secretion by 
moDCs, mDCs and pDCs.
Results for ATP and ATPyS refer to 500 \iW\ concentration only. For moDCs, all information relates to 
the effect of ATP. For mDCs and pDCs, unless otherwise indicated by the information in parenthesis, 
the effect is seen for both ATP and ATPyS. For flow cytometry results: ^  indicates a change of up to 
10%, or up to 5000 MFI; 44  indicates a change of up to 20% or up to 10000 MFI; 4 4 4  indicates a 
change of up to 50% or up to 15000 MFI. For cytokines: 4 indicates a change of up to 10 pg/m l;4 4 
indicates a change of up to 1 0 0  pg/ml; 4 4 4 indicates a change of up to 1 0 0 0  pg/ml. o  indicates no 
change. CD14 indicates marker not measured for this treatment.
This chapter provides evidence of the effect of extracellular ATP on human blood derived moDC, mDC 
and pDC subtypes, as summarised in table 3.1. In moDCs, which are assumed to be similar to mDCs, 
ATP decreased the maturation state induced by LPS to an anti-inflammatory immune response. On 
the whole this agrees with La Sala et al. (2001) and extends these studies by showing statistically 
conclusive results that are more reliable.
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This study also showed that mDC enriched from human blood do not appear to respond in exactly the 
same manner as moDCs. ATP with or without LPS was able to increase the maturation state of mDC, 
however not fully. Inhibition of anti-inflammatory cytokines was caused by ATP, which suggests that 
while ATP may act as a danger signal in mDCs, it is not the same response as seen in moDCs. Osugi et 
al. (2002) showed that levels of co-stimulatory marker expression in moDC and C D llc+ mDCs were 
the same, which was also seen in the current study, with control levels being within similar levels 
(Osugi et al., 2002). This suggests that while the two cell types are similar in their structure, their 
response to ATP differs slightly and this must, therefore, be taken into account when studying these 
cell types. The differences in the responses of these cell types may be due to the initial maturation 
state of the cells. mDCs are made in the bone marrow, from which they migrate in the blood and 
enter the tissues where they reside, and pick up antigen to present to T cells in the lymph node 
(Mellman & Steinman, 2001). This means that cells extracted from the blood are very immature, in 
that they have not yet been exposed to antigens, danger signals, or other stress markers in the 
tissues. In contrast, moDCs are differentiated from blood monocytes (Zhou et al., 1996). The 
maturation state of the monocytes from the blood may affect the maturation state of moDCs, but 
also the 7 days of culture during the differentiation process may expose these cells to some molecules 
that induce changes in the cell state. Therefore, the two cell types may represent different states of 
maturity before they are stimulated, and this may lead to different results to LPS or nucleotides. This 
also shows the importance of studying tissue-specific DC subtypes, as again their microenvironment 
may alter their responses to treatments. It must also be taken into account that the purity of mDCs in 
this study was low meaning that any contaminating cells may have affected the mDC culture.
pDCs were studied in order to extend the subtypes of DC looked at with ATP. ATP caused a decrease 
in maturation markers in pDCs, towards a more immature phenotype compared to control, which was 
the same case in the presence of resiquimod. The cytokine profile of these cells showed an increase in
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IL-10 and IL- 6  release, and a decrease in IL-4 release to ATP/ATPyS which suggests that an immune 
response may occur in response to these nucleotides, however this effect is unclear.
This shows that the effect of nucleotides on mDCs differs to that of pDCs extracted from the blood. 
While in mDCs, P2 receptor activation induced DC maturation, in pDCs a reduction in the maturation 
state was induced by P2 receptor activation. This difference in response is to be expected, as these 
cells have different roles in the body (Penna et al., 2002). It also shows that while cell contamination 
was present in both cultures, the response to treatments varied between cell types. This suggests that 
the responses seen are due to DCs, although the contaminating cells may still play a role in the 
responses found.
Overall, LPS-matured moDCs show decreased maturation and decreased secretion of pro- 
inflammatory cytokines in response to ATP, while mDCs showed an increased maturation state to 
ATP, and pDCs showed a decreased maturation state to ATP. ATP may act as a danger signal by 
enhancing the response of mDCs to inflammatory stimuli, and inhibiting the tolerogenic effects of 
pDCs.
Chapter 4 - The effect of extracellular nucleotides in human lung 
parenchyma, and lung dendritic cell subsets
4.1. Introduction
The previous chapter showed that extracellular ATP is immuno-modulatory to the immune response 
induced by DCs from the blood. DCs migrate from the blood to the peripheral tissues, where they act 
as sentinels, capturing antigens from the extracellular environment which can be presented to T cells 
and initiate an immune response if necessary. The main tissues involved are those at sites of 
pathogen entry to the body, including the lungs (respiratory tract), intestines (gastrointestinal tract) 
and bladder (genitourinary tract). In these tissues, DCs are assumed to play the same role as they 
have been shown to in the blood. However it is important to determine whether this is the case, or 
whether their location, environment, and the signals received affect how tissue-specific DCs respond.
In this study, the lungs were chosen as a tissue of interest for a number of reasons. Firstly it is known 
that DCs are found within the lung tissue, where they form a dense network of cells under the 
epithelium of the bronchioles and are also found in the alveoli. Here they extend their dendrites into 
the lumen and sample inhaled antigens which can then be presented to T cells in the draining lymph 
nodes (Masten et al., 2006). Inhaled antigens include foreign organisms (viruses and bacteria), 
pollutants, cigarette smoke and environmental particulates (Afshar et o/., 2008). mDCs make up 
around 2% of lung mononuclear cells, while pDCs make up around 1% of lung mononuclear cells, 
indicating that they, alongside other immune cells, are an important feature in the immune response 
of the lungs (Masten et al., 2006). The role of DCs in the lungs is to induce tolerance to innocuous 
antigens, and to induce an immune response against harmful antigens. Secondly, it is clear that ATP 
plays a role in immunity in the lungs, specifically in the case of allergic asthma where an immune 
response is induced to a normally innocuous allergen. Patients with allergic asthma have increased
levels of ATP in their bronchiolar lavage fluid compared to healthy subjects (Idzko et al., 2007), and it 
has also been shown that administration of ATP and AMP to the lungs of asthmatics caused 
bronchoconstriction which is due to the effects of adenosine on smooth muscle and histamine 
release from mast cells (Basoglu et al., 2005). This indicates a role for both ATP and adenosine in the 
pathogenesis of asthma. It is possible therefore, that ATP release affects the maturation state of DCs 
in the lung, and may be involved in determining the type of immune response induced.
ATP may also be involved in the induction of allergic asthma. The presence of ATP in the lungs or an 
increased responsiveness of lung cells to ATP may cause the maturation of DCs to normally innocuous 
stimuli. This may, on second exposure to the antigen lead to the induction of an asthmatic reaction 
(see Fig. 1.3). Alongside this, multiple other cell types are found in the lung which may release ATP 
(such as epithelial cells and mast cells) and respond to ATP (such as macrophages and lymphocytes) 
(Holt, 2001). This makes the understanding of the effects of ATP in the whole lung complicated.
Many of the studies carried out on the effects of ATP in the lungs have been performed on mouse 
tissue, and using mouse models of asthma. This is both due limited access to human tissue compared 
to mouse tissue, and due to the ethical issues in inducing asthmatic responses in humans. Murine 
studies have provided vital evidence that the administration of the antigen OVA to previously OVA 
sensitised mice (a model of allergic airway inflammation) caused the recruitment of DCs, eosinophils, 
lymphocytes, neutrophils and macrophages to the lungs, and increased the concentration of ATP in 
the lungs. Administration of apyrase (which breaks down ATP) prior to OVA challenge inhibits this 
effect (Idzko et al., 2007). This indicates that ATP is involved in the recruitment of immune cells to the 
lungs and in the activation of an immune response.
However there are disadvantages of using murine models of allergic airway inflammation. For 
example, mice do not express the P2Yu receptor which is the main receptor implicated in the immune
response to ATP on human mDCs (von Kugelgen, 2006). Therefore species differences in receptor 
expression and general physiology may affect results. Also the murine model of asthma is likely to be 
different from the actual disease progression in humans, as this process in humans is not fully 
understood. This may make relating murine results back to humans unreliable. It is important, 
therefore, that experiments should be performed on human lung tissue in order to determine if the 
current opinions are correct and relatable from mouse to human.
The aim of this chapter was to determine the effect of extracellular nucleotides on the release of 
cytokines from human lung parenchyma, which consists of the alveoli, structural cells and blood 
vessels which make up the spongy lung tissue. This would provide an indication of the whole tissue 
response to nucleotides and take into account multiple cell responses. The second aim was to 
determine the effect of extracellular nucleotides on the release of cytokines from mDCs and pDCs 
isolated from human lung parenchyma, in order to determine if these cells respond in the same 
manner as blood-derived DCs, and if they are the source of the cytokines released from lung 
parenchyma. The range of nucleotides used in this study was extended to include other P2 receptor 
agonists, nucleotide breakdown products and enzymes involved in this breakdown. This would help 
determine which receptors have been involved in the response. The compounds used were ATPyS, a 
non-hydrolysable form of ATP which acts on P2Y^ 2, 11, 12, is and P2X receptors; ATP which acts on 
P2Yi)2, 11, 12,13 and P2X receptors but is rapidly broken down; ADP which is formed from the breakdown 
of ATP and acts on P2Y1, 12, 13 receptors; UTP which can also be released from cells and acts on P2Y2j 4/ 6 
receptors; a,|3-methyleneATP which acts on P2X receptors; 2-methylthioATP which acts on P2Yi; 3j 7 
and P2X receptors; PiP4-DiATP which acts on P2X receptors; BzATP which acts on P2X7 receptors;
AMP which does not act on P2 receptors but will be broken down by ecto-nucleotidases to adenosine; 
adenosine which acts on PI receptors (Kumar et al., 2009); adenosine deaminase which breaks
adenosine down to inosine which is taken up by cells (Cristalli et al., 2001); and apyrase which breaks
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ATP and ADP to AMP (see tables 1.2 and 1.3, and figure 1.2 for chemical structures). These agonists 
cover a range of receptors, and allow for the identification of which receptors or receptor types are 
involved in the response to be determined. Due to the lack of specific agonists and antagonists for P2 
receptors, this is the most suitable approach for this study.
It is hypothesised that extracellular ATP will induce the release of Th2 cytokines, including IL-4, IL-5 
and IL-10 and decrease the release of Th l cytokines IL-12 and IFNy from human lung, and that mDC 
are a major source of cytokine release.
4.2. Methods
4.2.1. Lung parenchyma
Human lungs from brain dead donors, which were not suitable for transplantation, were obtained 
from the National Disease Research Interchange (Philadelphia), a not-for-profit tissue procurement 
organisation based in the USA, under the US Uniform Anatomical Gifts Act. Consent for research was 
obtained from the next of kin. The lung parenchyma was processed to achieve <1 mm fragments as 
stated in section 2.7. In brief, a 5 cm piece of parenchyma was finely chopped with scissors in a Petri 
dish. The suspension was then filtered through a 1 mm square sieve into a sterile Petri dish. The 
filtered fragments were transferred into a fresh, pre-weighed Falcon tube. Residual tissue was further 
chopped using scissors, and filtered once more. These fragments were added to the pre-weighed 
Falcon tube and made up to 50 ml with lung-tissue culture media. Fragments were centrifuged at 200 
g for 2 minutes, 5 times to remove blood, followed by a final spin of 300 g for 5 minutes. The 
supernatant was discarded and the pellet weighed. Fragments were plated at 0.04 g/well in 700 pi 
lung tissue culture media in a 48 well tissue culture plate. Nucleotides and LPS were then added and 
plates incubated for 24 hours at 37°C in a 5% C02 atmosphere. After 24 hours, 200 pi supernatant was 
removed from wells, and stored at -80°C.
4.2.2. Myeloid and plasmacytoid dendritic cells from lung parenchyma
Lung fragments were obtained as in lung parenchyma experiments, and used to isolate mDC and pDCs 
as stated in section 2.7. In brief, lung fragments were incubated in digestion media for 30 minutes, 
followed by further 15 minute incubation. The tissue was washed by centrifugation and fragments 
were passed through a 40 pM strainer, followed by a second 70 pM strainer. This single cell 
suspension was separated by density gradient centrifugation as in section 2 .1  to isolate mononuclear 
cells. mDCs and pDCs were then isolated from this cell suspension as stated in section 2.2. Cells were 
plated at 2x l04 cells per well in a 96 well plate, and stimulated with nucleotides and LPS (mDC) or 
resiquimod (pDC) and incubated for 48 hours at 37°C in a 5% C02 atmosphere. At 24 and 48 hours, 
lOOpI of supernatant was removed from wells and stored at -80°C for future analysis.
4.2.3. MSD immunoassays
Supernatants were used to analyse cytokine levels using MSD immunoassays according to 
manufacturer's instructions (see section 2.4).
4.2.4. Statistics
The normalised data from all studies were analysed for statistical significance using Graphpad Prism 
software (Graphpad software Inc.). A one way repeated measures ANOVA with post-hoc Dun nett's 
test was used to compare nucleotide concentrations against LPS control. In order to compare the 
effect of LPS/resiquimod against untreated control, a paired t-test was used. The normalised results 
were shown in graphs in order to remove variation between donors. Although each nucleotide was 
analysed separately, multiple nucleotides have been shown on the same graph.
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4.3. Results
4.3.1. Lung parenchyma
LPS caused an increase in the release of IL-1(3 (p<0.01), TNFa (p<0.01), IFNy (p<0.01), IL- 6  (p<0.05), IL- 
8  (p<0.01), IL-2 (p<0.01) and IL-10 (p<0.001) from lung parenchyma compared to untreated control. 
There was no significant effect of LPS on the secretion of IL-17 (p>0.05, paired t-test. Fig. 4.1).
ATPyS caused a dose-dependent increase in IL-1(3 release from lung parenchyma compared to LPS 
control (1000 pM p<0.005, 330 pM p<0.01, Dunnett's post hoc test. Fig. 4.3). ATPyS also caused a 
dose-dependent increase in IFNy (1000 pM p<0.01, 300 pM p<0.05, Dunnett's post hoc test, Fig 4.4) 
and IL-17 release from lung parenchyma compared to LPS control (1000 pM p<0.005, 330 pM 
p<0.005, Dunnett's post hoc test, Fig 4.5) and a decrease in TNFa release compared to LPS control 
(1000 pM p<0.005, 300 pM p<0.05, Dunnett's post hoc test, Fig 4.6)There were no significant effects 
seen with ATPyS for the cytokines IL-6 , IL-8 , IL-2 and IL-10 (p>0.05, one way repeated measures 
ANOVA, Fig. 4.4-4.10).
ATP caused a decrease in TNFa release from lung parenchyma compared to LPS control (1000 pM 
p<0.05, Dunnett's post hoc test, Fig. 4.6) and a decrease in IL-2 release compared to LPS control (1000 
pM p<0.05, post hoc Dunnett's test, Fig. 4.9). There were no significant effects seen with ATP for the 
cytokines IL-1(3, IFNy, IL-17, IL-6 , IL-8  and IL-10 (p>0.05, one way repeated measures ANOVA, Fig. 4.3-
4.5, 4.7-4.8 , 4.10).
ADP caused a decrease in IL-2 release from lung parenchyma compared to LPS control (1000 pM 
p<0.05, Dunnett's post hoc test, Fig. 4.9). There were no significant effects seen with ADP for the 
cytokines IL-1(3, IFNy, IL-17, TNFa IL-6 , IL- 8  and IL-10 (p>0.05, one way repeated measures ANOVA,
Fig. 4.3-4.8 , 4.10).
UTP caused an increase in IFNy release from lung parenchyma compared to LPS control, (1000 pM 
p<0.05, Dunnett's post hoc test, Fig. 4.4).There were no obvious effects seen with UTP for the 
cytokines IL-1(3, IL-17, TNFa, IL-6 , IL-8 , IL-2 and IL-10 (p>0.05, one way repeated measures ANOVA, Fig.
4.3, 4.5-4.10).
AMP caused a decrease in the release of IL-17 from lung parenchyma compared to LPS control (1000 
pM p<0.01, 330 pM p<0.05, Dunnett's post hoc test, Fig 4.5), and an increase in TNFa release 
compared to LPS control, (1000 pM p<0.05. Fig. 4.6). There were no significant effects seen with AMP 
for the cytokines IL-lp IFNy, IL-6 , IL-8 , IL-2 and IL-10 (p>0.05, one way repeated measures ANOVA, Fig. 
43-4.4, 4.7-4.10).
a,(3-methyleneATP caused a decrease in TNFa release from lung parenchyma compared to LPS 
control, (1000 pM p<0.005, Dunnett's post hoc test. Fig. 4.6). There were no significant effects seen 
with a,(3-methyleneATP for the cytokines IL-1(3, IL-17, IFNy, IL-6 , IL-8 , IL-2 and IL-10 (p>0.05, one way 
repeated measures ANOVA, Fig. 43-4.5, 4.7-4.10). 2methylthioATP caused a decrease in TNFa 
release from lung parenchyma compared to LPS control (1000 pM p<0.005, 330 pM p<0.005,110 pM 
p<0.01, 37 pM p<0.01, Dunnett's post hoc test, Fig 4.6). 2methylthioATP also caused a decrease in IL- 
2 release compared to LPS control (1000 pM p<0.05, Dunnett's post hoc test, Fig 4.9). There were no 
significant effects seen with 2methylthioATP for the cytokines IL-1(3, IL-17, IFNy, IL-6 , IL-8 and IL-10 
(p>0.05, one way repeated measures ANOVA, Fig. 43-4.5, 4.7-4.8 , 4.10).
P1P4DiATP caused a decrease in TNFa release from lung parenchyma compared to LPS control (1000 
pM p<0.005, Dunnett's post hoc test, Fig. 4.6). There were no significant effects seen with P1P4DiATP 
for the cytokines IL-1(3, IFNy, IL-17, IL-6 , IL-8 , IL-2 and IL-10 (p>0.05, one way repeated measures 
ANOVA, Fig. 43-4.5, 4.7-4.10).
BzATP caused a decrease in TNFa release from lung parenchyma compared to LPS control (1000 pM, 
p<0.005, Dunnett's post hoc test, Fig. 4.6), and also caused a decrease in IL-10 secretion (1000 pM 
p<0.01, post hoc Dunnett's test, Fig. 4.10). There were no significant effects seen with BzATP for the 
cytokines IL-13, IL-17, IFNy, IL-6 , IL-8 , and IL-2 (p>0.05, one way repeated measures ANOVA, Fig. 4.3-
4.5, 4.7-4.9).
Apyrase caused an increase in IL-13 release from lung parenchyma compared to LPS control (36 
units/ml p<0.05), and a decrease in IL-2 secretion compared to LPS control (36 units/ml p<0.05,12 
units/ml p<0.05, post hoc Dunnett's test, Fig 4.13). There were no significant effects seen with 
apyrase for the cytokines TNFa, IFNy, IL-17, IL-6 , IL-8  and IL-10 (p>0.05, one way repeated measures 
ANOVA, Fig. 4.13).
Adenosine (0.28-70 pM, p>0.05, Fig. 4.11) and adenosine deaminase (0.1-25 units/ml, p>0.05, one 
way repeated measures ANOVA, Fig. 4.2) caused no change to any of the cytokines measured.
After experiments were completed, where possible lungs were separated based on whether the 
donors were smokers or non-smokers. This was only possible for the nucleotides ATPyS, ATP, ADP and 
UTP as there were three non-smokers and two smokers. For the other nucleotides all donors were 
smokers. In the lungs tested, non-smokers appeared to release an increased amount of IL-13, TNFa, 
IFNy and IL-17 due to control and LPS compared to smokers, while the levels of IL-6 , IL-8 , IL-2 and IL- 
10 were similar (Fig. 4.12). When non-smokers were analysed, LPS caused a significant increase in the 
release of IL-13 (p<0.01), TNFa (p<0.01), IFNy (p<0.01), IL- 6  (p<0.01), IL- 8  (p<0.01), IL-2 (p<0.001) and 
IL-10 (pO.OOl, paired t-test, Fig 4.12). No significant effect of LPS was seen for IL-17 (p>0.05, paired t- 
test, Fig. 4.12 B). In smokers, LPS caused a significant increase in the release of IL-13 (p<0.005), TNFa 
(p<0.005), IFNy (p<0.01), IL-2 (p<0.01) and IL-10 (p<0.005, paired t-test, Fig 4.12 A). No significant 
effect of LPS was seen for IL-17, IL- 6  or IL- 8  (p>0.05, paired t-test, Fig. 4.12 A).
ATPyS induced a 10 fold greater increase in the response to LPS in smokers than in non-smokers, as 
shown for IL-1(3 (Fig. 4.14 A, B) and IFNy (Fig. 4.14 C, D). The effect of ATPyS on the LPS response to 
TNFa, IL-6 , IL-8 , IL-2 and IL-10 were similar levels between smokers and non-smokers (Fig. 4.14-15). In 
non-smokers the IL-17 released in response to LPS was apparently increased in response to 
nucleotides (Fig. 4.14 H). Although small amounts of IL-17 were released in response to LPS in 
smokers (Fig. 4.1), none was detectable in the presence of LPS and the nucleotides (Fig. 4.14 G), 
suggesting that the nucleotides inhibited this response to LPS.
Only non-smokers could be analysed statistically, as there were only 2 subjects that were smokers.
For non-smokers, ATPyS caused a dose-dependent increase in IL-1(3 release compared to LPS control 
(1000 pM p<0.01, Dunnett's post hoc test, Fig. 4.14 B) and in IL-17 release compared to control (1000 
pM p<0.05, 330 pM p<0.05, Dunnett's post hoc test, Fig. 4.14 H). There were no significant effects 
seen at any other cytokines, for any of the treatments (p>0.05, one way repeated measures ANOVA, 
Fig. 4.14-15).
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Figure 4.1 -Effect of LPS on the release of cytokines from human lung parenchyma
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated LPS (10 pg/ml) and incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 5 
independent experiments. The individual cytokines data were analysed by paired t-test between 
control and LPS. * = p<0.05, **  = p<0.01, * * *  = p<0.005, * * * *  = pcO.001.
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Figure 4.2 -Effect of LPS on the release of cytokines from human lung parenchyma from smokers 
and non-smokers.
Lung donors were separated based on their smoking status. Graph A represents cytokine release from 
smokers (N=2) while graph B represents cytokine release from non-smokers (N=3). For non-smokers, 
values are expressed as mean ± SEM of 3 independent experiments. The individual cytokines data 
were analysed by paired t-test between control and LPS. * = p<0.05, ** = p<0.01, * * *  = p<0.005, * * * *
= p<0 .0 0 1 .
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Figure 4.3 - Effect of nucleotides in the presence of LPS on the release of IL-lp from human lung 
parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated with ATP, ATPyS, ADP, UTP, AMP, a, (3-methyleneATP, P1P4DiATP, 2methylthioATP or 
BzATP at concentrations ranging from 4 pM to 1000 pM in the presence of LPS (10 pg/ml) and 
incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 4 or 5 independent experiments 
and are normalised to LPS control. The normalised data were analysed by one way repeated 
measures ANOVA with post-hoc Dunnett's test. For ATPyS p=0.0004. * * *  = p<0.005.
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Figure 4.4 - Effect of nucleotides in the presence of LPS on the release of IFNy from human lung 
parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated with ATP, ATPyS, ADP, UTP, AMP, a, [3-methyleneATP, P1P4DiATP, 2methylthioATP or 
BzATP at concentrations ranging from 4 pM to 1000 pM in the presence of LPS (10 pg/ml) and 
incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 4 or 5 independent experiments 
and are normalised to LPS control. The normalised data were analysed by one way repeated 
measures ANOVA with post-hoc Dunnett's test. * = p<0.05, **  = p<0.01.
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Figure 4.5 - Effect of nucleotides in the presence of LPS on the release of IL-17 from human lung 
parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated with ATP, ATPyS, ADP, UTP, AMP, a, (3-methyleneATP, P1P4DiATP, 2methylthioATP or 
BzATP at concentrations ranging from 4 pM to 1000 pM in the presence of LPS (10 pg/ml) and 
incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 4 or 5 independent experiments 
and are normalised to LPS control. The normalised data were analysed by one way repeated 
measures ANOVA with post-hoc Dunnett's test. For ATPyS p=0.0055. * = p<0.05, **  = p<0.01, * * *  = 
p<0.005.
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Figure 4.6 - Effect of nucleotides in the presence of LPS on the release of TNFa from human lung 
parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated with ATP, ATPyS, ADP, UTP, AMP, a, (3-methyleneATP, P1P4DiATP, 2methylthioATP or 
BzATP at concentrations ranging from 4 pM to 1000 pM in the presence of LPS (10 pg/ml) and 
incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 4 or 5 independent experiments 
and are normalised to LPS control. The normalised data were analysed by one way repeated 
measures ANOVA with post-hoc Dunnett's test. * = p<0.05, ** = p<0.01, * * *  = p<0.005.
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Figure 4.7 - Effect of nucleotides in the presence of LPS on the release of IL-6 from human lung 
parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to obtain <1 mm pieces, plated, 
stimulated with ATP, ATPyS, ADP, UTP, AMP, a, (3-methyleneATP, P1P4DiATP, 2methylthioATP or 
BzATP at concentrations ranging from 4 pM to 1000 pM in the presence of LPS (10 pg/ml) and 
incubated at 37°C for 24 hours. Values are shown as mean ± SEM of 4 or 5 independent experiments 
and are normalised to LPS control. The normalised data were analysed by one way repeated 
measures ANOVA with post-hoc Dunnett's test.
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Figure 4.8 - Effect of nucleotides in the presence of LPS on the release of IL-8 from human lung 
parenchyma.
P ost-m o rtem  hum an lung parenchym a was chopped  and sieved to  o b ta in  <1 m m  pieces, p la ted , 
s tim u la te d  w ith  ATP, ATPyS, ADP, UTP, AM P, a, (3-methyleneATP, P1P4DiATP, 2 m e thy lth ioA T P  o r 
BzATP at co nce n tra tion s  rang ing  fro m  4 pM  to  1000 pM  in th e  presence o f LPS (10 p g /m l)  and 
incuba ted  a t 37°C fo r  24 hours. Values are show n as m ean ± SEM o f 4 o r 5 in d e p e n d e n t e xp e rim e n ts  
and are no rm a lised  to  LPS c o n tro l. The norm a lised  data w ere  analysed by one w ay repea ted  
m easures ANOVA w ith  pos t-hoc  D u n n e tt's  te s t.
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Figure 4.9 - Effect of nucleotides in the presence of IPS on the release of IL-2 from human lung 
parenchyma.
P o st-m o rtem  hum an lung parenchym a was chopped  and sieved to  o b ta in  <1 m m  pieces, p la ted , 
s tim u la te d  w ith  ATP, ATPyS, ADP, UTP, AM P, a, (3-m ethyleneATP, P1P4DiATP, 2m e thy lth ioA T P  o r 
BzATP a t co n ce n tra tio n s  rang ing  fro m  4 pM  to  1000 pM  in th e  presence o f LPS (10 p g /m l) and 
incuba ted  a t 37°C fo r  24 hours. Values are show n as m ean ± SEM o f 4 o r 5 in d e p e n d e n t e xpe rim en ts  
and are norm a lised  to  LPS c o n tro l. The norm a lised  data  w ere  analysed by one w ay  repea ted  
m easures ANO VA w ith  pos t-hoc D u n n e tt's  te s t. *  = p<0.05.
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Figure 4.10 - Effect of nucleotides in the presence of LPS on the release of IL-10 from human lung 
parenchyma.
P ost-m o rtem  hum an lung parenchym a was chopped  and sieved to  o b ta in  <1 m m  pieces, p la ted , 
s tim u la te d  w ith  ATP, ATPyS, ADP, UTP, AM P, a, (3-methyleneATP, P1P4DiATP, 2 m e thy lth ioA T P  o r 
BzATP a t co nce n tra tion s  rang ing  fro m  4 pM  to  1000 pM  in th e  presence o f LPS (10 p g /m l)  and 
incuba ted  a t 37°C fo r  24 hours. Values are show n as m ean ± SEM o f 4 o r 5 in d e p e n d e n t e xpe rim en ts  
and are norm a lised  to  LPS c o n tro l. The norm a lised  data  w e re  analysed by one w ay repea ted  
m easures ANO VA w ith  pos t-hoc  D u n n e tt's  te s t. * *  = p<0.01.
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Figure 4.11 - Effect of adenosine in the presence of LPS on the release of IL-lp, TNFa, IFNy and IL-17 
from human lung parenchyma.
P o st-m o rtem  hum an lung parenchym a was chopped  and sieved to  o b ta in  <1 m m  pieces, p la ted , 
s tim u la te d  w ith  adenosine  a t co nce n tra tion s  rang ing  fro m  0.28 to  70 pM  in th e  presence o f LPS (10 
p g /m l) and incuba ted  a t 37°C fo r  24 hours. Results are no rm a lised  to  LPS to  accoun t fo r  hum an 
va ria tio n . Values are show n as m ean ± SEM o f 4 in d e p e n d e n t expe rim en ts , and s ta tis tics  w e re  
p e rfo rm e d  on norm a lised  data , analysed by one w ay  ANO VA w ith  pos t-hoc  D u n n e tt's  te s t. There 
w ere  no s ign ifican t e ffec ts  fo u n d .
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Figure 4.12 - Effect of adenosine deaminase in the presence of LPS on the release of IL-lp, TNFa, 
IFNy and IL-17 from human lung parenchyma.
P o st-m o rtem  hum an lung parenchym a was chopped  and sieved to  o b ta in  <1 m m  pieces, p la ted , 
s tim u la te d  w ith  adenosine  deam inase at co n ce n tra tio n s  ranging fro m  0.1 to  25 u n its /m l in th e  
presence o f LPS (10 p g /m l) and incuba ted  a t 37°C fo r  24 hours. Results are no rm a lised  to  LPS to  
accoun t fo r  hum an v a ria tio n . Values are show n as m ean ± SEM o f 4 in d e p e n d e n t e xp e rim e n ts , and 
s ta tis tics  w ere  p e rfo rm e d  on norm a lised  data , analysed by one w ay ANOVA w ith  pos t-ho c  D u n n e tt's  
te s t. There  w ere  no s ign ifican t e ffec ts  fo un d .
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Figure 4.13 - Effect of apyrase in the presence of LPS on the release of IL-ip, TNFa, IFNy and IL-17 from 
human lung parenchyma.
Post-mortem human lung parenchyma was chopped and sieved to  obtain <1 mm pieces, plated, stim ulated 
w ith  apyrase at concentrations ranging from  0.148 to  36units/m l in the presence o f LPS (10 pg/m l) and 
incubated at 37°C fo r 24 hours. Results are normalised to  LPS control to  account fo r human variation. Values 
are shown as mean ± SEM o f 5 independent experiments, and statistics were perform ed on normalised data, 
analysed by one way ANOVA w ith  post-hoc Dunnett's test. *  = p<0.05.
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Figure 4.14 -Effect of nucleotides on cytokine release from human lung parenchyma from smokers and non- 
smokers.
Lung donors were separated based on the ir smoking status. Graphs A, C, E and G represent cytokine release 
from  smokers (N=2) while graphs B, D, F and H represent cytokine release from  non-smokers (N=3). For non- 
smokers, values are shown as mean ± SEM o f 3 independent experiments, and statistics were perform ed on 
the normalised data, analysed by one way ANOVA w ith  post-hoc Dunnett's test. For IL -ip  there  was a 
significant effect o f concentration (p<0.01) and trea tm ent (p<0.01). * = p<0.05.
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Figure 4.15 -Effect of nucleotides on cytokine release from human lung parenchyma from smokers and non- 
smokers.
Lung donors were separated based on the ir smoking status. Graphs A, C, E and G represent cytokine release 
from  smokers (N=2) while graphs B, D, F and H represent cytokine release from  non-smokers (N=3). For non- 
smokers, values are shown as mean ± SEM o f 3 independent experiments, and statistics were perform ed on 
the normalised data, analysed by one way ANOVA w ith  post-hoc Dunnett's test.
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4.3.2. Myeloid dendritic cells from lung parenchyma
LPS caused no significant changes to the release of IL-1(3 or TNFa compared to untreated control 
(p>0.05, paired t-test, Fig 4.16 A, B). However there were apparent increases the secretion of both IL- 
1(3 and TNFa caused by LPS, but these did not reach significance due to human variation in response.
After 24 hours incubation, there were no significant effects caused by any of the nucleotides on IL-1(3 
and TNFa release from mDCs (p>0.05, one way repeated measures ANOVA, Fig 4.16 C, D). However 
there was an apparent increase in IL-1(3 release but this did not reach significance. IFNy and IL-17 
were only detected for one subject out of four (data not shown).
After 48 hours incubation, however ATPyS caused an increase in IL-1(3 release, and a decrease in TNFa 
release but this did not reach significance (p>0.05, one way repeated measures ANOVA, Fig 4.16 E, F). 
IFNy and IL-17 were only detected for one subject out of four (data not shown).
It was not possible to separate mDC results based on the lungs being from smokers and non-smokers 
as the lungs represented 3 non-smokers and 1 smoker (data not shown).
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Figure 4.16 - Effect of 24 and 48 hour stimulation with LPS or various nucleotides on the secretion of IL-lp 
and TNFa from mDCs isolated from human lung parenchyma.
mDCs enriched from  human lung parenchyma were stim ulated w ith  ATP, ATPyS, ADP or UTP at concentrations 
ranging from  4 to  1000 p.M in the presence o f LPS (10 pg/m l) and incubated at 37°C fo r 48 hours. Graphs A and 
B show the response o f mDCs to  LPS stim ulation at 24 hours (A) and 48 hours (B), analysed by paired t-test 
between control and LPS. Graphs C and 0 show the normalise response o f mDCs to  nucleotides at 24 hours 
and graphs E and F show the normalised response o f mDCs to  nucleotides at 48 hours. The normalised data 
were analysed by one way repeated measures ANOVA w ith  post-hoc Dunnett's test. Values are shown as mean 
± SEM o f 4 independent experiments. IL-17 and IFNy were only detected fo r one experim ent (data not shown). 
No significant effects were found.
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4.3.3. Plasmacytoid dendritic cells from lung parenchyma
Resiquimod caused no significant changes to the release of IL-1(3 or TNFa compared to untreated 
control (p>0.05, paired t-test, Fig 4.17 A, B). However there were apparent increases the secretion of 
both IL-lp and TNFa caused by resiquimod, but these did not reach significance due to human 
variation in response.
After 24 hours incubation, there were no significant effects caused by any of the nucleotides on IL-1(3 
and TNFa release from pDCs (p>0.05, two way repeated measures ANOVA, Fig 4.16 C, D). IFNy and IL- 
17 were only detected for one subject out of four (data not shown).
After 48 hours incubation, there were no significant effects caused by any of the nucleotides on IL-lp
and TNFa release from mDCs (p>0.05, two way repeated measures ANOVA, Fig 4.16 E, F). IFNy and IL- 
17 were only detected for one subject out of four (data not shown).
It was not possible to separate pDC results based on the lungs being from smokers and non-smokers
as the lungs represented 3 non-smokers and 1 smoker (data not shown).
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Figure 4.17 - Effect of 24 and 48 hour stimulation with resiquimod or various nucleotides on the secretion of 
IL-ip, TNFa, IFNy and IL-17 from pDCs isolated from human lung parenchyma.
pDCs enriched from  human lung parenchyma was stim ulated w ith  ATP, ATPyS, ADP or UTP at concentrations 
ranging from  4 to  1000 pM in the presence o f LPS (10 pg/m l) and incubated at 37°C fo r 48 hours. Graphs A and 
B show the response o f mDCs to  resiquimod stim ulation at 24 hours (A) and 48 hours (B), analysed by paired t-  
test between control and resiquimod. Graphs C and D show the normalised response o f mDCs to  nucleotides 
at 24 hours and graphs E and F show the normalised response o f mDCs to  nucleotides at 48 hours. The 
normalised data were analysed by one way repeated measures ANOVA w ith  post-hoc Dunnett's test. Values 
are shown as mean ± SEM o f 4 independent experiments. IFNy and IL-17 were only detected fo r one 
experim ent (data not shown). No significant effects were found.
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4.4. Discussion
4.4.1. Lung parenchyma
The aim of this study was to determine the effect of extracellular ATP and other nucleotides on 
cytokine release from human lung parenchyma, and then to isolate mDCs and pDCs from the 
parenchyma to determine if these cells are the source of the cytokines and are therefore responsible 
for the immune response to ATP in the lungs. This would also reveal if the effect of ATP as an 
immuno-modulatory signal in the blood is transferable to tissue DCs in the lungs.
In the lung parenchyma experiments, 24 hour stimulation with nucleotides was used, as this protocol 
had been established by GlaxoSmithKline to induce cytokine secretion in whole lung fragments. To 
follow this, experiments using enriched populations of mDCs and pDCs used both 24 and 48 hour time 
points, in order to relate the results back to both the lung data, and blood derived cell data.
The lung parenchyma consists of structural cells including epithelial cells, connective tissue and blood 
vessels, as well as immune cells. In the lung immune cell population, around 50% are large 
mononuclear cells (monocytes, macrophages and DCs), and 50% are small mononuclear cells 
(lymphocytes, natural killer cells) (Masten et al., 2006). The presence of multiple cell types indicates 
that the effects of treatments in lung parenchyma experiments may be due to receptor activation on 
any of these cell subsets. In order to ensure that all blood cells, including immune cells and 
erythrocytes were removed from the lung tissue, the tissue was washed multiple times by 
centrifugation. This means that the results should not be due to blood immune cell contamination of 
lung cells, but instead due to cells resident in the lungs.
LPS was used in these experiments as a lung cell stimulus for a number of reasons. The inhalation of 
LPS by asthmatic subjects has been shown to induce an increase in neutrophil recruitment to the
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lungs, and the maturation of DCs shown by an increase in the expression of HLA-DR, CD80 and CD86 
and the release of IL-1(3 (but not IL-4, IL-12 or TNFa). This suggests that lung DCs mature after allergen 
challenge, and that LPS is capable of causing this effect (Alexis et al., 2000). Also, LPS was used as a 
stimulus in blood cell experiments, allowing comparison of results.
In pilot studies, it was found that stimulation of lung parenchyma with nucleotides in the absence of 
LPS caused no effect on cytokine release from lung parenchyma (data not shown). This may be due to 
the cells involved being immature, and therefore unresponsive to nucleotides. This suggests that 
another signal must be present to cause changes in cytokine release and that nucleotides alone do 
not activate immune cells to initiate an immune response, but that an antigen or other stimulus, such 
as a TLR ligand is required. For this reason, the effect of nucleotides alone was not studied further as 
it was in blood cells.
It has been shown that the response of LPS in the lung depends on its concentration. A high 
concentration of LPS (100 pg) induced a Thl response in the lungs of OVA sensitised mice, while low 
concentrations of LPS (0.1-10 pg) induced a Th2 response (Eisenbarth et al., 2002). 10 pg/ml LPS was 
used in this study, which induced an increase in the release of IL-1(3, TNFa, IFNy, IL-6, IL-8, IL-2 and IL- 
10 from lung cells compared to control. This suggests that LPS induced a pro-inflammatory response 
in the lungs. The levels of IL-12, IL-4, IL-5, and IL-13 were below the level of detection. LPS is known to 
induce airway hyper responsiveness, increase immune cell recruitment and mucus secretion in the 
lungs (Corinti et al., 2001).
ATPyS caused the most profound effect on lung parenchyma. It induced a dramatic dose-dependent 
increase in IL-1(3 release compared to LPS control. IL-1(B is a pro-inflammatory cytokine whose main 
function is to activate T cells. The consequences of high IL-1(3 in the lungs include increased activation 
of CD4+ and CD8+ T cells via IL-1(3 binding to the IL-1(3 receptor (Dinarello, 2002). IL-1(3 requires two
signals to lead to its release. The first is the transcription of pro IL-1(3, an inactive form of the cytokine 
which is stored in the cytosol. On receiving a second signal, the N-terminal amino acids are cleaved by 
caspase-1 within the inflammasome to form IL-1(3, the active cytokine. This is released from cells by 
vesicular exocytosis (Dinarello, 2002). LPS is able to induce pro IL-1(3 transcription, although it only 
causes the release of 10% cellular IL-1(3 (Ferrari et al., 2006). This indicates that the second signal 
ATPyS induces caspase-1 activation and an increase in IL-1(3 release. Other studies have shown that 
activation of the P2X7 receptor by ATPyS leads to the efflux of K+ ions from the cell (Ferrari et al., 
1997). This reduction in K+ ions from the cell stimulated high levels of IL-1(3 release via an unknown 
mechanisms (Walev et al., 1995). This has been shown to occur in human and mouse macrophages 
and is not associated with increased cell death (Perregaux et al., 2000; Myrtek et al., 2007). This is 
consistent with the demonstration that some danger-associated molecules, such as silica, aluminium 
particles and uric acid which may act as danger signals, cause the release of ATP from ion channels on 
the cell surface, which then binds to P2X7 receptors on the same cell, inducing IL-1(3 maturation and 
release (Riteau et al., 2012). As DCs express P2X7 receptors, it is possible that they may be a source of 
IL-1(3 release in this study. However the P2X7 receptor agonist BzATP had no effect on IL-1|3 release so 
it is possible that another receptor is involved. It is possible that the P2Yn receptor is responsible for 
this response as ATPyS is an agonist at this receptor, and agonists at other P2 receptors had no effect. 
Apyrase also caused an increase in IL-1(3 release from lung parenchyma, although to a lesser extent 
then IL-1(3. As apyrase breaks down ATP into AMP, this may indicate that AMP, or adenosine may be 
involved in the IL-1(3 response. However, as no effects were seen with AMP and adenosine, this effect 
is unclear.
ATPyS also caused a dose dependent increase in IFNy secretion compared to LPS control. UTP also 
caused an increase in IFNy although the final concentration was slightly lower than that induced by 
ATPyS. IFNy is mainly secreted by CD4+ and CD8+ lymphocytes and is a Thl cytokine which increases
NK cell activation, promotes Thl cell activation and activates macrophages (Schroeder et al., 2008). It 
can be induced by IL-12 secretion; however this cytokine was below the level of detection in this 
assay so this may not be the case in this study. The pattern of increase in IFNy secretion seen here 
may be due to P2 receptor activation on lymphocytes within the parenchyma, possibly via P2Y2 
receptors due to the effect of ATPyS and UTP. In the lung, an increase in IFNy results in a Thl skewing 
of the immune response, and the activation of macrophages indicating a pro-inflammatory response 
(Young & Hardy, 1995).
ATPyS induced a dose-dependent increase in IL-17 secretion compared to LPS control, which was also 
been with AMP. IL-17 is secreted by T cells, neutrophils, DCs and other immune cells, and binds to the 
IL-17 receptor, resulting in activation of NFkB, which transcribes pro-inflammatory genes including IL- 
6, IL-1(3 and TNFa, increasing their release. In the lungs this results indirectly in an increase in 
neutrophil recruitment. Neutrophils are involved in phagocytosis of bacteria and particles and in the 
killing of bacteria by the release of enzymes that cause cell lysis (Witowski et al., 2004). LPS has been 
shown to induce the release of IL-17 from macrophages, but only in the presence of an antigen 
presenting cell (e.g. DCs). This may be what is occurring in this study. IL-17 is increased in the lungs of 
asthmatic patients but not in healthy control subjects, while neutralising IL-17 increases the 
symptoms of asthma, possibly due to neutrophil activation or the transcription of other pro- 
inflammatory genes such as IL-1(B (Schnyder-Candrian et al., 2006). Therefore the increase in IL-17 
may also contribute to the increase in IL-1(3 in this experiment. The effect of AMP may be indicative of 
activation of PI receptors by adenosine, however this was not responsible for the high amount of IL- 
17 released due to ATPyS.
ATPyS also caused a decrease in TNFa secretion compared to LPS control, which was also seen with 
ATP, apmethyleneATP, 2methylthioATP, P1P4DiATP and BzATP. . TNFa is produced mainly by
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macrophages, but also by other cells including DCs. It is produced as an active membrane-anchored 
precursor protein that is cleaved by TNFa converting enzyme to release the free homotrimeric form. 
This binds to the TNFa receptor, leading to activation of NFkB and transcription of pro-inflammatory 
genes including IL-6, IL-8 and TNFa (positive feedback loop) (Babu et a i, 2011). The effect of multiple 
agonists on the effect of TNFa may indicate activation of P2Yi, n, 12 or P2X receptor involvement, 
specifically the P2X7 receptor due to the effect of BzATP and ATPyS. It is possible that a multi-cell, or 
multi-receptor effect is seen here. It is also clear that a high concentration of nucleotides are required 
to elicit a response for TNFa release, which may not occur in the body, or only occur in certain 
inflammatory circumstances. TNFa induces airway hyper responsiveness through the induction of 
histamine release from macrophages, and direct activation of airway smooth muscle, so is pro- 
inflammatory in the lungs (Berry et al., 2007). The reduction in TNFa secretion may suggest a 
reduction in airway hyper responsiveness which contradicts the increased pro-inflammatory response 
seen with other cytokines, however as the response to TNFa did not reach significance it is likely that 
it caused no effect.
AMP caused an increase in TNFa release which was not seen with adenosine. AMP was used as it is 
rapidly broken down into adenosine by enzymes on the surface of immune cells. Adenosine is difficult 
to dissolve in water, and it was only possible to achieve a final concentration of 70 pM in the media, 
which may not be sufficient to induce a response here. AMP is easily soluble and therefore can be 
used to achieve a high concentration of adenosine. The effect of AMP at 1000 pM seen in this 
experiment indicates that a high concentration of adenosine is required to elicit a response, as 
adenosine at 70pM had no effect. It is possible that AMP is acting directly on A i or A 2a receptors, as 
suggested by Panther et al. (2012) who showed that AMP, but not adenosine was able to induce a Th2 
like immune response in mouse DCs and human moDCs. However this group saw a decrease in TNFa 
secretion from moDCs due to AMP, whereas in the present study, an increase in TNFa was seen
(Panther et al., 2012). This may be due to activation of other cells in lung parenchyma, or due to the 
response being due to adenosine binding to PI receptors, not AMP.
None of the nucleotides/nucleosides tested caused a significant effect on the secretion of IL-6. IL-6 is 
a neutrophil recruiting cytokine that is secreted by macrophages and other immune cells. Neutrophils 
phagocytose particles at the site of infection and secrete granzymes that lyse bacteria (Kukulski et al., 
2009). IL-6 also supports B cell growth and is required to overcome T regulatory cell suppression of 
the immune response, by inducing Thl7 cell activation and suppressing T regulatory cell formation 
(Kimura et al., 2010).
IL-8 is a neutrophil recruiting cytokine that is released from macrophages and epithelial cells where it 
is stored in vesicles, meaning that high concentrations are available for fast release from the cells. IL-8 
activates neutrophils and to a lesser extent eosinophils, which release reactive oxygen species and 
granules containing enzymes which lyse and kill invading pathogens (Barnes, 2008a). None of the 
nucleotides/nucleosides tested caused a significant effect on the secretion of IL-8, which may be due 
to the fact that LPS only caused a small increase in IL-8 secretion compared to control.
IL-2 is an important T cell promoting cytokine, secreted by activated T cells to provide autocrine 
stimulation. IL-2 binding to the IL-2 receptor leads to activation of NFkB and transcription of genes 
required for T cell survival (Blanco et al., 2008). In this study, ATP, ADP, 2methylthioATP and apyrase 
caused a decrease in IL-2 release from lung parenchyma indicating decreased T cell activation. This 
may suggest activation of the P2Yi receptor; however a high concentration of all nucleotides is 
required to elicit an effect. IL-10 is an anti-inflammatory cytokine that is secreted by monocytes, 
dendritic cells, T cells and mast cells. It acts to inhibit the immune response by inhibiting DC 
maturation, impairing IL-12 release and therefore impairing the Thl immune response (Corinti et al., 
2001). BzATP caused a decrease in IL-10 release from lung parenchyma, but only at a high
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concentration. This suggests the response is due to activation of P2X7 receptors, and would reduce 
the inhibitory effects of IL-10 on the immune response.
The levels of IL-12p70, IL-4, IL-5 and IL-13 were below the level of detection in all samples suggesting 
that LPS was unable to induce their release.
As can be seen from the results presented here, in LPS stimulated lung parenchyma, ATPyS induced 
an increase in the release of IL-1(3, IFNy and IL-17, and a decrease in the release of TNFa. This non- 
hydrolysable form of ATP is most potent on the P 2Y n  receptor and P2X7 receptor, however it also 
acts on P2Yi, 2, 12,13 and P2X1-6 receptors where it has varying affinities (see tables 1.2 and 1.3). To 
attempt to elucidate which specific receptors are activated in this response, other nucleotides were 
tested. ATP is rapidly broken down to ADP and adenosine by ecto-nucleotidases, so its lack of effect 
here may be due to its breakdown and not because its receptors are not involved in the response.
ADP only effected IL-2 release, which again may be due to its rapid breakdown to adenosine. UTP 
caused an increase in IFNy, but had no effect on the other cytokines. The action of UTP and ATPyS on 
IFNy suggests activation of P2Y2 receptors on immune cells or epithelial cells but rules these receptors 
out of other cytokines, a,(3-methyleneATP acts on P2X1, 3, 7 as well as P2Y: and n , and caused a 
decrease in TNFa, which may implicate these receptors in TNFa release due to the effects of ATPyS 
and BzATP which are also agonists at these receptors. P1P4DiATP also acts on P2X receptors and also 
caused a decrease in TNFa release, confirming involvement of P2X7. 2methylthioATP acts on P2Yi,i2, 
i3/ and P2X receptors and caused a decrease in TNFa and IL-2. This again implicates P2Yi and P2X7 
receptors in these responses.. BzATP acts on P2X7 as well as P2Yi and llt but only caused a decrease 
in IL-10 and TNFa secretion. BzATP is rapidly broken down in culture, which may means that the true 
effects of P2X7 receptor activation are unclear.
Overall, the effects of ATPyS appear to be due to activation of the P2Yn or P2X7 receptors on immune 
cells in the lung, which caused a pro-inflammatory and pro-asthmatic effect in the lungs. It has been 
shown that both a(3methyleneATP and BzATP act on P2Yi and n which could implicate P2Yi in the 
cytokine response (King & Townsend-Nicholson, 2007). However, as neither of these nucleotides 
caused a change in IL-1(3 release, and due to the fact that cx(3methyleneATP is a stable nucleotide, this 
may not be the case. Therefore, an increase in the concentration of ATP in the lungs during allergen 
challenge may act on the receptors to induce or exacerbate the features of asthma. Involvement of 
other agonists in the response of various cytokines implicates other P2 receptors, specifically P2Yi /2 
and P2X receptors in the immune response to nucleotides. It is also possible that the effects seen are 
due to receptor activation on multiple cell types, complicating the analysis of the response seen. For 
example, multiple nucleotides caused a decrease in TNFa release, which may suggest activation of 
P2Yi,n or P2X receptors.
After the experiments had been completed, and based on results reported in published studies 
suggesting that nucleotides may play a role in smoke-induced lung disease (Cicko et al., 2010) it 
seemed of interest to reanalyse the data separating the donors into smokers (minimum of 10 
cigarettes a day for over 2 years) or non-smokers. This had not been the focus of the experiments, so 
this was not possible for all of the nucleotides and for the lung-derived dendritic cells, however it 
produced some striking and interesting results. In lung parenchyma, for the lungs treated with ATPyS, 
ATP, ADP and UTP there were 3 non-smokers and 2 smokers. Unfortunately, the lungs treated with 
a,(3-methyleneATP, 2methylthioATP, P1P4DiATP and BzATP were all from smoking subjects, meaning 
that these experiments could not be separated.
Smoking has been shown to cause an increase in the number of mDCs in the bronchiolar lavage fluid 
after smoking a cigarette which suggests an inflammatory response occurs to smoking (Lommatzsch
et al., 2010). In non-smokers, LPS caused a significant increase in IL-lp, TNFa, IFNy, IL-6, IL-8, IL-2 and 
IL-10 compared to untreated control, which matches the combined data. In smokers, LPS caused a 
significant increase in IL-lp, TNFa, IFNy, IL-2 and IL-10 compared to untreated control, but had no 
effect on the release of IL-17, IL-6 and IL-8. This may suggest that smoking decreases the response of 
the lungs to LPS, possibly due to cell damage.
In this study, lungs from non-smokers released higher concentrations of IL-1(3, TNFa, IFNy and IL-17 
both spontaneously and when treated with LPS compared to smokers, while levels of IL-6, IL-8, IL-2 
and IL-10 were similar. When comparing the two phenotypes, it is possible that smoking decreases 
the basal levels of cytokines released in the lung.
When the response to nucleotides was analysed, the difference in response was much clearer. In the 
case of IL-1|3 release the smokers released a 10 fold higher concentration of IL-1|3 in response to 
ATPyS compared to non-smokers. A similar effect was seen with IFNy in response to ATPyS and UTP, 
where smokers induced a 10 fold increase in IFNy release compared to non-smokers. TNFa, IL-6, IL-8, 
IL-10 and IL-2 release was similar between the two groups, while only non-smokers released IL-17, as 
this cytokine was below the level of detection in smokers. It was not possible to analyse the effects of 
cytokines on smokers. These results indicate that smokers have an increased pro-inflammatory 
cytokine response to nucleotides compared to non-smokers. Interestingly, in smokers nucleotides 
inhibited IL-17 release, while in non-smokers 11-17 release was enhanced. IL-17 is a pro-inflammatory 
cytokine involved in neutrophil recruitment. The lack of IL-17 secretion in smokers may suggest a 
reduction in the neutrophil response in these subjects.
The overall increased cytokine response in smokers may be due to increased tissue damage caused by 
smoking, or an increased sensitivity of P2 receptors to ATP in the lungs, which could be due to 
increased receptor expression or increased sensitivity of these receptors. On statistical analysis of the
non-smoking data, it was seen that ATPyS caused a significant increase in IL-1(3 and IL-17 release from 
lung parenchyma, whereas no significant effect was seen for any of the other nucleotides at any of 
the cytokines tested. This matches the results seen when all the data sets were combined, and shows 
that the response of IL-1(3 and IL-17 to P2 receptor activation is not smoking-specific, but it is possible 
that this effect is enhanced in smokers. It would be of interest to further investigate this effect and 
provide a statistical analysis of the smoking results. Other studies have shown that exposure of mice 
to cigarette smoke lead to an increase in IL-1(3 and the influx of alveolar macrophages in the lungs of 
mice, which was attenuated by the use of anti-IL-ip monoclonal antibodies. This confirms the data 
shown in the present study, showing that cigarette smoke induces cytokine release, and this may 
affect other stimuli (Castro et al., 2011). This effect may be a leading contributor to smoking related 
diseases, such as chest infections and COPD.
4.4.2. Myeloid dendritic cells
The next aim of this study was to determine the effects of extracellular nucleotides on mDCs isolated 
from human lung parenchyma and to determine if they are the source of the cytokines from the lung 
parenchyma experiment. Unfortunately it was not possible to perform flow cytometry on these cells 
which meant that it was difficult to determine their exact purity. However it was assumed that they 
were a similar purity as in the blood. As with the blood cells, this shows an enrichment of cells but 
also brings the problems of contaminating cells in culture affecting the results due to receptor 
expression and cytokine release. mDCs make up around 2% of mononuclear cells in the lung (Masten 
et al., 2006), which means that low cell yields were obtained for the lung, as only a limited sample of 
tissue was available. To improve the number and purities of DCs isolated from lung, more lung tissue 
would be required. Despite this, an enriched lung mDC population was studied in this project, which 
allowed for the determination of the role of these cells in the whole lung response to nucleotides.
LPS caused an increase in the release of IL-lp and TNFa from mDCs, although these effects were not 
significant. This is likely to be due to variation between donors, and may explain why the effects of 
nucleotides also do not reach significance.
24 hour stimulation of mDCs with ATPyS caused an apparent increase in IL-1(3 secretion, while no 
effect was seen with the other nucleotides. There was no effect on TNFa secretion. This indicates that 
mDCs may be source of the IL-1(3 released from lung parenchyma experiments, most likely due to 
activation of the P2Yn receptor as this is expressed on mDC, however as statistical significance was 
not reached, this effect is not clear. It is possible that there is involvement of the P2Yi, 2, 11, 12, is 
receptors, however this can be ruled out due to inactivity of agonists of these receptors in lung 
fragment experiments, which suggested that these receptors were not involved in this response. The 
levels of IFNy or IL-17 were below the level of detection in this assay, suggesting that other cell types 
are responsible for the secretion of these cytokines from the lung.
At 48 hours, the same pattern of cytokine release as seen with ATP and ATPyS at 24 hours can be 
seen. This indicates that there are long, chronic changes in IL-1(3 secretion induced by both LPS and 
the nucleotides as there is an increased concentration of this cytokine then seen at 24 hours. For 
TNFa, a similar pattern of cytokine release and concentration was seen, indicating that the release of 
this cytokine occurs early in the culture. Again, IFNy and IL-17 concentrations were below the level of 
detection, which supports the conclusion that mDCs are not a source of these cytokines in the lung.
Overall, this indicates that mDC are a likely source of IL-lp secretion in the lung, although they may 
not be the main source of these cytokines, as the concentration released was lower than in the whole 
lung experiment. It may also be the case that fewer viable cells were obtained in these cultures, 
thereby reducing the cytokine levels detected. These results may suggest that nucleotides, acting on 
P2Yn receptors are pro-inflammatory in the lungs and that DCs are partly responsible for this
response. Only four cytokines were analysed in this experiment, due to a low volume of supernatant 
being collected, and limited assay availability. A similar response to nucleotides has been shown in 
mice, where the administration of suramin (P2 receptor antagonist) reduced the features of asthma 
due to decreased levels of DC maturation and decreased release of IL-4, 5, and 13, whereas ATPyS 
caused an increase in the release of IL-4, 5 and 13 and increased the features of asthma. This suggests 
that ATP changes the maturation state of lung DCs, to promote the sensitisation to an allergen (Idzko 
et al., 2007). This confirms the results in the current study, as an increased release of IL-1(3 from mDCs 
and other immune cells would promote a pro-inflammatory immune response in the lung.
It is possible that contaminating cells in the culture may be a source of the cytokines detected in this 
experiment. It is also possible that contaminating cells may affect the response of mDCs to 
treatments, due to the release of mediators in response to the nucleotides or LPS. This may also be 
due to the age of the post-mortem lung, which was received around 24 hours after removal from the 
body. This would lead to some level of cell necrosis, meaning that the mDC population may be 
contaminated with a number of dead cells. This can be seen clearly in figure 2.3 which clearly shows 
that the majority of cells were dead in the blood cell preparation, and it is assumed that a similar level 
of dead cells would be seen in the lung preparation. As with the blood mDC population, this could 
lead to activation of the lung mDCs, masking the effect of the nucleotides.
Unfortunately it was not possible to separate the mDC results based on the lung donors being 
smokers or non-smokers as there was only one smoker and three non-smokers. It has been shown 
that levels of mDCs in the bronchiolar lavage fluid are increased due to smoke exposure, while 
numbers of blood macrophages, lymphocytes, neutrophils and pDCs remained the same (Lommatzsch 
et al., 2010). This suggests smoking induces the recruitment of mDCs to the lungs, and that that these 
cells may be a source of pro-inflammatory cytokines. Therefore it is expected that mDCs from
smokers would show an increased response than non-smokers. It would be of interest to increase the 
number of subjects in these experiments, and also to use pure mDC populations, which may be 
obtained using FACS sorting, to determine if the increases in cytokine response seen by smokers in 
the whole lung experiment are due to effects of mDCs.
4.4.3. Plasmacytoid dendritic cells
The aim of this study was to determine the effects of extracellular nucleotides on pDCs isolated from 
lung parenchyma and to determine if they are a source of the cytokines from the whole lung 
experiment. pDCs represent about 1% of mononuclear cells in the lung, so represent a rare cell 
population (Masten et al., 2006). pDCs are involved in the induction of tolerance to allergens, and so 
may be key in the protection against the induction of asthma. This has been shown by the depletion 
of pDCs from healthy mice, which leads to the induction of an asthmatic immune response (De Heer 
et al., 2004).
Resiquimod caused an increase in the release of IL-1(B and TNFa from pDCs, however this effect was 
not significant due to variation between donors.
Stimulation of pDCs for 24 hours with resiquimod and nucleotides induced the release of IL-1(3 and 
TNFa, but the levels of IFNy and IL-17 were below the levels of detection suggesting that pDCs may 
not be a source of these cytokines from lung parenchyma. For IL-1(3 and TNFa there were no patterns 
of release, but large standard error of responses are seen. 48 hour stimulation of pDCs saw similar 
responses, and no statistical differences in the response to nucleotides were found. Again, the levels 
of IFNy and IL-17 were below the level of detection. The results show large variation between donors, 
due to human variation which suggests that the number of experimental repeats carried out on purer 
pDCs needs to be increased in order to counteract this variation and show a conclusive response. It is 
also possible that the sources of the cytokines detected in these experiments may not be from pDCs,
but from contaminating cells. This makes the analysis of these results even more complex, as it is not 
clear what cells are present.
It is likely that pDCs are not a main source of the cytokines secreted in whole lung experiments, and 
that pDCs do not induce a pro-inflammatory response to ATP in the lungs. pDCs lack TLR-4 receptors 
which bind LPS, which lead to the use of resiquimod (a TLR-7 agonist) to provide stimulation of 
immune cells alongside nucleotides. This may provide an explanation for the different response of 
pDCs, however resiquimod should have provided a similar type of stimulation to LPS, enabling the 
effect of nucleotides to be seen. It is clear, therefore, that pDCs are not a main source of the pro- 
inflammatory cytokines as seen in whole lung experiments.
It has been shown that pDCs in the lungs of mice are capable of taking up FITC-OVA particles and 
migrate to the draining lymph nodes but are unable to stimulate T cells due to low levels of cytokines 
(De Heer et a l, 2004). This corresponds with the results presented here, as while resiquimod induced 
the release of cytokines, nucleotides did not affect this response.
As with mDCs, the age of the lung may have affected the purities of cells isolated form the tissue. The 
post-mortem lung was received around 24 hours after removal from the body. This would lead to 
some level of cell necrosis, meaning that the pDC population may be contaminated with a number of 
dead cells. As with the blood pDC population, this could lead to activation of the lung pDCs, masking 
the effect of the nucleotides. This must be taken into account when analysing the data, as the 
variation of response to nucleotides may be due to the cells already being activated by nucleotides 
released from necrotic cells.
Unfortunately it was not possible to separate the pDC results based on the lung donors being smokers
or non-smokers as there was one smoker and three non-smokers. It has been shown that pDCs
exposed to cigarette smoke extract induced increased release of IL-8 and suppressed release of TNFa,
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IL-6 and IFNy. This suggests that smoking diminished anti-viral activity of pDCs, and may contribute to 
development of CORD due to increased levels of IL-8 (Mortaz et al., 2009b). It would be of interest to 
increase in number of subjects in these experiments, and also to use pure pDC populations to 
determine if there is a difference between the response of smokers and non-smokers in pDCs.
4.4.4. General discussion
This chapter provides evidence of the effect of nucleotides on lung parenchyma, and on mDCs and 
pDCs enriched from lung parenchyma. In lung fragments, ATPyS elicited a pro-inflammatory cytokine 
response which could be attributed to activation of P2Yn or P2X7 receptors on multiple cell types 
including DCs, macrophages, lymphocytes and epithelial cells. It is difficult to prove exactly which 
receptor is involved, due to agonist cross-over on receptor subtypes. It is clear that activation of P2Yif 
2 and P2X receptors also lead to changes in cytokine release from lung parenchyma, implicating both 
multiple receptors and multiple cell involvement in the response. This provides direct evidence that 
an increase in levels of ATP in the lungs of asthmatics, if in the presence of another stimulus (TLR 
agonist), induces a pro-inflammatory asthmatic response. This suggests that ATP released from the 
lungs due to tissue damage or cells stress may be linked to not only exacerbating the asthmatic 
response, but may be involved in the induction of asthma, as if tissue damage is present alongside 
allergen inhalation contaminated with LPS or a virus, this may lead to asthma development. Idzko et 
al. (2007) showed that mice sensitised to OVA experienced an increase in the concentration of ATP 
and the numbers of eosinophils, neutrophils, lymphocytes and macrophages in the bronchiolar lavage 
fluid in response to OVA challenge. It is possible that the increase in cytokine release induced by ATP 
in the current experiment results in the recruitment of these immune cells to the lungs in vivo.
mDCs were enriched from lung to determine the effects of nucleotides on this cell population. In this 
cell population, ATPyS appeared to increase 11-1(3 secretion, although this did not reach significance.
This matches the pattern of response seen in the whole lung experiment indicating that mDCs may be 
involved in the induction of an immune response in the lungs to ATP, but that other lung cells are also 
involved in the release of IFNy, IL-17 and TNFcx. The concentration of cytokine released from DCs was 
lower than that of the whole lung experiment. This may be due to the isolation of mDCs which 
removed the cells responsible for the majority of the cytokine release, such as alveolar macrophages 
which have been shown to secrete IL-1(3 (Myrtek et al., 2012), or due to the isolation process itself 
affecting the ability of mDCs to secrete cytokines. In future experiments it would be useful to culture 
the discarded cells from the mDC isolation protocol, and incubate these cells with nucleotides. This 
would show whether it is another cell type that was removed during the isolation was responsible for 
secreting IL-ip, or whether mDCs are affected by the isolation process, resulting in lower 
concentrations of cytokines being released.
pDCs were enriched from the lungs to determine the effects of nucleotides on this cell population. 
There were no changes in cytokine production caused by the nucleotides on this cell type, and the 
responses seen appeared to be highly variable between donors. This suggests that pDCs may not be 
the source of the pro-inflammatory cytokines in response to ATP due to their role in tolerance 
induction in asthma.
Overall, the results presented here indicate that P2 receptor activation on lung immune cells elicits a 
pro-inflammatory immune response in the lungs and that mDCs, but not pDCs may be partly 
responsible for this effect.
Chapter 5 - Discussion and future work
The identification of purinergic receptors on human DCs has led to the suggestion that extracellular 
ATP acts as a danger signal in the immune system. Extracellular ATP released from cells due to 
necrosis, cell activation or cell stress binds to P2 receptors on dendritic cells, and other immune cells 
and may influence the immune response to pathogens, or have implications for the initiation of 
immune-related disorders (Ferrari et al., 2007). The presence of multiple DC subsets at the site of 
inflammation complicates this theory, while the use of in vitro generated moDCs in many studies 
instead of mDCs isolated directly from the blood/tissues means that results obtained may not 
represent the response in the body. This thesis aimed to analyse the effects of extracellular 
nucleotides on various aspects of DC immunity, on multiple blood and tissue derived DC subsets 
isolated from human subjects.
In moDCs there are conflicting studies suggesting that ATP alone may or may not be able to induce 
the maturation of moDCs and initiate a Thl response, and that in LPS-matured moDCs ATP is able to 
induce either a Thl, or Th2 skewing of the immune response (Schnurr et al., 2000; la Sala et al., 2001; 
Wilkin et al., 2001). These studies show variation in results, which are further complicated by the lack 
of statistical analysis which makes their interpretation difficult. Accounting for variation is important 
when studying human donors, as the wide genetic pool leads to variation in immune responses, and 
this must be considered when making statements about results. Statistical analysis of similar 
experiments repeated several times in this thesis confirms that under the experimental conditions 
used in the present study, ATP alone has no effect on moDC maturation, and that ATP inhibited the 
maturation and pro-inflammatory cytokine profile induced by LPS on moDCs. This suggests that ATP 
which is released due to tissue damage at the site of infection caused by a pathogen modulates the 
immune response to the pathogen which results in a dampening of the immune response to limit the
severity of damage produced. This may be important in controlling the severity of the immune 
response, or in changing the type of response that is activated. It is important that ATP alone was 
unable to affect moDCs, as this shows that the release of ATP in the absence of a pathogen cannot 
initiate an immune response, limiting auto-immune development (Blanco et al., 2008).
A pro-inflammatory cytokine profile was studied to cover the majority of important cytokines in the 
DC response, however it would be of interest to conclusively determine whether a T h l or Th2 
response is initiated. Therefore, it would be of interest to study the release of IL-4 (Th2 promoting) 
from moDCs in comparison to IL-12, or to extend the analysis of T cell activation by DCs and 
determine the type of T cells induced by moDCs. This would show whether ATP is able to change the 
immune response to a pathogen from a cell mediated Th l response, to an antibody mediated Th2 
response. However, inherently, the use of moDCs may not be representative of the effects in the 
body, and a higher precedence should be put on the study of DC subtypes isolated directly from the 
blood.
Further experiments looked at the effect of ATP on mDCs enriched from human blood. P2 receptor 
activation induced partial maturation of mDCs accompanied with a reduction in anti-inflammatory 
cytokine secretion. In LPS-matured mDCs, P2 receptor activation had little effect. The response to ATP 
shows that ATP may be acting as a danger signal in mDCs, increasing their maturation state, however 
full maturation was not achieved which may suggest that ATP alone is not sufficient to induce an 
immune response in these cells. There are currently no other studies in this area, so this thesis is the 
first study to indicate a role for P2 receptor activation on mDCs .
It is clear that the response of mDCs differed compared to moDCs, which indicates that moDCs are 
not truly representative of blood mDCs. One of the limitations of this study was the low purities of 
mDCs and the contamination of cell populations with dead cells, which may release nucleotides and
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other molecules that could pre-activate the DCs, masking the true effect of nucleotides on these cells 
It would be of interest to verify these results using mDCs of increased purity which may be obtained 
using FACS sorting, in order to eradicate any effects of contaminating cells in culture.
These experiments were extended to study pDCs, which are known to have a different function (viral 
immunity/tolerance) and phenotype to mDCs. P2 receptor activation on pDCs decreased their 
maturation and increased the secretion of anti-inflammatory cytokines, but had no effect on 
resiquimod-induced secretion of pro-inflammatory cytokines. This suggests that ATP may aid in the 
reduction of the immune response during bacterial infection by releasing anti-inflammatory cytokines 
which act to limit the immune response, but in the presence of a viral infection ATP does not affect 
pDCs which allows for a full immune response against the virus to occur. This disagrees with work by 
Shin et al. (2008) who showed that nucleotides inhibited cytokine release by activated pDCs. However 
this group used a TLR-9 agonist, whereas resiquimod is a TLR-7 agonist. Differences in the responses 
to these agonists may suggest that the response of pDCs is specific to the virus encountered, as 
different viruses activate different TLRs. The group also found that uridine nucleotides were more 
potent than adenine nucleotides in pDCs (Shin et al., 2008). This suggests that the response of pDCs is 
dependent on P2Y 2,4, e rather than adenine nucleotide preferring receptors which were studied in this 
thesis. As with mDC experiments, the use of purer cultures of pDCs would verify these results, and it 
would also be of interest to stimulate cells with an agonist at TLR-7 and an agonist at TLR-9 to 
determine whether the variation in response seen in this and other studies are due to viral specific 
effects.
It has been suggested that the balance between mDCs and pDCs determines whether an immune 
response or tolerance to an antigen is induced (Matsuda, 2002). It has been shown in this thesis that 
ATP may aid in this effect, acting on both DC subsets to modulate the immune response to pathogens.
ATP acts on mDCs to reduce anti-inflammatory cytokine secretion, and on pDCs to increase anti­
inflammatory cytokine secretion, which may result in an overall dampening of the immune response 
to a pathogen.
DCs migrate from the blood to the tissues where they reside and function to capture antigens 
entering the body to protect against infection. Due to differences in the local microenvironment it is 
possible that tissue DCs act in a different manner to blood DCs (Bell, 2008). Lung tissue was used in 
this study as it is known that mDCs and pDCs are vital in lung immunity, and that ATP is implicated in 
the pathogenesis of asthma (Idzko et al., 2007).
The main result from this thesis was that activation of P2Y receptors on LPS-stimulated lung 
parenchyma induced a pro-inflammatory cytokine response. This effect was dramatic and although 
some cytokine responses were seen with other P2 agonists, a multi-cytokine effect was seen in 
response to ATPyS, which suggests that the P 2Y n  and P2X7 receptors are most likely to be 
responsible for this effect. The lack of specific agonists and antagonists for P2 receptors means that 
the receptor subtype cannot be definitively stated so it is possible that P2Yi; 2 and P2X receptors are 
also involved. Lung parenchyma consists of multiple cell types including monocytes, macrophages, 
lymphocytes, DCs and endothelial cells (Barnes, 2008b). Therefore, the source of these cytokines may 
be due to receptor activation on any of these cells, or due to cell-cell interactions. It is likely that a T h l 
response is induced due to the increase in IFNy, however due to the lack of response of other T h l 
promoting cytokines such as IL-12 this is unclear. In asthma, an increase in the concentration of ATP 
due to infection or other sources may lead to sensitisation to innocuous antigen, or increase the 
severity of the asthmatic response due to cytokine release. Interestingly, nucleotides had no effect in 
the absence of LPS stimulation, suggesting that the response to ATP requires infection, or a DC- 
stimulating antigen to be present. Again, this supports the idea that ATP is immuno-modulatory and
cannot affect the immune response alone. It is of interest to determine which cell types are 
responsible for the effects of ATP in the lungs in order to identify possible treatment targets.
Although an investigation of the effect of smoking was not the original aim of this thesis, an important 
unexpected result is the identification of an increased cytokine response in smokers compared to 
non-smokers. Unfortunately, statistical analysis was not possible on the smokers due to low 
experimental numbers when samples were divided, but it is clear that the results are different. The 
increased cytokine response in smokers may aid in the pathogenesis of smoking related diseases such 
as COPD and emphysema. This work compliments other studies showing that exposure to cigarette 
smoke increases the numbers of DCs in the lungs alongside increased alveolar wall destruction 
(D'hulst et al., 2005), and that DCs from mice exposed to cigarette smoke show enhanced survival and 
therefore an enhanced immune response can occur (Vassallo et al., 2010). Together this suggests an 
important role for DCs in smoking-related diseases, and that extracellular nucleotides released due to 
cigarette smoke induced lung damage may enhance this effect. It would be of great interest to 
continue the comparison of smokers and non-smokers to study cytokine release from individual lung 
cells to determine the source of these cytokines. It was not possible to analyse whether smoking had 
an effect on lung mDC and pDC responses due to the lack of availability of smoking donors. It may also 
be interesting to analyse results based on whether they were asthmatic or healthy as this may also 
show variation in response. This was not possible in this thesis as there was low availability of 
asthmatic lungs, however this may be an interesting observation for future studies.
Due to the importance of DCs in lung immunology, these cells were isolated from lung tissue. It was 
seen that mDCs but not pDCs were responsible for an amount of the IL-1(B, and possibly TNFcx release 
in whole lung. This may suggest that ATP released during infection acts on mDCs to further increase 
the pro-inflammatory immune response to eradicate the pathogen. This works supports other studies
showing that pulmonary mDCs were able to induce pro-inflammatory cytokine release to stimuli and 
activate T cells, whereas pDCs did not (Demedts et a i, 2006). As in the case of blood DCs, FACS sorting 
of lung immune cells would lead to increased purity of cultures which may confirm these results. It 
would also be of interest to study other cell types from the lung parenchyma in order to determine if 
other cells are also sources of cytokine release in response to nucleotides. For example, alveolar 
macrophages which make up a large proportion of human lung immune cells express P2 receptors 
and release IL-1(3 in response to ATP making them a possible source of cytokines analysed in this 
thesis (Myrtek et al., 2012).
Blood and lung DCs responded in similar patterns to ATP, and ATPyS. pDCs from blood and lung both 
showed no change in the release of IL-1(3 and TNFa in response to nucleotides, however mDCs in 
blood showed similar patterns of cytokine release to lung cells, although there were lower 
concentrations of cytokine released from blood cells, and the pattern of response was reduced which 
meant that significance was not achieved. This suggests that tissue resident DCs have increased 
cytokine responses, possibly due to an increased basal maturation state, or due to other stimulation 
present in the local environment. It would also be of interest to extend the cytokines studied in lung 
cells to match that of blood DCs to obtain a more complete comparison. Increasing the purities of 
both blood and lung DC subsets would also confirm these results.
The study of multiple DC subtypes isolated directly from the body has shown the importance of this 
cell type in immunity. Interest in purinergic signalling is increasing, and this area is proving important 
in many fields including immunology. This thesis combined the fields of purinergic signalling and 
immunology and shows an important role of P2 receptor activation on DCs leading to alterations in 
the immune response. Overall, in LPS-stimulated moDCs, P2 receptor activation inhibited maturation 
and the release of pro-inflammatory cytokines; in blood DCs P2 receptor activation acted as a danger
signal to increase the maturation state of mDCs and the release of anti-inflammatory cytokines in 
pDCs; and in lung parenchyma P2 receptor activation enhanced the pro-inflammatory immune 
response to LPS stimulation which was partially due to P2 receptor activation of mDCs but not pDCs. 
This thesis has also identified a striking effect of smoking on the response of lung cells to nucleotides 
which is an important aspect for future research.
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Appendix 1 -  Information sheet for volunteers
The role of P2-purinoceptors in human immune cell biology
Background
Your blood will be used as a source of cells to investigate the control of immune cells and in particular dendritic 
cells. Dendritic cells are the cells of the immune system that are responsible for recognizing foreign elements 
and presenting them to lymphocytes in such a way as to stimulate an immune response. They also play a role 
in inflammatory diseases such as asthma where the immune system is activated inappropriately. A better 
understanding of how dendritic cell activity is regulated, and how these cells interact with lymphocytes, could 
lead to the development of better drugs for the treatment and prevention of asthma.
The aim of this project is to investigate the control of these processes by nucleotides, a group of endogenous 
extracellular signalling molecules that act on receptors known as P2-purinoceptors. There is evidence for a role 
for extracellular nucleotides acting on dendritic cells in the development of allergic airway inflammation in 
animals, and this suggests that studying P2-purinoceptors on dendritic cells may lead to novel therapeutic 
approaches to the treatment of asthma. There are several different subtypes of P2 receptors which have the 
potential to be targeted selectively by drugs, and the major objectives of this project are to identify the 
subtypes present on human dendritic cells and the effects that activation of these receptors have on the cells.
Procedure
Your blood will be taken by a trained phlebotomist, and no more than 100 ml of blood will be taken from you 
at one time. Blood is usually taken from a vein inside the elbow. The skin over the area is wiped with an 
antiseptic, and a tourniquet is placed around the upper arm, making the veins more visible. You will be asked 
to make a fist, and the person taking the blood feels the veins in order to select an appropriate one. When a 
vein is selected, a needle is inserted into the vein and the appropriate amount of blood is drawn into a syringe. 
The tourniquet is then released and the needle is withdrawn from the vein while a cotton wool pad is held 
against the vein. We will ask you to hold the cotton wool pad tightly against the vein until the bleeding has 
stopped (normally a couple of minutes), to reduce the risk of bruising. A plaster is usually then applied unless 
you tell us that you would prefer not to have one, and you can then leave when you wish. Some people feel 
faint or dizzy after giving blood, and if you do then you should lie down until you recover, and if necessary you 
will be given a drink or something to eat.
Possible risks
There may be mild discomfort at the site of the needle placement, and there is the rare possibility of 
developing a small blood clot, inflammation or local infection around the vein where the needle is inserted, or 
in very rare cases a generalized infection spread through the bloodstream. All the materials used for collecting 
blood are sterile and used only once, so it is not possible to contract HIV (AIDS) or Hepatitis B or C by donating 
your blood.
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General
If you wish to withdraw at any time then you may do so without giving us a reason, and if there is any reason 
why you should not give blood then please tell us. In particular, you should not give blood if you are at risk 
from HIV (AIDS) or hepatitis, if you have ever had malaria, hepatitis or tuberculosis, if you have had glandular 
fever within the last two years, if you have had an infection or contagious disease (other than colds or flu) 
within the last month, or if you have ever had a serious disease such as heart disease, stroke, chronic lung 
problems, diabetes, epilepsy or cancer.
No genetic testing will be carried out on the blood, and no personal or medical information will be collected 
from you except that needed to ensure that you can be contacted if necessary and that you are fit to act as a 
donor.
You will be asked to sign a consent form, and you will be given a copy of the signed consent form and this 
information sheet. Unless you tell us that you do not wish us to, we will keep you contact details on file and 
may contact you again in the future to ask you whether you are willing to give us further blood samples. We 
will not take more than 450 ml of blood from you in any 4 month period.
Appendix 2 -  Consent form for the donation of blood 
for teaching or research
UNIVERSITY OF
SURREY
Please read this carefully before signing. Your signature on the consent form is taken as evidence that you 
have read the statements. You will be given a signed and dated copy of this consent form.
The purpose of this consent form is to act as an obvious means of screening for situations which could put the 
donor, phlebotomist (trained person taking the blood) or user of the specimen at risk. It allows the donor the 
opportunity at any time to withdraw from blood donation without having to justify a reason for doing so.
You may be invited at intervals as part of a Volunteer Blood Donation Panel to donate blood, but this will not 
exceed more than 450mls (a single 'unit' of blood) in any four month period. For volunteers intending to 
donate blood on more than one occasion for a particular study it is sufficient to sign this form only once on the 
understanding that if reasons arise which make donation inadvisable, no further samples are donated.
There is minimal risk or discomfort from donating blood. Occasional minor bruising or irritation may follow a 
blood donation around the site of the puncture. In very rare cases there may be local infection. Please note 
that all the materials used for collecting blood are sterile and used only once, it is not possible to contract HIV 
(AIDS) or Hepatitis B or C by donating your blood.
Please note that genetic research (DNA genotyping studies) will NOT be performed using these blood samples. 
Usually, any remaining unused sample will be discarded once a specific piece of work has been completed. 
However, in a few instances processed samples may be stored for later subsequent research.
If you have any queries about the research, your rights or any study-related injuries, please contact Professor 
Susanna Hourani (01483 689707 or s.hourani(a>surrev.ac.uk) or Dr Ernesto Ovieda-Orta (01483 689624 or 
e.ovieda-orta@surrey.ac.uk).
Consent Form
I the undersigned vo lun tarily  ag ree  to take p a rt in the study on the ro le of P 2-p u rino cepto rs  in hum an im mune cell biology.
•  I have read  and understood the In fo rm ation  S heet provided. I have been given a full explanation by the investigators of the natu re ,
purpose, location and likely duration  of the study, and of w hat I will be expected to do. I have been advised about any d isco m fo rt and
possible ill-e ffe c ts  on my health  and w ell-being  which may resu lt. I have been given the opportunity to ask questions on all aspects of the
study and have understood the advice and in fo rm ation  given as a result.
•  I consent to my personal data, as outlined in the accom panying in form ation  sheet, being used fo r the re s e a rc h  p ro jec t detailed in the
in form ation  sheet, and agree th a t data co llected  may be shared  w ith o ther re s e a rc h e rs  or in te res ted  parties . I understand th a t all
personal data re la ting  to vo lun teers is held and p rocessed  in the s tr ic te s t confidence, and in accordance w ith the Data P ro tection  Act 
(1938).
•  I understand th at I am fre e  to w ith d raw  fro m  the study at any tim e w ithout needing to jus tify  my decision and w ithout p rejudice.
•  I understand th at in the event of my su ffering  a significant and enduring injury (including illness or d isease) as a d irec t re su lt of my
p artic ipation  in the study, com pensation will be paid to me by the University, subject to ce rta in  provisos and lim itations. The am ount of 
com pensation will be ap p ro pria te  to the n ature , severity  and p ers is ten ce of the injury and will, in genera l te rm s , be consistent w ith the  
am ount of dam ages com m only aw arded  fo r s im ila r injury by an English co u rt in cases w here the liability has been adm itted
•  I am over 18 years of age and not knowingly su ffering  fro m  any m edical condition which would m ake it inadvisable fo r me to donate blood.
•  I ag ree  to cease donating blood should reasons arise  fo r doing so.
•  I understand th at I will not rece ive  any financia l benefit th a t m ight com e fro m  the re se arc h  resu lts
•  I confirm  th at I have read  and understood the above and fre e ly  consent to partic ipating  in this study. I have been given ad eq u ate  tim e to
consider my partic ipation  and agree to com ply w ith the instructions and re s tric tio n s  of the study.
Name of vo lun teer (BLOCK CAPITALS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Signed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Date . . . . . . . . . . . . . . . . . . . . . . . . .
Name of re s e a rc h e r /p e rs o n  taking consent (BLOCK CAPITALS)
Signed
Date
-I 225
Appendix 3 -  Ethics
U N I V E R S I T Y  O F
SURREY
Professor Susanna Hourani
Pharmacology
FHIVIS
Ethics C om m ittee
15 September 2008
Dear Professor Hourani
The role of P2-purmoceptors in human immune cell biology 
EC/2008/72/FHMS
On behalf o f the Ethics Committee, I am pleased to  confirm a favourable ethical 
opinion fo r the above research on the basis described in the submitted protocol and 
supporting documentation.
Date o f confirmation o f ethical opinion: 15 September 2008.
The final list o f documents reviewed by the Committee is as follows:
oc r, ,
Summary o f the project 15 Sept 08
Detailed protocol 15 Sept 08
Information sheet 15 Sept 08
Consent form 15 Sept 08
Risk assessment 15 Sept 08
Protocol Submission Proforma: Insurance 15 Sept 08
This opinion is given on the understanding tha t you w ill comply w ith the University's 
Ethical Guidelines for Teaching and Research.
The Committee should be notified o f any amendments to  the protocol, any adverse 
reactions suffered by research participants, and if the study is terminated earlier than 
expected w ith reasons.
You are asked to  note that a further submission to  the Ethics Committee w ill be 
required in the event that the study is not completed w ith in  five years o f the above 
date.
Please inform me when the research has been completed.
Yours sincerely
Aimee Cox (Miss)
Secretary, University Ethics Committee 
Registry
cc: Professor T Desombre, Chairman, Ethics Committee
